• Efficacy and safety of PARP inhibitors for maintenance treatment of ovarian cancer, regardless of BRCA or HRD status: a comprehensive updated meta-analysis.
    • Li Y.
    • J Obstet Gynaecol. 2023 Dec;43(1):2171282. doi: 10.1080/01443615.2023.2171282.
    • Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial.
    • Sabatier R, Rousseau F, Joly F, Cropet C, Montégut C, Frindte J, Cinier S, Guerra Alía EM, Polterauer S, Yoshida H, Vergote I, Colombo N, Hietanen S, Largillier R, Canzler U, Gratet A, Marmé F, Favier L, Pujade-Lauraine E, Ray-Coquard I.
    • Eur J Cancer. 2022 Dec 10 [2023 Mar];181:42-52. doi: 10.1016/j.ejca.2022.11.029. Epub ahead of print.

    •• Identifier: NCT02477644: Platine, Avastin and OLAparib in 1st Line (PAOLA-1). (ClinicalTrials.gov . Accessed 2023 Jan 10.)

    • Prognostic and Predictive Biomarkers in Familial Breast Cancer.
    • Deb S, Chakrabarti A, Fox SB.
    • Cancers (Basel). 2023 Feb 20;15(4):1346. doi: 10.3390/cancers15041346.
    • Functional homologous recombination assay on FFPE specimens of advanced high-grade serous ovarian cancer predicts clinical outcomes.
    • Pikkusaari S, Tumiati M, Virtanen A, Oikkonen J, Li Y, Perez-Villatoro F, Muranen T, Salko M, Huhtinen K, Kanerva A, Koskela H, Tapper J, Koivisto-Korander R, Joutsiniemi T, Haltia UMLassus H, Hautaniemi S, Farkkila A, Hynninen J, Hietanen S, Carpén O, Kauppi L.
    • Clin Cancer Res. 2023 Feb 20:ccr.22.3156. doi: 10.1158/1078-0432.CCR-22-3156. Epub ahead of print.
    • Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast Cancer.
    • Galland L, Roussot N, Desmoulins I, Mayeur D, Kaderbhai C, Ilie S, Hennequin A, Reda M, Albuisson J, Arnould L, Boidot R, Truntzer C, Ghiringhelli F, Ladoire S.
    • Cancers (Basel). 2023 Feb 17;15(4):1299. doi: 10.3390/cancers15041299.
    • Multi-maintenance olaparib therapy in relapsed, germline BRCA1/2-mutant high-grade serous ovarian cancer (MOLTO): a phase II trial.
    • Morgan RD, Clamp AR, White DJ, Price M, Burghel GJ, Ryder WDJ, Mahmood RD, Murphy AD, Hasan J, Mitchell CL, Salih Z, Wheeler C, Buckley E, Truelove J, King G, Ainaoui Y, Bhaskar SS, Shaw J, Evans DGR, Kilerci B, Pearce SP, Brady G, Dive C, O'Connor JPB, Wallace AJ, Rothwell DG, Edmondson RJ, Jayson GC.
    • Clin Cancer Res. 2023 Feb 17:CCR-22-3282. doi: 10.1158/1078-0432.CCR-22-3282. Epub ahead of print.

    •• Identifier: NCT02855697: Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian Cancer (MOLTO). (ClinicalTrials.gov . Accessed 2023 Feb 18.)

    • Drugmakers Pushing Frontline PARP Inhibitor Combos for All mCRPC Patients Amid Oncologists' Concerns.
    • Hopkins C.
    • Precision Oncology News. 2023 Feb 17.
    • Press
    • Long-term Data for Niraparib Support Continued Use of PARP Inhibitors in HRD+ Ovarian Cancer.
    • Roque DR, Scott R.
    • OncLive. 2023 Feb 14.
    • PARP inhibitors in the treatment of ARID1A mutant ovarian clear cell cancer: PI3K/Akt1-dependent mechanism of synthetic lethality.
    • Yakovlev V, Sullivan SA, Fields E, Temkin SM.
    • Front Oncol. 2023 Feb 13;13:1124147. doi: 10.3389/fonc.2023.1124147.
    • A Phase I Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Bone Metastases (COMRADE).
    • Pan E, Xie W, Ajmera A, Araneta A, Jamieson C, Folefac E, Hussain A, Kyriakopoulos CE, Olson A, Parikh M, Parikh R, Saraiya B, Ivy SP, Van Allen EM, Lindeman NI, Kochupurakkal BS, Shapiro GI, McKay RR.
    • Mol Cancer Ther. 2023 Feb 10:MCT-22-0583. doi: 10.1158/1535-7163.MCT-22-0583. Epub ahead of print.
    • Homologous repair deficiency-associated genes in invasive breast cancer revealed by WGCNA co-expression network analysis and genetic perturbation similarity analysis.
    • Chen H, Liu Y, Yin Z, Chen H, Wang Y, Qian Y.
    • Cell Cycle. 2023 Feb 9:1-24. doi: 10.1080/15384101.2023.2174339. Epub ahead of print.
    • Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors.
    • Musacchio L, Boccia S, Marchetti C, Minucci A, Camarda F, Cassani C, Ventriglia J, Salutari V, Ghizzoni V, Giudice E, Perri MT, Carbone MV, Ricci C, Pignata S, Fagotti A, Scambia G, Lorusso D.
    • Int J Gynecol Cancer. 2023 Feb 9:ijgc-2022-003903. doi: 10.1136/ijgc-2022-003903. Epub ahead of print.
    • Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study.
    • Tuninetti V, Ghisoni E, Pignata S, Picardo E, Raspagliesi F, Andreetta C, Maldi E, Artioli G, Mammoliti S, Zanchi L, Sikokis A, Biglia N, Parisi A, Mandato VD, Carella C, Cormio G, Marinaccio M, Puppo A, Paolini B, Borsotti L, Scotto G, Turinetto M, Sangiolo D, Di Maio M, Valabrega G.
    • Cancers (Basel). 2023 Feb 6;15(4):1032. doi: 10.3390/cancers15041032.
    • Homologous Recombination Inquiry Through Ovarian Malignancy Investigations: JGOG3025 study.
    • Yoshihara K, Baba T, Tokunaga H, Nishino K, Sekine M, Takamatsu S, Matsumura N, Yoshida H, Kajiyama H, Shimada M, Kagimura T, Oda K, Sasajima Y, Yaegashi N, Okamoto A, Sugiyama T, Enomoto T.
    • Cancer Sci. 2023 Feb 6. doi: 10.1111/cas.15747. Epub ahead of print.

    •• Identifier: NCT03159572: Homologous Recombination Inquiry Through Ovarian Malignancy Investigations (HITOMI). (ClinicalTrials.gov . Accessed 2023 Feb 7.)

    • BRCA1/2 pathogenic variants are not common in Merkel cell carcinoma: Comprehensive molecular study of 30 cases and meta-analysis of the literature.
    • Gaubert A, Kervarrec T, Montaudié H, Burel-Vandenbos F, Cardot-Leccia N, Di Mauro I, Fabas T, Tallet A, Kubiniek V, Pedeutour F, Dadone-Montaudié B.
    • J Invest Dermatol. 2023 Feb 6:S0022-202X(23)00068-4. doi: 10.1016/j.jid.2023.01.014. Epub ahead of print.
    • Homologous recombination deficiency prediction using low-pass whole genome sequencing in breast cancer.
    • Liu Y, Li Y, Zhang MZ, Chen D, Leng Y, Wang J, Han BW, Wang J.
    • Cancer Genet. 2023 Feb 4;272-273:35-40. doi: 10.1016/j.cancergen.2023.02.001. Epub ahead of print.
    • Utility of Comprehensive Genomic Profiling Tests for Patients with Incurable Pancreatic Cancer in Clinical Practice.
    • Yamai T, Ikezawa K, Sugimoto N, Urabe M, Kai Y, Takada R, Nakabori T, Uehara H, Kawamura T, Kunimasa K, Yamamoto S, Wakamatsu T, Hayashi T, Kukita Y, Fujisawa F, Inoue T, Yamaguchi Y, Yamasaki T, Honma K, Ohkawa K.
    • Cancers (Basel). 2023 Feb 3;15(3):970. doi: 10.3390/cancers15030970.
    • Pyrosequencing assay for BRCA1 methylation analysis: results from a cross-validation study.
    • Sahnane N, Rivera D, Libera L, Carnevali I, Banelli B, Facchi S, Gismondi V, Paudice M, Cirmena G, Vellone VG, Sessa F, Varesco L, Tibiletti MG.
    • J Mol Diagn. 2023 Feb 3:S1525-1578(23)00005-3. doi: 10.1016/j.jmoldx.2023.01.003. Epub ahead of print.
    • Homologous Recombination Deficiency in Ovarian Cancer: From the Biological Rationale to Current Diagnostic Approaches.
    • Mangogna A, Munari G, Pepe F, Maffii E, Giampaolino P, Ricci G, Fassan M, Malapelle U, Biffi S.>
    • J Pers Med. 2023 Feb 2;13(2):284. doi: 10.3390/jpm13020284.
    • Mutation Status Drives PARP Inhibitor Investigation and Treatment in mCRPC.
    • Wahner A.
    • OncLive. 2023 Feb 1.
    • Genetic variants in African-American and Hispanic patients with breast cancer.
    • Dutta P, Keung MY, Wu Y, Vadgama JV.
    • Oncol Lett. 2022 Dec 16 [eCollection 2023 Feb];25(2):51. doi: 10.3892/ol.2022.13637.
    • Efficacy of Olaparib in Treatment-Refractory, Metastatic Breast Cancer with Uncommon Somatic BRCA Mutations Detected in Circulating Tumor DNA.
    • Yoon JK, Ahn J, Kim S, Kim HP, Kang JK, Bang D, Lim Y, Kim TY.
    • Cancer Res Treat. 2023 Jan 31. doi: 10.4143/crt.2022.1529. Epub ahead of print.
    • Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer.
    • Penson RT, Ambrosio AJ, Whalen CA, Krasner CN, Konstantinopoulos PA, Bradley C, Matulonis UA, Birrer MJ.
    • Oncologist. 2023 Jan 30:oyac275. doi: 10.1093/oncolo/oyac275. Epub ahead of print.

    •• Identifier: NCT01033123: A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer. (ClinicalTrials.gov . Accessed 2023 Jan 31.)

    •• Identifier: NCT01033292: A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer. (ClinicalTrials.gov . Accessed 2023 Jan 31.)

    • Implementing HRD Testing in Routine Clinical Practice on Patients with Primary High-Grade Advanced Ovarian Cancer.
    • Heitz F, Ataseven B, Staniczok C, Denkert C, Rhiem K, Hahnen E, Heikaus S, Moubarak M, Welz J, Dagres T, Vrentas V, Bommert M, Schneider S, Concin N, Harter P.
    • Cancers (Basel). 2023 Jan 29;15(3):818. doi: 10.3390/cancers15030818.
    • Genetics, Genomics and Emerging Molecular Therapies of Pancreatic Cancer.
    • Liu J, Mroczek M, Mach A, Stępień M, Aplas A, Pronobis-Szczylik B, Bukowski S, Mielczarek M, Gajewska E, Topolski P, Król ZJ, Szyda J, Dobosz P.
    • Cancers (Basel). 2023 Jan 27;15(3):779. doi: 10.3390/cancers15030779.
    • PARP inhibitors: risk factors for toxicity and matching patients to the proper poly (ADP-ribose) polymerase inhibitor (PARPi) therapy.
    • Chelariu-Raicu A, Trillsch F, Burges A, Czogalla B, Hester A, Wuerstlein R, Harbeck N, Mahner S.
    • Int J Gynecol Cancer. 2023 Jan 27:ijgc-2022-003990. doi: 10.1136/ijgc-2022-003990. Epub ahead of print.
    • Review
    • Is Reflex Germline BRCA1/2 Testing Necessary in Women Diagnosed with Non-Mucinous High-Grade Epithelial Ovarian Cancer Aged 80 Years or Older?
    • Morgan RD, Burghel GJ, Flaum N, Bulman M, Smith P, Clamp AR, Hasan J, Mitchell CL, Salih Z, Woodward ER, Lalloo F, Crosbie EJ, Edmondson RJ, Schlecht H, Jayson GC, Evans DGR.
    • Cancers (Basel). 2023 Jan 25;15(3):730. doi: 10.3390/cancers15030730.
    • Pathogenic Variants in Adult-Onset Cancer Predisposition Genes in Pediatric Cancer: Prevalence and Impact on Tumor Molecular Features and Clinical Management.
    • McGee RB, Oak N, Harrison L, Xu K, Nuccio R, Blake AK, Mostafavi R, Lewis S, Taylor LM, Kubal M, Ouma A, Hines-Dowell SJ, Cheng C, Furtado LV, Nichols KE.
    • Clin Cancer Res. 2023 Jan 24:ccr.22.2482. doi: 10.1158/1078-0432.CCR-22-2482. Epub ahead of print.
    • PARP inhibition utilized in combination therapy with Olaparib-Temozolomide to achieve disease stabilization in a rare case of BRCA1-mutant, metastatic myxopapillary ependymoma.
    • Mahalingam P, Smith S, Lopez J, Sharma RK, Millard T, Thway K, Fisher C, Reardon DA, Jones R, Nicholson AG, Cunningham D, Welsh L, Sharma B.
    • Rare Tumors. 2023 Jan 19;15:20363613231152333. doi: 10.1177/20363613231152333.
    • Real-World Efficacy and Safety of PARP Inhibitors in Recurrent Ovarian Cancer Patients With Somatic BRCA and Other Homologous Recombination Gene Mutations.
    • Pan YE, Hood A, Ahmad H, Altwerger G.
    • Ann Pharmacother. 2023 Jan 18:10600280221149136. doi: 10.1177/10600280221149136. Epub ahead of print.
    • Landscape of DNA damage response gene alterations in breast cancer: A comprehensive investigation.
    • Jin J, Cao J, Li B, Li T, Zhang J, Cao J, Zhao M, Wang L, Wang B, Tao Z, Hu X.
    • Cancer. 2023 Jan 18. doi: 10.1002/cncr.34618. Epub ahead of print.
    • Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance.
    • Wang LM, Wang P, Chen XM, Yang H, Song SS, Song Z, Jia L, Chen HD, Bao XB, Guo N, Huan XJ, Xi Y, Shen YY, Yang XY, Su Y, Sun YM, Gao YL, Chen Y, Ding J, Lang JY, Miao ZH, Zhang A, He JX.
    • EMBO Mol Med. 2023 Jan 18:e16235. doi: 10.15252/emmm.202216235. Epub ahead of print.
    • Identification of a large intra-exonic deletion in BRCA2 exon 18 in a pancreatic ductal adenocarcinoma.
    • Debbabi I, Vacher S, Neuzillet C, Cros J, Revillon F, Petitalot A, Turpin A, Antonio S, Girard E, Dupain C, Kamal M, Hammel P, Bièche I, Masliah-Planchon J, Caputo SM.
    • Ther Adv Med Oncol. 2023 Jan 18;15:17588359221146132. doi: 10.1177/17588359221146132.
    • Genetic testing and prognosis of sarcomatoid hepatocellular carcinoma patients.
    • Jia B, Xia P, Dong J, Feng W, Wang W, Liu E, Jiang G, Qin Y.
    • Front Oncol. 2023 Jan 17;12:1086908. doi: 10.3389/fonc.2022.1086908.
    • Positive response to Niraparib in chemo-refractory patient with metastatic appendiceal mucinous adenocarcinoma harboring ATM mutations: a case report.
    • Wang J, He H, Xu W, Chen J.
    • Front Oncol. 2023 Jan 17;12:1010871. doi: 10.3389/fonc.2023.1010871.
    • CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer.
    • Tsujino T, Takai T, Hinohara K, Gui F, Tsutsumi T, Bai X, Miao C, Feng C, Gui B, Sztupinszki Z, Simoneau A, Xie N, Fazli L, Dong X, Azuma H, Choudhury AD, Mouw KW, Szallasi Z, Zou L, Kibel AS, Jia L.
    • Nat Commun. 2023 Jan 17;14(1):252. doi: 10.1038/s41467-023-35880-y.
    • Genetic Analysis Helps Maximize Clinical Benefit with PARP Inhibitors in BRCA+ Ovarian Cancer.
    • Flaherty C, Guntupalli S.
    • OncLive. 2023 Jan 17.
    • Metastatic Prostate Cancer—A Review of Current Treatment Options and Promising New Approaches.
    • Posdzich P, Darr C, Hilser T, Wahl M, Herrmann K, Hadaschik B, Grünwald V.
    • Cancers (Basel). 2023 Jan 11;15(2):461. doi: 10.3390/cancers15020461.
    • Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study.
    • Bellier C, Gladieff L, Le Du F, Berton D, Bonnard C, Suau D, Richard AC, Brenner O, Lahouegue A, Freyer G, Floquet A, Frank S, Kfoury M.
    • Drugs Real World Outcomes. 2023 Jan 11. doi: 10.1007/s40801-022-00349-9. Epub ahead of print.
    • A Glance at Molecular Advances in Cancer Genetics: A Baffling Puzzle Still to Be Solved.
    • Ghiorzo P, Bruno W.
    • Int J Mol Sci. 2023 Jan 11;24(2):1394. doi: 10.3390/ijms24021394.
    • Novel Combination Regimens Strengthen and Expand Treatment Paradigm for Genitourinary Cancers.
    • Flaherty C, Dorff TB.
    • OncLive. 2023 Jan 10.
    • Dr. Dorff on the Investigation of PARP Inhibitors in mCRPC.
    • Dorff TB.
    • OncLive. OncLive TV. 2023 Jan 10.
    • Diagnostic and Therapeutic Pathway of Advanced Ovarian Cancer with Peritoneal Metastases.
    • Ghirardi V, Fagotti A, Ansaloni L, Valle M, Roviello F, Sorrentino L, Accarpio F, Baiocchi G, Piccini L, De Simone M, Coccolini F, Visaloco M, Bacchetti S, Scambia G, Marrelli D.
    • Cancers (Basel). 2023 Jan 7;15(2):407. doi: 10.3390/cancers15020407.
    • Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status.
    • Wu Y, Xu S, Cheng S, Yang J, Wang Y.
    • J Ovarian Res. 2023 Jan 7;16(1):6. doi: 10.1186/s13048-023-01094-5.
    • Targeting the DNA damage response for cancer therapy.
    • Curtin NJ.
    • Biochem Soc Trans. 2023 Jan 6:BST20220681. doi: 10.1042/BST20220681. Epub ahead of print.
    • Mutations of TP53 and genes related to homologous recombination repair in breast cancer with germline BRCA1/2 mutations.
    • Kim J, Jeong K, Jun H, Kim K, Bae JM, Song MG, Yi H, Park S, Woo GU, Lee DW, Kim TY, Lee KH, Im SA.
    • Hum Genomics. 2023 Jan 6;17(1):2. doi: 10.1186/s40246-022-00447-3.
    • Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial.
    • Rodler E, Sharma P, Barlow WE, Gralow JR, Puhalla SL, Anders CK, Goldstein L, Tripathy D, Brown-Glaberman UA, Huynh TT, Szyarto CS, Godwin AK, Pathak HB, Swisher EM, Radke MR, Timms KM, Lew DL, Miao J, Pusztai L, Hayes DF, Hortobagyi GN.
    • Lancet Oncol. 2023 Jan 6:S1470-2045(22)00739-2. doi: 10.1016/S1470-2045(22)00739-2. Epub ahead of print.

    •• Identifier: NCT02595905: Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases. (ClinicalTrials.gov . Accessed 2023 Jan 7.)

    • Current Issues in the Management of Patients With Newly Diagnosed Advanced-Stage High-Grade Serous Carcinoma of the Ovary.
    • Penn CA, Alvarez RD.
    • JCO Oncol Pract. 2023 Jan 5:OP2200461. doi: 10.1200/OP.22.00461. Epub ahead of print.
    • Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial.
    • Landen CN, Molinero L, Hamidi H, Sehouli J, Miller A, Moore KN, Taskiran C, Bookman M, Lindemann K, Anderson C, Berger R, Myers T, Beiner M, Reid T, Van Nieuwenhuysen E, Green A, Okamoto A, Aghajanian C, Thaker PH, Blank SV, Khor VK, Chang CW, Lin YG, Pignata S.
    • Clin Cancer Res. 2023 Jan 3:CCR-22-2032. doi: 10.1158/1078-0432.CCR-22-2032. Epub ahead of print.

    •• Identifier: NCT03038100: A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (IMagyn050). (ClinicalTrials.gov . Accessed 2023 Jan 3.)

    • Treatment Complexities Continue to Mount in Gynecologic Cancers.
    • Lovely B.
    • OncLive. OncologyLive. 2023 Jan 3;23(24):35.
    • Prognostic relevance of HRDness gene expression signature in ovarian high-grade serous carcinoma; JGOG3025-TR2 study.
    • Takamatsu S, Yoshihara K, Baba T, Shimada M, Yoshida H, Kajiyama H, Oda K, Mandai M, Okamoto A, Enomoto T, Matsumura N.
    • Br J Cancer. 2023 Jan 2. doi: 10.1038/s41416-022-02122-9. Epub ahead of print.
    • Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective.
    • Herzog TJ, Vergote I, Gomella LG, Milenkova T, French T, Tonikian R, Poehlein C, Hussain M.
    • Eur J Cancer. 2022 Dec 21 [2023 Jan 1];179:136-146. doi: 10.1016/j.ejca.2022.10.021. Epub ahead of print.
    • Two cases of CRPC with BRCA mutation treated by olaparib after favorable response to cisplatin.
    • Miyazawa Y, Shimizu T, Sekine Y, Arai S, Ohtsu A, Fujizuka Y, Nomura M, Koike H, Matsui H, Suzuki K.
    • IJU Case Rep. 2022 Oct 9 [eCollection 2023 Jan];6(1):37-40. doi: 10.1002/iju5.12543.

    •• Letter:

    Editorial Comment on "Two cases of CRPC with BRCA mutation treated by olaparib after favorable response to cisplatin".

    • Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial.
    • Pujade-Lauraine E, Brown J, Barnicle A, Wessen J, Lao-Sirieix P, Criscione SW, du Bois A, Lorusso D, Romero I, Petru E, Yoshida H, Vergote I, Colombo N, Hietanen S, Provansal M, Schmalfeldt B, Pignata S, Martín Lorente C, Berton D, Runnebaum IB, Ray-Coquard I.
    • JCO Precis Oncol. 2023 Jan;7:e2200258. doi: 10.1200/PO.22.00258.

    •• Identifier: NCT02477644: Platine, Avastin and OLAparib in 1st Line (PAOLA-1). (ClinicalTrials.gov . Accessed 2023 Jan 30.)

    • Impact of Homologous Recombination Deficiency on Outcomes in Patients With Triple-Negative Breast Cancer Treated With Carboplatin-Based Neoadjuvant Chemotherapy: Secondary Analysis of the NeoCART Randomized Clinical Trial.
    • Zhang L, Wu Z, Li J, Zhu D, Yang L, Shao Y, Lin Y, Liu Z, Cao Y, Zhang G, Shang S, Zhang Y, Wang K.
    • JCO Precis Oncol. 2023 Jan;7:e2200337. doi: 10.1200/PO.22.00337.

    •• Identifier: NCT03154749: DCb (Docetaxel/Carboplatin) Versus EC-D (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer. (ClinicalTrials.gov . Accessed 2023 Jan 18.)

    • Validation of multi-gene panel next-generation sequencing for the detection of BRCA mutation in formalin-fixed, paraffin-embedded epithelial ovarian cancer tissues.
    • Kim ET, Jeong HE, Yoon HJ, Kim KH, Suh DS.
    • Taiwan J Obstet Gynecol. 2023 Jan;62(1):66-70. doi: 10.1016/j.tjog.2022.07.010.
    • Widespread genomic/molecular alterations of DNA helicases and their clinical/therapeutic implications across human cancer.
    • Qin X, Wang J, Wang X, Huang T, Fang Z, Yan L, Fan Y, Xu D.
    • Biomed Pharmacother. 2022 Dec 29;158:114193. doi: 10.1016/j.biopha.2022.114193. Epub ahead of print.
    • Optimized detection of homologous recombination deficiency improves the prediction of clinical outcomes in cancer.
    • Perez-Villatoro F, Oikkonen J, Casado J, Chernenko A, Gulhan DC, Tumiati M, Li Y, Lavikka K, Hietanen S, Hynninen J, Haltia UM, Tyrmi JS, Laivuori H, Konstantinopoulos PA, Hautaniemi S, Kauppi L, Färkkilä A.
    • NPJ Precis Oncol. 2022 Dec 29;6(1):96. doi: 10.1038/s41698-022-00339-8.
    • CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.
    • Kang EY, Weir A, Meagher NS, Farrington K, Nelson GS, Ghatage P, Lee CH, Riggan MJ, Bolithon A, Popovic G, Leung B, Tang K, Lambie N, Millstein J, Alsop J, Anglesio MS, Ataseven B, Barlow E, Beckmann MW, Berger J, Bisinotto C, Bösmüller H, Boros J, Brand AH, Brooks-Wilson A, Brucker SY, Carney ME, Casablanca Y, Cazorla-Jiménez A, Cohen PA, Conrads TP, Cook LS, Coulson P, Courtney-Brooks M, Cramer DW, Crowe P, Cunningham JM, Cybulski C, Darcy KM, El-Bahrawy MA, Elishaev E, Erber R, Farrell R, Fereday S, Fischer A, García MJ, Gayther SA, Gentry-Maharaj A, Gilks CB; AOCS Group, Grube M, Harnett PR, Harrington SP, Harter P, Hartmann A, Hecht JL, Heikaus S, Hein A, Heitz F, Hendley J, Hernandez BY, Polo SH, Heublein S, Hirasawa A, Høgdall E, Høgdall CK, Horlings HM, Huntsman DG, Huzarski T, Jewell A, Jimenez-Linan M, Jones ME, Kaufmann SH, Kennedy CJ, Khabele D, Kommoss FKF, Kruitwagen RFPM, Lambrechts D, Le ND, Lener M, Lester J, Leung Y, Linder A, Loverix L, Lubiński J, Madan R, Maxwell GL, Modugno F, Neuhausen SL, Olawaiye A, Olbrecht S, Orsulic S, Palacios J, Pearce CL, Pike MC, Quinn CM, Mohan GR, Rodríguez-Antona C, Ruebner M, Ryan A, Salfinger SG, Sasamoto N, Schildkraut JM, Schoemaker MJ, Shah M, Sharma R, Shvetsov YB, Singh N, Sonke GS, Steele L, Stewart CJR, Sundfeldt K, Swerdlow AJ, Talhouk A, Tan A, Taylor SE, Terry KL, Tołoczko A, Traficante N, Van de Vijver KK, van der Aa MA, Van Gorp T, Van Nieuwenhuysen E, van-Wagensveld L, Vergote I, Vierkant RA, Wang C, Wilkens LR, Winham SJ, Wu AH, Benitez J, Berchuck A, Candido Dos Reis FJ, DeFazio A, Fasching PA, Goode EL, Goodman MT, Gronwald J, Karlan BY, Kommoss S, Menon U, Sinn HP, Staebler A, Brenton JD, Bowtell DD, Pharoah PDP, Ramus SJ, Köbel M.
    • Cancer. 2022 Dec 26. doi: 10.1002/cncr.34582. Epub ahead of print.
    • Determination of BRCAness Phenotype in Breast Tumors for the Appointment of Neoadjuvant Chemotherapy Based on Platinum and Taxanes.
    • Mihajlovich Tsyganov MM, Ibragimova MK, Garbukov EY, Bragina OD, Karchevskaya AA, Usynin EA, Litvyakov NV.
    • Int J Mol Sci. 2022 Dec 22;24(1):207. doi: 10.3390/ijms24010207.
    • Mechanisms of PARP1 inhibitor resistance and their implications for cancer treatment.
    • Jackson LM, Moldovan GL.
    • NAR Cancer. 2022 Dec 22;4(4):zcac042. doi: 10.1093/narcan/zcac042.
    • Locally Performed HRD Testing for Ovarian Cancer? Yes, We Can!
    • Magliacane G, Brunetto E, Calzavara S, Bergamini A, Pipitone GB, Marra G, Redegallin M, Grassini G, Rabaiotti E, Taccagni G, Pecciarini L, Carrera P, Mangili G, Doglioni C, Cangi MG.
    • Cancers (Basel). 2022 Dec 21;15(1):43. doi: 10.3390/cancers15010043.
    • CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors.
    • Lu X, He Y, Johnston RL, Nanayakarra D, Sankarasubramanian S, Lopez JA, Friedlander M, Kalimutho M, Hooper JD, Raninga PV, Khanna KK.
    • J Exp Clin Cancer Res. 2022 Dec 21;41(1):355. doi: 10.1186/s13046-022-02570-4.
    • LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone Approved in the EU as Treatment for Certain Patients With Metastatic Castration-Resistant Prostate Cancer.
    • [No author given]
    • Merck.com . News releases. 2022 Dec 21.

    •• Press release: Lynparza in combination with abiraterone approved in the EU as 1st-line treatment for patients with metastatic castration-resistant prostate cancer. (AstraZeneca. Media.)

    • Deep learning identifies morphological patterns of homologous recombination deficiency in luminal breast cancers from whole slide images.
    • Lazard T, Bataillon G, Naylor P, Popova T, Bidard FC, Stoppa-Lyonnet D, Stern MH, Decencière E, Walter T, Vincent-Salomon A..
    • Cell Rep Med. 2022 Dec 20;3(12):100872. doi: 10.1016/j.xcrm.2022.100872. Epub 2022 Dec 13.

    •• Commentary:

    HRD-related morphology discovery in breast cancer by controlling for confounding factors.

    • Dr. Rimel on the Importance of BRCA and HRD Testing in Ovarian Cancer.
    • Rimel BJ.
    • OncLive. OncLive TV. 2022 Dec 19.
    • Mechanisms of Drug Resistance in Ovarian Cancer and Associated Gene Targets.
    • Alatise KL, Gardner S, Alexander-Bryant A.
    • Cancers (Basel). 2022 Dec 18;14(24):6246. doi: 10.3390/cancers14246246.
    • Individualized Maintenance Niraparib Dosing Confers Favorable OS in Recurrent Ovarian Cancer.
    • Seymour C.
    • OncLive. 2022 Dec 16.

    •• Identifier: NCT03705156: Clinical Trial Evaluating the Efficacy and Safety of ZL-2306 (Niraparib) in Ovarian Cancer Patient. (ClinicalTrials.gov . Accessed 2022 Dec 16.)

    • Update on US regulatory priority review of Lynparza in combination with abiraterone in metastatic castration-resistant prostate cancer.
    • Kemp A.
    • AstraZeneca. Media. Press Releases. 2022 Dec 15.
    • Towards Personalized Management of Ovarian Cancer.
    • Algethami M, Kulkarni S, Sadiq MT, Tang HKC, Brownlie J, Jeyapalan JN, Mongan NP, Rakha EA, Madhusudan S.
    • Cancer Manag Res. 2022 Dec 15;14:3469-3483. doi: 10.2147/CMAR.S366681.
    • Interstitial brachytherapy combined with PARP inhibitors in the treatment of chemoresistant recurrent epithelial ovarian cancer: A case report.
    • Bian Y, Guan P, Li D, Tan L, Pang H, Wen Q, Chen P, Zhang Z.
    • Front Oncol. 2022 Dec 15;12:1071383. doi: 10.3389/fonc.2022.1071383.
    • FDA Delays PDUFA Hearing for Olaparib/Abiraterone Combo in mCRPC.
    • Harris J.
    • OncLive. 2022 Dec 15.

    •• Identifier: NCT03732820: Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer. (ClinicalTrials.gov . Accessed 2022 Dec 15.)

    • Concordance between single-nucleotide polymorphism-based genomic instability assays and a next-generation sequencing-based homologous recombination deficiency test.
    • Cristescu R, Liu XQ, Arreaza G, Chen C, Albright A, Qiu P, Marton MJ.
    • BMC Cancer. 2022 Dec 14;22(1):1310. doi: 10.1186/s12885-022-10197-z.
    • Next-generation sequencing of homologous recombination genes could predict efficacy of platinum-based chemotherapy in non-small cell lung cancer.
    • Zhang L, Guan S, Meng F, Teng L, Zhong D.
    • Front Oncol. 2022 Dec 14;12:1035808. doi: 10.3389/fonc.2022.1035808.
    • Molecular profiling of male breast cancer by multigene panel testing: implications for precision oncology.
    • Valentini V, Silvestri V, Bucalo A, Conti G, Karimi M, Di Francesco L, Pomati G, Mezi S, Cerbelli B, Pignataro MG, Nicolussi A, Coppa A, D'Amati G, Giannini G, Ottini L.
    • Front Oncol. 2022 Dec 12;12:1092201. doi: 10.3389/fonc.2022.1092201.
    • Neoadjuvant Olaparib Combo Fails to Surpass Carboplatin/Paclitaxel in HER2– Early Breast Cancer.
    • Lovely B.
    • OncLive. 2022 Dec 9.

    •• Identifier: NCT02789332: Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency (GeparOla). (ClinicalTrials.gov . Accessed 2022 Dec 10.)

    • BRCA1 deficiency in triple-negative breast cancer: Protein stability as a basis for therapy.
    • Choi E, Mun GI, Lee J, Lee H, Cho J, Lee YS.
    • Biomed Pharmacother. 2022 Dec 6;158:114090. doi: 10.1016/j.biopha.2022.114090. Epub ahead of print.
    • RNA-Based Classification of Homologous Recombination Deficiency in Racially Diverse Patients with Breast Cancer.
    • Walens A, Van Alsten SC, Olsson LT, Smith MA, Lockhart A, Gao X, Hamilton AM, Kirk EL, Love MI, Gupta GP, Perou CM, Vaziri C, Hoadley KA, Troester MA.
    • Cancer Epidemiol Biomarkers Prev. 2022 Dec 5;31(12):2136-2147. doi: 10.1158/1055-9965.EPI-22-0590.
    • Homologous Recombination Deficiency and Cyclin E1 Amplification Are Correlated with Immune Cell Infiltration and Survival in High-Grade Serous Ovarian Cancer.
    • van Wagensveld L, van Baal JOAM, Timmermans M, Gaillard D, Borghuis L, Coffelt SB, Rosenberg EH, Lok CAR, Nijman HW, Kooreman LFS, Sanders J, de Bruijn M, Wessels LFA, van der Wiel R, Rausch C, Broeks A, Kruitwagen RFPM, van der Aa MA, Sonke GS, Schouten PC, Van de Vijver KK, Horlings HM.
    • Cancers (Basel). 2022 Dec 2;14(23):5965. doi: 10.3390/cancers14235965.
    • The BRCAness Landscape of Cancer.
    • Guo M, Wang SM.
    • Cells. 2022 Dec 1;11(23):3877. doi: 10.3390/cells11233877.
    • Comments on "Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial".
    • Bhatt A, Bhandoria G, Kepenekian V, Bakrin N, Glehen O.
    • Int J Cancer. 2022 Dec 1;151(11):2055-2056. doi: 10.1002/ijc.34220. Epub 2022 Aug 5.
    • Comment. Letter.

    •• Reply, Letter:

    Reply to: Comments on "Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial".

    •• Original research:

    Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial.

    • Case report: olaparib use in metastatic lung adenocarcinoma with BRCA2 pathogenic variant.
    • Soon Jian Hao J, Hoai CS, Weng DTS, Ngeow J, Chiang J.
    • Cold Spring Harb Mol Case Stud. 2022 Dec 28 [Print 2022 Dec];8(7):a006223. doi: 10.1101/mcs.a006223.
    • Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.
    • O'Malley DM, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, Swisher EM, Maloney L, Goble S, Lin KK, Kwan T, Ledermann JA, Coleman RL.
    • Gynecol Oncol. 2022 Dec;167(3):404-413. doi: 10.1016/j.ygyno.2022.08.021. Epub 2022 Oct 20.

    •• Identifier: NCT01968213: A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer (ARIEL3). (ClinicalTrials.gov . Accessed 2022 Oct 22.)

    •• Letter:

    AML and MDS associated with PARP inhibitor treatment of ovarian cancer.

    •• Reply, Letter:

    Response to letter to the editor "AML and MDS associated with PARP inhibitor treatment of ovarian cancer".

    •• Podcast: December 2022 Editor’s Choice: Exceptional PARP inhibitor responders: the good and the bad. (Gynecologic Oncology. Podcasts.)

    • December 2022 Editor’s Choice: Exceptional PARP inhibitor responders: the good and the bad.
    • Matulonis U, O'Malley D.
    • Gynecol Oncol. Podcasts. 2022 Dec.

    •• Original research:

    Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.

    • Society of Gynecologic Oncology Journal Club: Controversial conversations in gynecologic cancer - Navigating maintenance therapy for homologous recombinant proficient ovarian cancer.
    • Goldsberry WN, Norquist BS, Rocconi RP, Modesitt SC, Urban RR.
    • Gynecol Oncol Rep. 2022 Nov 8 [eCollection 2022 Dec];44:101103. doi: 10.1016/j.gore.2022.101103.
    • Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer.
    • Inderjeeth AJ, Topp M, Sanij E, Castro E, Sandhu S.
    • Cancers (Basel). 2022 Nov 30;14(23):5922. doi: 10.3390/cancers14235922.
    • Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis.
    • Labidi-Galy SI, Rodrigues M, Sandoval JL, Kurtz JE, Heitz F, Mosconi AM, Romero I, Denison U, Nagao S, Vergote I, Parma G, Nøttrup TJ, Rouleau E, Garnier G, El-Balat A, Zamagni C, Martín-Lorente C, Pujade-Lauraine E, Fiévet A, Ray-Coquard IL.
    • Ann Oncol. 2022 Nov 28:S0923-7534(22)04733-0. doi: 10.1016/j.annonc.2022.11.003. Epub ahead of print.
    • Pre-Existing and Acquired Resistance to PARP Inhibitor-Induced Synthetic Lethality.
    • Viet Le B, Podszywalow-Bartnicka P, Piwocka K, Skorski T.
    • Cancers (Basel). 2022 Nov 24;14(23):5795. doi: 10.3390/cancers14235795.
    • Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies.
    • Murciano-Goroff YR, Schram AM, Rosen EY, Won H, Gong Y, Noronha AM, Janjigian YY, Stadler ZK, Chang JC, Yang SR, Mandelker D, Offit K, Berger MF, Donoghue MTA, Bandlamudi C, Drilon A.
    • Nat Commun. 2022 Nov 23;13(1):7182. doi: 10.1038/s41467-022-34109-8.
    • Precision Medicine Provides Continued Benefit in mCRPC.
    • George DJ, Scott R.
    • OncLive. 2022 Nov 21.
    • Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers.
    • Ballot E, Galland L, Mananet H, Boidot R, Arnould L, Desmoulins I, Mayeur D, Kaderbhai C, Ilie S, Hennequin A, Bergeron A, Derangère V, Ghiringhelli F, Truntzer C, Ladoire S.
    • Breast Cancer Res. 2022 Nov 18;24(1):80. doi: 10.1186/s13058-022-01572-6.
    • FDA Seeks to Restrict Rucaparib to Second-line Maintenance Therapy in Recurrent Ovarian Cancer.
    • Harris J.
    • OncLive. 2022 Nov 18.
    • Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial.
    • Yap TA, Bardia A, Dvorkin M, Galsky MD, Beck JT, Wise DR, Karyakin O, Rubovszky G, Kislov N, Rohrberg K, Joy AA, Telli ML, Schram AM, Conte U, Chappey C, Stewart R, Stypinski D, Michelon E, Cesari R, Konstantinopoulos PA.
    • JAMA Oncol. 2022 Nov 17. doi: 10.1001/jamaoncol.2022.5228. Epub ahead of print.

    •• Identifier: NCT03330405: Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors. (ClinicalTrials.gov . Accessed 2022 Nov 19.)

    •• Commentary:

    Combining PARP Inhibitor With Immunotherapy-Does the Promise of Preclinical Data Translate to Clinic?

    • Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial.
    • Schram AM, Colombo N, Arrowsmith E, Narayan V, Yonemori K, Scambia G, Zelnak A, Bauer TM, Jin N, Ulahannan SV, Colleoni M, Aftimos P, Donoghue MTA, Rosen E, Rudneva VA, Telli ML, Domchek SM, Galsky MD, Hoyle M, Chappey C, Stewart R, Blake-Haskins JA, Yap TA.
    • JAMA Oncol. 2022 Nov 17. doi: 10.1001/jamaoncol.2022.5218. Epub ahead of print.

    •• Identifier: NCT03565991: Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors. (ClinicalTrials.gov . Accessed 2022 Nov 19.)

    •• Commentary:

    Combining PARP Inhibitor With Immunotherapy-Does the Promise of Preclinical Data Translate to Clinic?

    • Potential value of the homologous recombination deficiency signature we developed in the prognosis and drug sensitivity of gastric cancer.
    • Wu X, Wang Q, Liu P, Sun L, Wang Y.
    • Front Genet. 2022 Nov 16;13:1026871. doi: 10.3389/fgene.2022.1026871.
    • Human metastatic cholangiocarcinoma patient-derived xenografts and tumoroids for preclinical drug evaluation.
    • Serra-Camprubí Q, Verdaguer H, Oliveros W, Lupión-Garcia N, Llop-Guevara A, Molina C, Vila-Casadesús M, Turpin A, Neuzillet C, Frigola J, Querol J, Yáñez-Bartolomé M, Castet F, Fabregat-Franco C, Escudero-Iriarte C, Escorihuela M, Arenas EJ, Bernado-Morales C, Haro N, Giles FJ, Pozo OJ, Miquel JM, Nuciforo PG, Vivancos A, Melé M, Serra V, Arribas J, Tabernero J, Peiró S, Macarulla T, Tian TV.
    • Clin Cancer Res. 2022 Nov 14:CCR-22-2551. doi: 10.1158/1078-0432.CCR-22-2551. Epub ahead of print.
    • Development of a novel BRCAness score that predicts response to PARP inhibitors.
    • Oshi M, Gandhi S, Wu R, Asaoka M, Yan L, Yamada A, Yamamoto S, Narui K, Chishima T, Ishikawa T, Endo I, Takabe K.
    • Biomark Res. 2022 Nov 12;10(1):80. doi: 10.1186/s40364-022-00427-8.
    • PARP Maintenance Therapy Provides Varying Benefit in Advanced Ovarian Cancer.
    • Doherty K, Miller EM.
    • OncLive. 2022 Nov 10.
    • Study Suggests a PARP Inhibitors Has Wider Cancer Applications.
    • [No author given]
    • Inside Precision Medicine. Topics. Oncology. 2022 Nov 9.

    •• Original research:

    A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes.

    • Tests to Guide PARP Inhibitors Emerge as New Focus for Public-Private Harmonization Effort.
    • Ashford K.
    • Precision Oncology News. 2022 Nov 8.
    • News
    • Cost-effectiveness of poly-(ADP-ribose) polymerase (PARP)-inhibitors for the maintenance treatment after responding to first- and second-line chemotherapy in advanced ovarian cancer.
    • Giuliani J, Mantoan B, Ferrario L, Candela MV, Aprile G.
    • J Oncol Pharm Pract. 2022 Nov 7:10781552221137705. doi: 10.1177/10781552221137705. Epub ahead of print.
    • Optimizing Therapy for Ovarian Cancer: Recent Data Highlights - Episode 9: The Rationale for PARP Inhibitor Treatment for HRD-Positive Ovarian Cancer.
    • Monk BJ, Coleman RL, Westin SN, Birrer MJ.
    • OncLive. Peer Exchange. 2022 Nov 4.
    • Thermo Fisher Introduces Homologous Recombination Deficiency Score for Cancer Profiling Assay.
    • Han AP.
    • GenomeWeb. 2022 Nov 7.
    • News
    • Exquisitely Platinum-Sensitive Triple-Negative Breast Cancer, Time for BRCA Methylation Testing?
    • Tan TJ, Fink JL, Tay TK, Jaradi B, Stone N, Waring P, Koo KM, Tan PH, Tan DS, Dent RA.
    • JCO Precis Oncol. [2022 Nov 3];6:e2200309. doi: 10.1200/PO.22.00309.
    • Case report
    • BRCA Mutations, HRD Status Drive PARP Inhibitor Selection in Ovarian Cancer Maintenance.
    • Scott R, Rimel BJ.
    • OncLive. 2022 Nov 3.
    • Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2 or ATM Alterations Identified by Testing Circulating Tumor DNA.
    • Matsubara N, de Bono J, Olmos D, Procopio G, Kawakami S, Ürün Y, van Alphen R, Flechon A, Carducci MA, Choi YD, Hotte SJ, Korbenfeld E, Kramer G, Agarwal N, Chi KN, Dearden S, Gresty C, Kang J, Poehlein C, Harrington EA, Hussain M.
    • Clin Cancer Res. 2022 Nov 1:CCR-21-3577. doi: 10.1158/1078-0432.CCR-21-3577. Epub ahead of print.

    •• Identifier: NCT02987543: Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study). (ClinicalTrials.gov . Accessed 2022 Nov 5.)

    • Recurrent Ovarian Cancer with BRCAness Phenotype: A Treatment Challenge.
    • Caeiro C, Leão I, Oliveira I, Sousa I, André T.
    • Adv Ther. 2022 Nov;39(11):5289-5299. doi: 10.1007/s12325-022-02259-2. Epub 2022 Sep 5.
    • Genomic Scar Score: A robust model predicting homologous recombination deficiency based on genomic instability.
    • Yuan W, Ni J, Wen H, Shi W, Chen X, Huang H, Zhang X, Lu X, Zhu C, Dong H, Yang S, Wu X, Chen X.
    • BJOG. 2022 Nov;129 Suppl 2:14-22. doi: 10.1111/1471-0528.17324.
    • A case of metastatic treatment-emergent small cell/neuroendocrine prostate cancer with BRCA2 mutation diagnosed by liver biopsy.
    • Naiki T, Naiki-Ito A, Kawai T, Komatsu H, Nishikawa R, Gonda M, Aoki M, Sugiyama Y, Tasaki Y, Yasui T.
    • IJU Case Rep. 2022 Jun 29 [eCollection 2022 Nov];5(6):431-435. doi: 10.1002/iju5.12501.

    •• Commentary:

    Editorial Comment from Dr Sekino and Dr Hinata to A case of metastatic treatment emergent small cell/neuroendocrine prostate cancer with BRCA2 mutation diagnosed by liver biopsy.

    •• Commentary:

    Editorial Comment from Dr Kato to A case of metastatic treatment-emergent small cell/neuroendocrine prostate cancer with BRCA2 mutation by liver biopsy.

    • Prostate cancer recurring as small-cell carcinoma with a BRCA2 somatic mutation.
    • Yabusaki R, Yoshimura K, Taku K, Suzuki M.
    • IJU Case Rep. 2022 Aug 12 [eCollection 2022 Nov];5(6):489-492. doi: 10.1002/iju5.12523.
    • Druggable gene alterations in Japanese patients with rare malignancy.
    • Ohmoto A, Hayashi N, Fukada I, Yamazaki M, Yunokawa M, Kasuga A, Shinozaki E, Ueki A, Tonooka A, Takeuchi K, Mori S, Kiyotani K, Takahashi S.
    • Neoplasia. 2022 Nov;33:100834. doi: 10.1016/j.neo.2022.100834. Epub 2022 Sep 8.
    • Germline and somatic variants in ovarian carcinoma: a next-generation sequencing (NGS) analysis.
    • Andrikopoulou A, Zografos E, Apostolidou K, Kyriazoglou T, Papatheodoridi AM, Kaparelou M, Koutsoukos K, Liontos M, Dimopoulos M, Zagouri F.
    • Front Oncol. 2022 Oct 31;12:1030786. doi: 10.3389/fonc.2022.1030786.
    • Somatic Inactivation of Breast Cancer Predisposition Genes in Tumours Associated with Pathogenic Germline Variants.
    • Lim BWX, Li N, Mahale S, Mcinerny S, Zethoven M, Rowley SM, Huynh J, Wang T, Lee JEA, Friedman M, Devereux L, Scott RJ, Sloan EK, James PA, Campbell IG.
    • J Natl Cancer Inst. 2022 Oct 31:djac196. doi: 10.1093/jnci/djac196. Epub ahead of print.
    • Overlapping gene dependencies for PARP inhibitors and carboplatin response identified by functional CRISPR-Cas9 screening in ovarian cancer.
    • Coelho R, Tozzi A, Disler M, Lombardo F, Fedier A, López MN, Freuler F, Jacob F, Heinzelmann-Schwarz V.
    • Cell Death Dis. 2022 Oct 28;13(10):909. doi: 10.1038/s41419-022-05347-x.
    • Integrative Genomic Tests in Clinical Oncology.
    • Imyanitov E, Sokolenko A.
    • Int J Mol Sci. 2022 Oct 28;23(21):13129. doi: 10.3390/ijms232113129.
    • PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: Whom to Treat?
    • Loguidice CT.
    • OncLive. 2022 Oct 28.
    • Concurrent Olaparib and Radiotherapy in Patients With Triple-Negative Breast Cancer: The Phase 1 Olaparib and Radiation Therapy for Triple-Negative Breast Cancer Trial.
    • Loap P, Loirat D, Berger F, Rodrigues M, Bazire L, Pierga JY, Vincent-Salomon A, Laki F, Boudali L, Raizonville L, Mosseri V, Jochem A, Eeckhoutte A, Diallo M, Stern MH, Fourquet A, Kirova Y.
    • JAMA Oncol. 2022 Oct 27. doi: 10.1001/jamaoncol.2022.5074. Epub ahead of print.

    •• Identifier: NCT03109080: Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC) (RadioPARP). (ClinicalTrials.gov . Accessed 2022 Oct 31.)

    • Optimizing Therapy for Ovarian Cancer: Recent Data Highlights - Episode 7: Novel Maintenance Strategies Being Explored in Advanced Ovarian Cancer Treatment.
    • Monk BJ, Coleman RL, Westin SN, Birrer MJ.
    • OncLive. Peer Exchange. 2022 Oct 27.
    • Replicative Instability Drives Cancer Progression.
    • Morris BB, Smith JP, Zhang Q, Jiang Z, Hampton OA, Churchman ML, Arnold SM, Owen DH, Gray JE, Dillon PM, Soliman HH, Stover DG, Colman H, Chakravarti A, Shain KH, Silva AS, Villano JL, Vogelbaum MA, Borges VF, Akerley WL, Gentzler RD, Hall RD, Matsen CB, Ulrich CM, Post AR, Nix DA, Singer EA, Larner JM, Stukenberg PT, Jones DR, Mayo MW.
    • Biomolecules. 2022 Oct 26;12(11):1570. doi: 10.3390/biom12111570.
    • Recurrent Cervical Cancer Treated Successfully with Single-Agent PARP-Inhibitor, Olaparib.
    • Gross M, Spencer RJ.
    • Case Rep Obstet Gynecol. 2022 Oct 25;2022:6579715. doi: 10.1155/2022/6579715.
    • Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors.
    • Chu YY, Yam C, Yamaguchi H, Hung MC.
    • J Biomed Sci. 2022 Oct 25;29(1):86. doi: 10.1186/s12929-022-00870-7.
    • Efficacy and safety of Gemogenovatucel-T (Vigil) immunotherapy for advanced ovarian carcinoma: A systematic review and meta-analysis of randomized controlled trials.
    • Zhang Y, Zhang L, Zhao Y, Wang S, Feng L.
    • Front Oncol. 2022 Oct 21;12:945867. doi: 10.3389/fonc.2022.945867.

    •• Review registration number: CRD42022300367: Efficacy and safety of Gemogenovatucel-T (Vigil) immunotherapy for advanced ovarian cancer: A systematic review and meta-analysis of randomized controlled trials. (PROSPERO register. Accessed 2022 Nov 7.)

    • Mutational landscape of DNA damage response deficiency-related genes and its association with immune biomarkers in esophageal squamous cell carcinoma.
    • Chen G, Zhu YJ, Chen J, Miao F, Wu N, Song Y, Mao BB, Wang SZ, Xu F, Chen ZM.
    • Neoplasma. 2022 Oct 21:220721N738. doi: 10.4149/neo_2022_220721N738. Epub ahead of print.
    • Optimizing Therapy for Ovarian Cancer: Recent Data Highlights - Episode 5: Niraparib Maintenance Therapy in Ovarian Cancer: The PRIMA Trial.
    • Monk BJ, Coleman RL, Westin SN, Birrer MJ.
    • OncLive. Peer Exchange. 2022 Oct 20.
    • Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984.
    • Kim JW, McKay RR, Radke MR, Zhao S, Taplin ME, Davis NB, Monk P, Appleman LJ, Lara PN Jr, Vaishampayan UN, Zhang J, Paul AK, Bubley G, Van Allen EM, Unlu S, Huang Y, Loda M, Shapiro GI, Glazer PM, LoRusso PM, Ivy SP, Shyr Y, Swisher EM, Petrylak DP.
    • J Clin Oncol. 2022 Oct 18:JCO2102947. doi: 10.1200/JCO.21.02947. Epub ahead of print.

    •• Identifier: NCT02893917: Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer. (ClinicalTrials.gov . Accessed 2022 Oct 19.)

    •• Research news: Cediranib Plus Olaparib Elicits rPFS Benefit in Metastatic Castration-Resistant Prostate Cancer. (OncLive)

    • Rucaparib as a Salvage Treatment in Platinum-Sensitive Relapsed Ovarian Carcinoma: A Case Report.
    • Biswas G.
    • Cureus. 2022 Oct 17;14(10):e30405. doi: 10.7759/cureus.30405.
    • The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment.
    • Li S, Wang L, Wang Y, Zhang C, Hong Z, Han Z.
    • J Hematol Oncol. 2022 Oct 17;15(1):147. doi: 10.1186/s13045-022-01360-x.
    • Optimizing Therapy for Ovarian Cancer: Recent Data Highlights - Episode 3: PARP Inhibitors as Frontline Maintenance Therapy in Ovarian Cancer.
    • Monk BJ, Coleman RL, Westin SN, Birrer MJ.
    • OncLive. Peer Exchange. 2022 Oct 17.
    • Optimizing Therapy for Ovarian Cancer: Recent Data Highlights - Episode 4: Olaparib Combinations for Frontline Maintenance Therapy in Ovarian Cancer Treatment: The PAOLA-1 Trial.
    • Monk BJ, Coleman RL, Westin SN, Birrer MJ.
    • OncLive. Peer Exchange. 2022 Oct 17.
    • The Role of PARP Inhibitors in Patients with Primary Malignant Central Nervous System Tumors.
    • Gueble SE, Vasquez JC, Bindra RS.
    • Curr Treat Options Oncol. 2022 Oct 15. doi: 10.1007/s11864-022-01024-5. Epub ahead of print.
    • Review
    • Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial.
    • Koole SN, Schouten PC, Hauke J, Kluin RJC, Nederlof P, Richters LK, Krebsbach G, Sikorska K, Alkemade M, Opdam M, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, de Hingh IHJT, Mom CH, Arts HJG, van Ham M, van Dam P, Vuylsteke P, Sanders J, Horlings HM, van de Vijver KK, Hahnen E, van Driel WJ, Schmutzler R, Sonke GS, Linn SC.
    • Int J Cancer. 2022 Oct 15;151(8):1394-1404. doi: 10.1002/ijc.34124. Epub 2022 Jun 4.

    Comment, Letter:

    Comments on "Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial".

    Reply, Letter:

    Reply to: Comments on "Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial".

    • Hereditary cancer variants and homologous recombination deficiency in biliary tract cancer.
    • Okawa Y, Iwasaki Y, Johnson TA, Ebata N, Inai C, Endo M, Maejima K, Sasagawa S, Fujita M, Matsuda K, Murakami Y, Nakamura T, Hirano S, Momozawa Y, Nakagawa H.
    • J Hepatol. 2022 Oct 12:S0168-8278(22)03137-3. doi: 10.1016/j.jhep.2022.09.025. Epub ahead of print.
    • Niraparib Maintenance Produces Long-Term Benefit in Advanced Ovarian Cancer, Irrespective of HRD Status.
    • Scott R, González-Martín A.
    • OncLive. 2022 Oct 12.

    Conference abstract:

    530P PRIMA/ENGOT-OV26/GOG-3012 study: Updated long-term PFS and safety.

    Identifier: NCT02655016: A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy. (ClinicalTrials.gov . Accessed 2022 Oct 12.)

    Video: Dr. González-Martín on Updated PFS Data From the PRIMA Trial in Advanced Ovarian Cancer. (OncLive TV)

    • Rucaparib Maintenance in Upfront Ovarian Cancer: The Long-Lasting Challenge of Predicting Response to Poly (ADP-ribose) Polymerase Inhibitors.
    • Marchetti C, Fagotti A, Scambia G.
    • J Clin Oncol. 2022 Oct 6:JCO2201585. doi: 10.1200/JCO.22.01585. Epub ahead of print.

    Letter, Reply:

    Reply to C. Marchetti et al.

    Original research:

    A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45).

    • Ovarian Cancer Therapy: Homologous Recombination Deficiency as a Predictive Biomarker of Response to PARP Inhibitors.
    • Miller RE, Elyashiv O, El-Shakankery KH, Ledermann JA.
    • Onco Targets Ther. 2022 Oct 4;15:1105-1117. doi: 10.2147/OTT.S272199.
    • Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial.
    • Lee JM, Moore RG, Ghamande S, Park MS, Diaz JP, Chapman J, Kendrick J, Slomovitz BM, Tewari KS, Lowe ES, Milenkova T, Kumar S, Dymond M, Brown J, Liu JF.
    • Clin Cancer Res. 2022 Oct 3;28(19):4186-4193. doi: 10.1158/1078-0432.CCR-21-1733.

    Identifier: NCT02889900: Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer (CONCERTO). (ClinicalTrials.gov)

    • Combined inhibition of PARP and EZH2 for cancer treatment: Current status, opportunities, and challenges.
    • Zhang X, Huo X, Guo H, Xue L.
    • Front Pharmacol. 2022 Oct 3;13:965244. doi: 10.3389/fphar.2022.965244.
    • Hyperthermic Intraperitoneal Chemotherapy in the Management of Primary Epithelial Ovarian Cancer: A Debated Issue for Gynecologic Oncologists.
    • Gadducci A, Cosio S, Lippolis PV.
    • Anticancer Res. 2022 Oct;42(10):4659-4665. doi: 10.21873/anticanres.15970.
    • Discovery and validation of a transcriptional signature identifying homologous recombination-deficient breast, endometrial and ovarian cancers.
    • Beinse G, Just PA, Le Frere Belda MA, Laurent-Puig P, Jacques S, Koual M, Garinet S, Leroy K, Delanoy N, Blons H, Gervais C, Durdux C, Chapron C, Goldwasser F, Terris B, Badoual C, Taly V, Bats AS, Borghese B, Alexandre J.
    • Br J Cancer. 2022 Oct;127(6):1123-1132. doi: 10.1038/s41416-022-01900-9. Epub 2022 Jun 25.
    • Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor in patients with newly diagnosed advanced epithelial ovarian cancer: individual patient data and trial-level meta-analysis.
    • Gulia S, Kannan S, Ghosh J, Rath S, Maheshwari A, Gupta S.
    • ESMO Open. 2022 Oct;7(5):100558. doi: 10.1016/j.esmoop.2022.100558. Epub 2022 Aug 22.
    • State of the Biomarker Science in Ovarian Cancer: A National Cancer Institute Clinical Trials Planning Meeting Report.
    • Ethier JL, Fuh KC, Arend R, Konecny GE, Konstantinopoulos PA, Odunsi K, Swisher EM, Kohn EC, Zamarin D.
    • JCO Precis Oncol. 2022 Oct;6:e2200355. doi: 10.1200/PO.22.00355.
    • Review
    • A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes.
    • Gruber JJ, Afghahi A, Timms K, DeWees A, Gross W, Aushev VN, Wu HT, Balcioglu M, Sethi H, Scott D, Foran J, McMillan A, Ford JM, Telli ML.
    • Nat Cancer. 2022 Oct;3(10):1181-1191. doi: 10.1038/s43018-022-00439-1. Epub 2022 Oct 17.

    •• Identifier: NCT02401347: Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors. (ClinicalTrials.gov . Accessed 2022 Oct 18.)

    •• Identifier: NCT04756765: Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer. (ClinicalTrials.gov . Accessed 2022 Oct 18.)

    •• Research news: Study Suggests a PARP Inhibitors Has Wider Cancer Applications. (Inside Precision Medicine)

    • Signatures associated with homologous recombination deficiency and immune regulation to improve clinical outcomes in patients with lung adenocarcinoma.
    • Shang X, Qi K, Liu X, Liu Q, Zhang X, Wang D, Huang W.
    • Front Oncol. 2022 Sep 30;12:854999. doi: 10.3389/fonc.2022.854999.
    • Clinicogenomic characteristics and synthetic lethal implications of germline homologous recombination-deficient HCC.
    • An J, Oh JH, Oh B, Oh YJ, Ju JS, Kim W, Kang HJ, Sung CO, Shim JH.
    • Hepatology. 2022 Sep 30. doi: 10.1002/hep.32812. Epub ahead of print.
    • Homologous recombination deficiency (HRD) as an ovarian cancer biomarker in a real-world cohort - validation of decentralized genomic profiling.
    • Denkert C, Romey M, Swedlund B, Hattesohl A, Teply-Szymanski J, Kommoss S, Kaiser K, Staebler A, du Bois A, Grass A, Knappmeyer C, Heitz F, Solimeno C, Ebel T, Harter P, Marmé F, Jank P, Gaiser T, Neff C, Wagner U, Timms KM, Rodepeter F.
    • J Mol Diagn. 2022 Sep 30:S1525-1578(22)00266-5. doi: 10.1016/j.jmoldx.2022.09.004. Epub ahead of print.
    • Recent advances in cancer therapy using PARP inhibitors.
    • Kaur SD, Chellappan DK, Aljabali AA, Tambuwala M, Dua K, Kapoor DN.
    • Med Oncol. 2022 Sep 30;39(12):241. doi: 10.1007/s12032-022-01840-7.
    • Review
    • PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage Signatures.
    • McNevin CS, Cadoo K, Baird AM, Finn SP, McDermott R.
    • Cancers (Basel). 2022 Sep 29;14(19):4751. doi: 10.3390/cancers14194751.
    • Deciphering the expression patterns of homologous recombination-related lncRNAs identifies new molecular subtypes and emerging therapeutic opportunities in epithelial ovarian cancer.
    • Hua T, Zhang XC, Wang W, Tian YJ, Chen SB.
    • Front Genet. 2022 Sep 29;13:901424. doi: 10.3389/fgene.2022.901424.
    • Integrated proteomics identifies PARP inhibitor-induced pro-survival signaling changes as potential vulnerabilities in ovarian cancer.
    • Deng O, Dash S, Nepomuceno TC, Fang B, Yun SY, Welsh EA, Lawrence HR, Marchion D, Koomen JM, Monteiro AN, Rix U.
    • J Biol Chem. 2022 Sep 29:102550. doi: 10.1016/j.jbc.2022.102550. Epub ahead of print.
    • HRD-MILN: Accurately estimate tumor homologous recombination deficiency status from targeted panel sequencing data.
    • Wang X, Xu Y, Zhang Y, Wang S, Zhang X, Yi X, Zhang S, Wang J.
    • Front Genet. 2022 Sep 28;13:990244. doi: 10.3389/fgene.2022.990244.
    • Alterations in Homologous Recombination-Related Genes and Distinct Platinum Response in Metastatic Triple-Negative Breast Cancers: A Subgroup Analysis of the ProfiLER-01 Trial.
    • Bonnet E, Haddad V, Quesada S, Baffert KA, Lardy-Cléaud A, Treilleux I, Pissaloux D, Attignon V, Wang Q, Buisson A, Heudel PE, Bachelot T, Dufresne A, Eberst L, Toussaint P, Bonadona V, Lasset C, Viari A, Sohier E, Paindavoine S, Combaret V, Pérol D, Ray-Coquard I, Blay JY, Trédan O.
    • J Pers Med. 2022 Sep 27;12(10):1595. doi: 10.3390/jpm12101595.
    • Precision medicine in the real-world setting. Clinical activity of talazoparib in a woman with hormone receptor-positive HER2-negative metastatic breast cancer with pathogenic mutation in somatic BRCA2.
    • Narváez D, Waisberg F, Soulé T, Angel M, Bruno L, Girotti MR, Pupareli C, Chacón M, Petracci FE.
    • Ecancermedicalscience. 2022 Sep 26;16:1448. doi: 10.3332/ecancer.2022.1448.
    • Deep-Learning to Predict BRCA Mutation and Survival from Digital H&E Slides of Epithelial Ovarian Cancer.
    • Nero C, Boldrini L, Lenkowicz J, Giudice MT, Piermattei A, Inzani F, Pasciuto T, Minucci A, Fagotti A, Zannoni G, Valentini V, Scambia G.
    • Int J Mol Sci. 2022 Sep 26;23(19):11326. doi: 10.3390/ijms231911326.
    • Using Patient-Derived Xenograft (PDX) Models as a ‘Black Box’ to Identify More Applicable Patients for ADP-Ribose Polymerase Inhibitor (PARPi) Treatment in Ovarian Cancer: Searching for Novel Molecular and Clinical Biomarkers and Performing a Prospective Preclinical Trial.
    • Chen J, Li Y, Wang H, Li T, Gu Y, Wang W, Shan Y, Yin J, Wang Y, Qin M, Li S, Pan L, Peng S, Jin Y.
    • Cancers (Basel). 2022 Sep 24;14(19):4649. doi: 10.3390/cancers14194649.
    • Targeting Homologous Recombination Deficiency in Ovarian Cancer with PARP Inhibitors: Synthetic Lethal Strategies That Impact Overall Survival.
    • Xie T, Dickson KA, Yee C, Ma Y, Ford CE, Bowden NA, Marsh DJ.
    • Cancers (Basel). 2022 Sep 23;14(19):4621. doi: 10.3390/cancers14194621.
    • Poly(ADP-Ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: ASCO Guideline Rapid Recommendation Update.
    • Tew WP, Lacchetti C, Kohn EC; PARP Inhibitors in the Management of Ovarian Cancer Guideline Expert Panel.
    • J Clin Oncol. 2022 Sep 23:JCO2201934. doi: 10.1200/JCO.22.01934. Epub ahead of print.
    • Preclinical and clinical trial results using Talazoparib and Low-Dose Chemotherapy.
    • Wainberg ZA, Singh AS, Konecny GE, McCann KE, Hecht JR, Goldman J, Chmielowski B, Finn RS, O'Brien N, von Euw E, Price MM, Martinez D, Yonemoto L, Brennan M, Glaspy JA, Slamon DJ.
    • Clin Cancer Res. 2022 Sep 22:CCR-22-1553. doi: 10.1158/1078-0432.CCR-22-1553. Epub ahead of print.
    • Germline BRCA mutation carriers are more likely to undergo cytoreductive surgery for relapsed, platinum sensitive, ovarian cancer.
    • Kadan Y, Kotait M, Beiner M, Hirte H, Josephy D, Salman L, Bruchim I, Pond G, Helpman L.
    • Gynecol Oncol. 2022 Sep 22:S0090-8258(22)00574-1. doi: 10.1016/j.ygyno.2022.08.020. Epub ahead of print.
    • Niraparib-induced STAT3 inhibition increases its antitumor effects.
    • Yu HE, Rodriguez-Rodriguez L, Zhao Q, Kohut A, Li YJ, Martincuks A, Austria T, Zhang C, Santiago NL, Borrero RM, Phan XT, Melstrom L.
    • Front Oncol. 2022 Sep 21;12:966492. doi: 10.3389/fonc.2022.966492.
    • Targeted molecular profiling of epithelial ovarian cancer from Italian BRCA wild-type patients with a BRCA and PARP pathways gene panel.
    • Salvati A, Carnevali I, Alexandrova E, Facchi S, Ronchi S, Libera L, Sahnane N, Memoli D, Lamberti J, Amabile S, Pepe S, Tarallo R, Sessa F, Weisz A, Tibiletti MG, Rizzo F.
    • Exp Mol Pathol. 2022 Sep 20;128:104833. doi: 10.1016/j.yexmp.2022.104833. Epub ahead of print.
    • Enhanced Antitumoral Activity of Encapsulated BET Inhibitors When Combined with PARP Inhibitors for the Treatment of Triple-Negative Breast and Ovarian Cancers.
    • Juan A, Noblejas-López MDM, Bravo I, Arenas-Moreira M, Blasco-Navarro C, Clemente-Casares P, Lara-Sánchez A, Pandiella A, Alonso-Moreno C, Ocaña A.
    • Cancers (Basel). 2022 Sep 15;14(18):4474. doi: 10.3390/cancers14184474.
    • Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling of cell-free DNA.
    • Swami U, Zimmerman RM, Nussenzveig RH, Hernandez EJ, Jo Y, Sayegh N, Wesolowski S, Kiedrowski LA, Barata PC, Lemmon GH, Bilen MA, Heath EI, Nandagopal L, Babiker HM, Pal SK, Lilly M, Maughan BL, Haaland B, Yandell M, Sartor O, Agarwal N.
    • Front Oncol. 2022 Sep 15;12:966534. doi: 10.3389/fonc.2022.966534.

    •• Commentary:

    Editorial: Prostate Cancer Genomics: Application at Different Stages of a Patient's Journey.

    • Genetic and functional homologous repair deficiency as biomarkers for platinum sensitivity in TNBC: a case report.
    • Gomez-Puerto D, Llop-Guevara A, Cruellas M, Torres-Esquius S, De La Torre J, Peg V, Balmaña J, Pimentel I.
    • Front Oncol. 2022 Sep 14;12:963728. doi: 10.3389/fonc.2022.963728.
    • B7-H3 as a Therapeutic Target in Advanced Prostate Cancer.
    • Guo C, Figueiredo I, Gurel B, Neeb A, Seed G, Crespo M, Carreira S, Rekowski J, Buroni L, Welti J, Bogdan D, Gallagher L, Sharp A, Fenor de la Maza MD, Rescigno P, Westaby D, Chandran K, Riisnaes R, Ferreira A, Miranda S, Calì B, Alimonti A, Bressan S, Nguyen AHT, Shen MM, Hawley JE, Obradovic A, Drake CG, Bertan C, Baker C, Tunariu N, Yuan W, de Bono JS.
    • Eur Urol. 2022 Sep 13:S0302-2838(22)02633-1. doi: 10.1016/j.eururo.2022.09.004. Epub ahead of print.
    • Imaging Agent May Have Potential as Noninvasive Test to Predict PARP Inhibitor Response.
    • Hopkins C.
    • Precision Oncology News. 2022 Sep 13.
    • Molecular Characterization of Adenocarcinomas Arising in the Urinary Bladder Following Augmentation Cystoplasty: A Multi-Institutional Study.
    • Stohr BA, Chan E, Anderson JA, Matoso A, Murati Amador BI, Cheng L, Osunkoya AO.
    • Hum Pathol. 2022 Sep 12:S0046-8177(22)00228-3. doi: 10.1016/j.humpath.2022.09.003. Epub ahead of print.
    • Multicenter Real-World Data of Subsequent Chemotherapy after Progression to PARP Inhibitors in a Maintenance Relapse Setting.
    • Romeo M, Gil-Martín M, Gaba L, Teruel I, Taus Á, Fina C, Masvidal M, Murata P, Fernández-Plana J, Martínez A, Pérez C, García Y, Rodriguez V, Cros S, Parera M, Zanui M, Catot S, Pardo B, Plaja A, Esteve A, Barretina-Ginesta MP.
    • Cancers (Basel). 2022 Sep 11;14(18):4414. doi: 10.3390/cancers14184414.
    • Lynparza Presents Possibility of Cure for Some Patients With Biomarker-Defined Ovarian Cancer.
    • Kanski A.
    • Precision Oncology News. Disease Areas. 2022 Sep 10.
    • Conference report
    • Constitutional BRCA1 Methylation and Risk of Incident Triple-Negative Breast Cancer and High-grade Serous Ovarian Cancer.
    • Lønning PE, Nikolaienko O, Pan K, Kurian AW, Eikesdal HP, Pettinger M, Anderson GL, Prentice RL, Chlebowski RT, Knappskog S.
    • JAMA Oncol. 2022 Sep 8. doi: 10.1001/jamaoncol.2022.3846. Epub ahead of print.
    • PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond.
    • Menezes MCS, Raheem F, Mina L, Ernst B, Batalini F.
    • Cancers (Basel). 2022 Sep 5;14(17):4332. doi: 10.3390/cancers14174332.
    • Evolutionary Trajectories of Primary and Metastatic Pancreatic Neuroendocrine Tumors Based on Genomic Variations.
    • Xu M, Yan J, Hu B, Wu C, Gu H, Qi Z, Chen T, Yang W, Zheng Y, Dong H, Sheng W, Long J.
    • Genes (Basel). 2022 Sep 4;13(9):1588. doi: 10.3390/genes13091588.
    • Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial.
    • González-Martín A, Desauw C, Heitz F, Cropet C, Gargiulo P, Berger R, Ochi H, Vergote I, Colombo N, Mirza MR, Tazi Y, Canzler U, Zamagni C, Guerra-Alia EM, Levaché CB, Marmé F, Bazan F, de Gregorio N, Dohollou N, Fasching PA, Scambia G, Rubio-Pérez MJ, Milenkova T, Costan C, Pautier P, Ray-Coquard I; PAOLA1/ENGOT-ov25 investigators.
    • Eur J Cancer. 2022 Sep 3;174:221-231. doi: 10.1016/j.ejca.2022.07.022. Epub ahead of print.
    • 530P PRIMA/ENGOT-OV26/GOG-3012 study: Updated long-term PFS and safety.
    • Gonzalez Martin AJ, Pothuri B, Vergote IB, Graybill W, Mirza MR, Mccormick C, Lorusso D, Freyer G, Backes F, Baumann KH, Redondo Sanchez A, Moore RG, Vulsteke C, O'Cearbhaill RE, Malinowska I, Shtessel L, Compton N, Monk BJ.
    • Ann Oncol. 2022 Sep 1;33(7 Suppl):S789. doi: 10.1016/j.annonc.2022.07.658.
    • Conference abstract

    Identifier: NCT02655016: A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy. (ClinicalTrials.gov . Accessed 2022 Oct 12.)

    Conference news: Niraparib Maintenance Produces Long-Term Benefit in Advanced Ovarian Cancer, Irrespective of HRD Status. (OncLive)

    • Mutational signature 3 detected from clinical panel sequencing is associated with responses to olaparib in breast and ovarian cancers.
    • Batalini F, Gulhan DC, Mao V, Tran A, Polak M, Xiong N, Tayob N, Tung NM, Winer EP, Mayer EL, Knappskog S, Lønning PE, Matulonis UA, Konstantinopoulos PA, Solit DB, Won H, Eikesdal HP, Park PJ, Wulf GM.
    • Clin Cancer Res. 2022 Sep 1:CCR-22-0749. doi: 10.1158/1078-0432.CCR-22-0749. Epub ahead of print.

    Identifier: NCT01623349: Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer. (ClinicalTrials.gov)

    Identifier: NCT02624973: PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial (PETREMAC). (ClinicalTrials.gov)

    • Metastatic involvement of inguinal lymph nodes as the first sign of endometroid carcinoma of the fallopian tube.
    • Maradová E, Jánošík M, Pilka R, Marek R.
    • Ceska Gynekol. 2022 Fall;87(5):328-332. English. doi: 10.48095/cccg2022328.
    • Case report
    • Upregulation of CXCL1 and LY9 contributes to BRCAness in ovarian cancer and mediates response to PARPi and immune checkpoint blockade.
    • Chen T, Yu T, Zhuang S, Geng Y, Xue J, Wang J, Ai L, Chen B, Zhao Z, Li Y, Wang J, Liang H, Xu Y, Gu Y.
    • Br J Cancer. 2022 Sep;127(5):916-926. doi: 10.1038/s41416-022-01836-0. Epub 2022 May 26.
    • Reconsidering the mechanisms of action of PARP inhibitors based on clinical outcomes.
    • Onji H, Murai J.
    • Cancer Sci. 2022 Sep;113(9):2943-2951. doi: 10.1111/cas.15477. Epub 2022 Jul 16.
    • Maintenance therapy with PARP inhibition in ovarian cancer.
    • Herzog TJ.
    • Clin Adv Hematol Oncol. 2022 Sep;20(9):539-541.
    • Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer.
    • Clarke NW, Armstrong AJ, Thiery-Vuillemin A, Oya M, Shore N, Loredo E Procopio G, de Menezes J, Girotto G, Arslan C, Mehra N, Parnis F, Brown E, Schlürmann F, Joung JY, Sugimoto M, Virizuela JA, Emmenegger U, Navratil J, Buchschacher GL, Poehlein C, Harrington EA, Desai C, Kang J, Saad F, for the PROpel Investigators.
    • NEJM Evid. 2022 Sep;1(9):EVIDoa2200043. doi: 10.1056/EVIDoa2200043. Epub 2022 Jun 3.

    •• Identifier: NCT03732820: Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer. (ClinicalTrials.gov . Accessed 2023 Feb 18.)

    •• Commentary: Should We “PROpel” Olaparib Forward for Metastatic Castration-Resistant Prostate Cancer? (NEJM Evidence)

    • Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis.
    • Cadoo K, Simpkins F, Mathews C, Liu YL, Provencher D, McCormick C, ElNaggar AC, Altman AD, Gilbert L, Black D, Kabil N, Bennett J, Munley J, Aghajanian C.
    • Gynecol Oncol. 2022 Sep;166(3):425-431. doi: 10.1016/j.ygyno.2022.06.017. Epub 2022 Jul 5.

    Identifier: NCT02983799: Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status. (ClinicalTrials.gov)

    • RAD54B mutations enhance the sensitivity of ovarian cancer cells to poly(ADP-ribose) polymerase (PARP) inhibitors.
    • Liu P, Lin C, Liu L, Lu Z, Tu Z, Liu H.
    • J Biol Chem. 2022 Sep;298(9):102354. doi: 10.1016/j.jbc.2022.102354. Epub 2022 Aug 9.
    • Peritoneal dissemination of high-grade serous ovarian cancer: pivotal roles of chromosomal instability and epigenetic dynamics.
    • Konishi I, Abiko K, Hayashi T, Yamanoi K, Murakami R, Yamaguchi K, Hamanishi J, Baba T, Matsumura N, Mandai M; Kyoto Study Group for Ovarian Cancer Research.
    • J Gynecol Oncol. 2022 Sep;33(5):e83. doi: 10.3802/jgo.2022.33.e83.
    • Clinico-genomic characterization of ATM and HRD in Pancreas Cancer: Application for Practice.
    • Park W, O'Connor CA, Bandlamudi C, Forman D, Chou JF, Umeda S, Reyngold M, Varghese AM, Keane F, Balogun F, Yu KH, Kelsen DP, Crane C, Capanu M, Iacobuzio-Donahue C, O'Reilly EM.
    • Clin Cancer Res. 2022 Aug 30:CCR-22-1483. doi: 10.1158/1078-0432.CCR-22-1483. Epub ahead of print.
    • Homologous Recombination Deficiency Scar: Mutations and Beyond—Implications for Precision Oncology.
    • van der Wiel AMA, Schuitmaker L, Cong Y, Theys J, Van Hoeck A, Vens C, Lambin P, Yaromina A, Dubois LJ.
    • Cancers (Basel). 2022 Aug 27;14(17):4157. doi: 10.3390/cancers14174157.
    • Bioinformatics: From NGS Data to Biological Complexity in Variant Detection and Oncological Clinical Practice.
    • Dotolo S, Esposito Abate R, Roma C, Guido D, Preziosi A, Tropea B, Palluzzi F, Giacò L, Normanno N.
    • Biomedicines. 2022 Aug 24;10(9):2074. doi: 10.3390/biomedicines10092074.
    • Updated Neoadjuvant Treatment Landscape for Early Triple Negative Breast Cancer: Immunotherapy, Potential Predictive Biomarkers, and Novel Agents.
    • Garufi G, Carbognin L, Schettini F, Seguí E, Di Leone A, Franco A, Paris I, Scambia G, Tortora G, Fabi A.
    • Cancers (Basel). 2022 Aug 23;14(17):4064. doi: 10.3390/cancers14174064.
    • Disparities in Biomarker Testing in Ovarian Cancer: A Real-World Analysis.
    • Bodurtha Smith AJ, Alvarez R, Heintz J, Haggerty A, Ko EM.
    • Am J Obstet Gynecol. 2022 Aug 22:S0002-9378(22)00686-X. doi: 10.1016/j.ajog.2022.08.043. Epub ahead of print.
    • Impact of homologous recombination deficiency biomarkers on outcomes in patients with early breast cancer: a systematic review protocol.
    • Liao H, Pei W, Zhong J, Li H.
    • BMJ Open. 2022 Aug 18;12(8):e059538. doi: 10.1136/bmjopen-2021-059538.
    • Japanese nationwide observational multicenter study of tumor BRCA1/2 variant testing in advanced ovarian cancer.
    • Oda K, Aoki D, Tsuda H, Nishihara H, Aoyama H, Inomata H, Shimada M, Enomoto T.
    • Cancer Sci. 2022 Aug 17. doi: 10.1111/cas.15518. Epub ahead of print.
    • Lynparza in combination with abiraterone granted Priority Review in the US for patients with metastatic castration-resistant prostate cancer.
    • Kemp A.
    • AstraZeneca. Media. Press Releases. 2022 Aug 16.
    • The disruption of the CCDC6 - PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma.
    • Morra F, Merolla F, Damia G, Ricci F, Varricchio S, Ilardi G, Arenare L, Califano D, Napolitano V, Fruscio R, Melillo RM, Palazzo L, Celetti A.
    • J Exp Clin Cancer Res. 2022 Aug 13;41(1):245. doi: 10.1186/s13046-022-02459-2.
    • A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma.
    • Crabb SJ, Hussain S, Soulis E, Hinsley S, Dempsey L, Trevethan A, Song Y, Barber J, Frew J, Gale J, Faust G, Brock S, McGovern U, Parikh O, Enting D, Sundar S, Ratnayake G, Lees K, Birtle AJ, Powles T, Jones RJ.
    • J Clin Oncol. 2022 Aug 12:JCO2200405. doi: 10.1200/JCO.22.00405. Epub ahead of print.
    • Further refining 2020 ESGO/ESTRO/ESP molecular risk classes in patients with early-stage endometrial cancer: A propensity score-matched analysis.
    • Nero C, Pasciuto T, Cappuccio S, Corrado G, Pelligra S, Zannoni GF, Santoro A, Piermattei A, Minucci A, Lorusso D, Fanfani F, Scambia G.
    • Cancer. 2022 Aug 1;128(15):2898-2907. doi: 10.1002/cncr.34331. Epub 2022 May 26.

    Commentary:

    Molecular classification in endometrial cancer: Opportunities for precision oncology in a changing landscape.

    • Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma.
    • Rimini M, Macarulla T, Burgio V, Lonardi S, Niger M, Scartozzi M, Rapposelli IG, Aprile G, Ratti F, Pedica F, Verdaguer H, Nappo F, Nichetti F, Lai E, Valgiusti M, Cappetta A, Febregat C, Fassan M, De Braud F, Puzzoni M, Frassineti GL, Simionato F, De Cobelli F, Aldrighetti L, Fornaro L, Cascinu S, Casadei-Gardini A.
    • Eur J Cancer. 2022 Aug;171:232-241. doi: 10.1016/j.ejca.2022.05.004. Epub 2022 Jun 21.
    • Optimizing treatment selection and sequencing decisions for first-line maintenance therapy of newly diagnosed advanced ovarian cancer.
    • Goh JCH, Gourley C, Tan DSP, Nogueira-Rodrigues A, Elghazaly H, Edy Pierre M, Giornelli G, Kim BG, Morales-Vasquez F, Tyulyandina A.
    • Gynecol Oncol Rep. 2022 Jun 17 [eCollection 2022 Aug];42:101028. doi: 10.1016/j.gore.2022.101028.
    • In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD Focus panel with Myriad myChoiceCDx assay.
    • Fumagalli C, Betella I, Ranghiero A, Guerini-Rocco E, Bonaldo G, Rappa A, Vacirca D, Colombo N, Barberis M.
    • Pathologica. 2022 Aug;114(4):288-294. doi: 10.32074/1591-951X-791.
    • Targeted Mutational Analysis of Circulating Tumor DNA to Decipher Temporal Heterogeneity of High-Grade Serous Ovarian Cancer.
    • Paracchini L, Mannarino L, Beltrame L, Landoni F, Fruscio R, Grassi T, Dalessandro ML, D'Incalci M, Marchini S.
    • Cancers (Basel). 2022 Jul 29;14(15):3697. doi: 10.3390/cancers14153697.
    • Whole-genome/exome analysis of circulating tumor DNA and comparison to tumor genomics from patients with heavily pre-treated ovarian cancer: subset analysis of the PERMED-01 trial.
    • Sabatier R, Garnier S, Guille A, Carbuccia N, Pakradouni J, Adelaide J, Provansal M, Cappiello M, Rousseau F, Chaffanet M, Birnbaum D, Mamessier E, Gonçalves A, Bertucci F.
    • Front Oncol. 2022 Jul 29;12:946257. doi: 10.3389/fonc.2022.946257.

    Identifier: NCT02342158: Identifying Molecular Alterations to Guide Individualized Treatment in Advanced Solid Tumors (PERMED01). (ClinicalTrials.gov)

    • Maintenance therapy for newly diagnosed epithelial ovarian cancer- a review.
    • Nag S, Aggarwal S, Rauthan A, Warrier N.
    • J Ovarian Res. 2022 Jul 28;15(1):88. doi: 10.1186/s13048-022-01020-1.
    • CA-125 KELIM as a Potential Complementary Tool for Predicting Veliparib Benefit: An Exploratory Analysis From the VELIA/GOG-3005 Study.
    • You B, Sehgal V, Hosmane B, Huang X, Ansell PJ, Dinh MH, Bell-McGuinn K, Luo X, Fleming GF, Friedlander M, Bookman MA, Moore KN, Steffensen KD, Coleman RL, Swisher EM.
    • J Clin Oncol. 2022 Jul 22:JCO2200430. doi: 10.1200/JCO.22.00430. Epub ahead of print.
    • A Systematic Review and Meta-Analysis on the Prognostic Value of BRCA Mutations, Homologous Recombination Gene Mutations, and Homologous Recombination Deficiencies in Cancer.
    • Shao C, Chang MS, Lam FC, Marley AR, Tang H, Song Y, Miller C, Brown M, Wan I, Han J, Adeboyeje G.
    • J Oncol. 2022 Jul 20;2022:5830475. doi: 10.1155/2022/5830475.
    • Comprehensive Genomic Profiling in the Management of Ovarian Cancer-National Results from Croatia.
    • Cerina D, Matkovic V, Katic K, Belac Lovasic I, Šeparovic R, Canjko I, Bajic Ž, Vrdoljak E.
    • J Pers Med. 2022 Jul 19;12(7):1176. doi: 10.3390/jpm12071176.
    • Genetic Testing and Its Clinical Application in Prostate Cancer Management: Consensus Statements from the Hong Kong Urological Association and Hong Kong Society of Uro-Oncology.
    • Chiu PKF, Lee EKC, Chan MTY, Chan WHC, Cheung MH, Lam MHC, Ma ESK, Poon DMC.
    • Front Oncol. 2022 Jul 18;12:962958. doi: 10.3389/fonc.2022.962958.

    •• Commentary:

    Editorial: Prostate Cancer Genomics: Application at Different Stages of a Patient's Journey.

    • Clinical use of PARP inhibitor in recurrent uterine leiomyosarcoma with presence of a somatic BRCA2 mutation.
    • Shammas N, Yang T, Abidi A, Amneus M, Hodeib M.
    • Gynecol Oncol Rep. 2022 Jul 14;42:101044. doi: 10.1016/j.gore.2022.101044.
    • Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer.
    • Revythis A, Limbu A, Mikropoulos C, Ghose A, Sanchez E, Sheriff M, Boussios S.
    • Int J Environ Res Public Health. 2022 Jul 14;19(14):8577. doi: 10.3390/ijerph19148577.
    • Oncologists Seeing Lack of PARP Inhibitor Response in MSI-High, BRCA-Mutant Prostate Cancer Patients.
    • Kanski A.
    • Precision Oncology News. Biomarkers. BRCA. 2022 Jul 13.
    • Research news

    Original research:

    PARP Inhibitor Insensitivity to BRCA1/2 Monoallelic Mutations in Microsatellite Instability-High Cancers.

    • Cost-Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Cancer Treatment: A Systematic Review.
    • Chan VKY, Yang R, Wong ICK, Li X.
    • Front Pharmacol. 2022 Jul 11;13:891149. doi: 10.3389/fphar.2022.891149.
    • Expression of DNA Helicase Genes Was Correlated with Homologous Recombination Deficiency in Breast Cancer.
    • Long M, Liu H, Wu J, Wang S, Liao X, Liu Y, Hu T.
    • Comput Math Methods Med. 2022 Jul 9;2022:5508301. doi: 10.1155/2022/5508301.
    • Exploiting replication gaps for cancer therapy.
    • Cong K, Cantor SB.
    • Mol Cell. 2022 Jul 7;82(13):2363-2369. doi: 10.1016/j.molcel.2022.04.023. Epub 2022 May 13.
    • Templated Insertions Are Associated Specifically with BRCA2 Deficiency and Overall Survival in Advanced Ovarian Cancer.
    • Moore G, Majumdar R, Powell SN, Khan AJ, Weinhold N, Yin S, Higginson DS.
    • Mol Cancer Res. 2022 Jul 6;20(7):1061-1070. doi: 10.1158/1541-7786.MCR-21-1012.
    • Genomic and epigenomic BRCA alterations predict adaptive resistance and response to platinum-based therapy in patients with triple-negative breast and ovarian carcinomas.
    • Menghi F, Banda K, Kumar P, Straub R, Dobrolecki L, Rodriguez IV, Yost SE, Chandok H, Radke MR, Somlo G, Yuan Y, Lewis MT, Swisher EM, Liu ET.
    • Sci Transl Med. 2022 Jul 6;14(652):eabn1926. doi: 10.1126/scitranslmed.abn1926. Epub 2022 Jul 6.

    Research news: Breast, Ovarian Cancer Study Finds Ties Between Types of BRCA Alterations, Treatment Response. (Precision Oncology News)

    • Rational design, synthesis and biological evaluation of dual PARP-1/2 and TNKS1/2 inhibitors for cancer therapy.
    • Xu Y, Wu H, Huang L, Zhai B, Li X, Xu S, Wu X, Zhu Q, Xu Q.
    • Eur J Med Chem. 2022 Jul 5;237:114417. doi: 10.1016/j.ejmech.2022.114417. Epub 2022 Apr 27.
    • Treatment patterns after poly-ADP ribose polymerase (PARP) inhibitors in epithelial ovarian cancer patients.
    • Sivakumaran T, Krasovitsky M, Freimund A, Lee YC, Webber K, So J, Norris C, Friedlander M, Mileshkin L, Au-Yeung G.
    • Int J Gynecol Cancer. 2022 Jul 4;32(7):906-912. doi: 10.1136/ijgc-2021-003009.
    • Comparison of Survival Outcomes According to BRCA1/2 Variant Type in High-grade Serous Ovarian Cancer.
    • Lee J, Kim JM, Lee YH, Chong GO, Lee NY, Lee IH, Park JY, Hong DG.
    • In Vivo. 2022 Jul-Aug;36(4):1903-1910. doi: 10.21873/invivo.12910.
    • A Phase II Trial to Evaluate the Efficacy of Bortezomib and Liposomal Doxorubicin in Patients With BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer (KGOG 3044/EBLIN).
    • Lee YJ, Seol A, Lee M, Kim JW, Kim HS, Kim K, Suh DH, Kim S, Kim SW, Lee JY.
    • In Vivo. 2022 Jul-Aug;36(4):1949-1958. doi: 10.21873/invivo.12917.

    Identifier: NCT03509246: Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Patients. (ClinicalTrials.gov)

    • A comprehensive literature review and meta-analysis of the prevalence of pan-cancer BRCA mutations, homologous recombination repair gene mutations, and homologous recombination deficiencies.
    • Shao C, Wan J, Lam FC, Tang H, Marley AR, Song Y, Miller C, Brown M, Han J, Adeboyeje G.
    • Environ Mol Mutagen. 2022 Jul;63(6):308-316. doi: 10.1002/em.22505. Epub 2022 Aug 30.
    • BRCA2 Alterations in Neuroendocrine/Small-Cell Carcinoma Prostate Cancer: A Case Series.
    • Symonds L, Konnick E, Vakar-Lopez F, Cheng HH, Schweizer MT, Nelson PS, Pritchard CC, Montgomery B.
    • JCO Precis Oncol. 2022 Jul;6:e2200091. doi: 10.1200/PO.22.00091.
    • Case report
    • Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting Therapies.
    • Zurita AJ, Graf RP, Villacampa G, Raskina K, Sokol E, Jin D, Antonarakis ES, Li G, Huang RSP, Casanova-Salas I, Vivancos A, Carles J, Ross JS, Schrock AB, Oxnard GR, Mateo J.
    • JCO Precis Oncol. 2022 Jul;6:e2200195. doi: 10.1200/PO.22.00195.
    • Biomarker-guided targeted therapy in platinum-resistant ovarian cancer (AMBITION; KGOG 3045): a multicentre, open-label, five-arm, uncontrolled, umbrella trial.
    • Lee JY, Kim BG, Kim JW, Lee JB, Park E, Joung JG, Kim S, Choi CH, Kim HS; Korean Gynecologic Oncology Group (KGOG) investigators.
    • J Gynecol Oncol. 2022 Jul;33(4):e45. doi: 10.3802/jgo.2022.33.e45. Epub 2022 Mar 4.

    Identifier: NCT03699449: An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION). (ClinicalTrials.gov)

    Commentary:

    A step towards the ambition of precision oncology in recurrent ovarian cancer.

    • Phase II study of niraparib in recurrent or persistent rare fraction of gynecologic malignancies with homologous recombination deficiency (JGOG2052).
    • Asano H, Oda K, Yoshihara K, Ito YM, Matsumura N, Shimada M, Watari H, Enomoto T.
    • J Gynecol Oncol. 2022 Jul;33(4):e55. doi: 10.3802/jgo.2022.33.e55. Epub 2022 May 3.

    Trial ID: jRCT2031210264: Phase 2 Study to Evaluate the Efficacy and Safety of Niraparib in Recurrent or Persistent Rare Gynecologic Malignancies with Homologous Recombination Deficiency (JGOG2052). (Japanese Registry of Clinical Trials)

    • Germline Aberrations in Pancreatic Cancer: Implications for Clinical Care.
    • Casolino R, Corbo V, Beer P, Hwang CI, Paiella S, Silvestri V, Ottini L, Biankin AV.
    • Cancers (Basel). 2022 Jun 30;14(13):3239. doi: 10.3390/cancers14133239.
    • PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer.
    • Dillon KM, Bekele RT, Sztupinszki Z, Hanlon T, Rafiei S, Szallasi Z, Choudhury AD, Mouw KW.
    • NPJ Precis Oncol. 2022 Jun 29;6(1):49. doi: 10.1038/s41698-022-00291-7.
    • Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU).
    • Rosenberg JE, Park SH, Kozlov V, Dao TV, Castellano D, Li JR, Mukherjee SD, Howells K, Dry H, Lanasa MC, Stewart R, Bajorin DF.
    • J Clin Oncol. 2022 Jun 23:JCO2200205. doi: 10.1200/JCO.22.00205. Epub ahead of print.
    • A patient with relapsed high-grade serous ovarian carcinoma with somatic RAD51C mutations treated with PARPi monotherapy: a case report.
    • Ngu SF, Ngan HYS, Chan KKL.
    • Cancer Drug Resist. 2022 Jun 22;5(3):662-666. doi: 10.20517/cdr.2022.12.
    • A Japanese case of castration-resistant prostate cancer with BRCA2 and RB1 co-loss and TP53 mutation: a case report.
    • Iwasawa T, Kosaka T, Morita S, Mikami S, Nakamura K, Hongo H, Nishihara H, Oya M.
    • BMC Med Genomics. 2022 Jun 20;15(1):138. doi: 10.1186/s12920-022-01286-w.
    • Investigation of BRCAness associated miRNA-gene axes in breast cancer: cell-free miR-182-5p as a potential expression signature of BRCAness.
    • Darbeheshti F, Kadkhoda S, Keshavarz-Fathi M, Razi S, Bahramy A, Mansoori Y, Rezaei N.
    • BMC Cancer. 2022 Jun 17;22(1):668. doi: 10.1186/s12885-022-09761-4.
    • A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers.
    • Tinker AV, Altman AD, Bernardini MQ, Ghatage P, Gien LT, Provencher D, Salvador S, Doucette S, Oza AM.
    • Curr Oncol. 2022 Jun 17;29(6):4354-4369. doi: 10.3390/curroncol29060348.
    • The Great Majority of Homologous Recombination Repair-Deficient Tumors Are Accounted for by Established Causes.
    • Štancl P, Hamel N, Sigel KM, Foulkes WD, Karlic R, Polak P.
    • Front Genet. 2022 Jun 17;13:852159. doi: 10.3389/fgene.2022.852159.
    • Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors.
    • Mekonnen N, Yang H, Shin YK.
    • Front Oncol. 2022 Jun 17;12:880643. doi: 10.3389/fonc.2022.880643.
    • The tumor mutational landscape of BRCA2-deficient primary and metastatic prostate cancer.
    • Kensler KH, Baichoo S, Pathania S, Rebbeck TR.
    • NPJ Precis Oncol. 2022 Jun 17;6(1):39. doi: 10.1038/s41698-022-00284-6.
    • PARP Inhibitors: A New Horizon for Patients with Prostate Cancer.
    • Congregado B, Rivero I, Osmán I, Sáez C, Medina López R.
    • Biomedicines. 2022 Jun 15;10(6):1416. doi: 10.3390/biomedicines10061416.
    • The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair.
    • Pacheco-Barcia V, Muñoz A, Castro E, Ballesteros AI, Marquina G, González-Díaz I, Colomer R, Romero-Laorden N.
    • Cancers (Basel). 2022 Jun 15;14(12):2950. doi: 10.3390/cancers14122950.
    • Pilot Study: PARP1 Imaging in Advanced Prostate Cancer.
    • Dehdashti F, Reimers MA, Shoghi KI, Chen DL, Luo J, Rogers B, Pachynski RK, Sreekumar S, Weimholt C, Zhou D.
    • Mol Imaging Biol. 2022 Jun 14. doi: 10.1007/s11307-022-01746-w. Epub ahead of print.
    • Biomarker Assessment of Homologous Recombination Deficiency in Epithelial Ovarian Cancer: Association With Progression-Free Survival After Surgery.
    • Yi H, Li L, Huang J, Ma Z, Li H, Chen J, Zheng X, Chen J, He H, Song J.
    • Front Mol Biosci. 2022 Jun 13;9:906922. doi: 10.3389/fmolb.2022.906922.
    • Pan-cancer analysis of genomic scar patterns caused by homologous repair deficiency (HRD).
    • Rempel E, Kluck K, Beck S, Ourailidis I, Kazdal D, Neumann O, Volckmar AL, Kirchner M, Goldschmid H, Pfarr N, Weichert W, Hübschmann D, Fröhling S, Sutter C, Schaaf CP, Schirmacher P, Endris V, Stenzinger A, Budczies J.
    • NPJ Precis Oncol. 2022 Jun 9;6(1):36. doi: 10.1038/s41698-022-00276-6.
    • Yondelis Fails to Improve Survival in BRCA1/2-Mutant Ovarian Cancer in Phase III ASCO Study.
    • Kanski A.
    • Precision Oncology News. Biomarkers. BRCA. 2022 Jun 9.

    Identifier: NCT02903004: Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients (MITO23). (ClinicalTrials.gov)

    • Characterization of rare histological subtypes of ovarian cancer based on molecular profiling.
    • Takahashi N, Hatakeyama K, Nagashima T, Ohshima K, Urakami K, Yamaguchi K, Hirashima Y.
    • Cancer Med. 2022 Jun 8. doi: 10.1002/cam4.4927. Epub ahead of print.
    • Genomic Signatures from Clinical Tumor Sequencing in Patients with Breast Cancer Having Germline BRCA1/2 Mutation.
    • Kim JW, Kang HE, Choi J, Yun SG, Jung SP, Bae SY, You JY, Choi YJ, Kim YH, Park KH.
    • Cancer Res Treat. 2022 Jun 8. doi: 10.4143/crt.2021.1567. Epub ahead of print.
    • A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45).
    • Monk BJ, Parkinson C, Lim MC, O'Malley DM, Oaknin A, Wilson MK, Coleman RL, Lorusso D, Bessette P, Ghamande S, Christopoulou A, Provencher D, Prendergast E, Demirkiran F, Mikheeva O, Yeku O, Chudecka-Glaz A, Schenker M, Littell RD, Safra T, Chou HH, Morgan MA, Drochýtek V, Barlin JN, Van Gorp T, Ueland F, Lindahl G, Anderson C, Collins DC, Moore K, Marme F, Westin SN, McNeish IA, Shih D, Lin KK, Goble S, Hume S, Fujiwara K, Kristeleit RS.
    • J Clin Oncol. 2022 Jun 6:JCO2201003. doi: 10.1200/JCO.22.01003. Epub ahead of print.

    Identifier: NCT03522246: A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA). (ClinicalTrials.gov)

    Letter, Commentary:

    Rucaparib Maintenance in Upfront Ovarian Cancer: The Long-Lasting Challenge of Predicting Response to Poly (ADP-ribose) Polymerase Inhibitors.

    • Ipilimumab/Nivolumab Therapy in Patients With Metastatic Pancreatic or Biliary Cancer With Homologous Recombination Deficiency Pathogenic Germline Variants.
    • Terrero G, Datta J, Dennison J, Sussman DA, Lohse I, Merchant NB, Hosein PJ.
    • JAMA Oncol. 2022 Jun 1;8(6):1-3. doi: 10.1001/jamaoncol.2022.0611.
    • Prevalence of Tumor Genomic Alterations in Homologous Recombination Repair Genes Among Taiwanese Breast Cancers.
    • Huang CC, Tsai YF, Liu CY, Lien PJ, Lin YS, Chao TC, Feng CJ, Chen YJ, Lai JI, Phan NN, Hsu CY, Chiu JH, Tseng LM.
    • Ann Surg Oncol. 2022 Jun;29(6):3578-3590. doi: 10.1245/s10434-022-11347-0. Epub 2022 Feb 28.
    • Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients.
    • de Boo LW, Józwiak K, Joensuu H, Lindman H, Lauttia S, Opdam M, van Steenis C, Brugman W, Kluin RJC, Schouten PC, Kok M, Nederlof PM, Hauptmann M, Linn SC.
    • Br J Cancer. 2022 Jun;126(10):1401-1409. doi: 10.1038/s41416-022-01711-y. Epub 2022 Feb 5.
    • Analytical tools to support detection of homologous recombination deficiency (HRD) using cytogenomic scar markers.
    • Saul D, Roytman M, Sherman W, Nasanovsky L.
    • Cancer Genet. 2022 Jun;264-265 (Suppl 1):2. doi: 10.1016/j.cancergen.2022.05.005.
    • Conference abstract
    • PTEN alterations in sporadic and BRCA1-associated triple negative breast carcinomas.
    • Jones N, Gros A, Velasco V, Dapremont V, Brouste V, Gastaldello B, Debled M, Tunon de Lara C, Bonnet F, Barouk-Simonet E, Bubien V, Venat L, MacGrogan G, Longy M, Sevenet N.
    • Cancer Genet. 2022 Jun;264-265:8-15. doi: 10.1016/j.cancergen.2022.02.008. Epub 2022 Feb 25.
    • Analytical tools to support detection of homologous recombination deficiency (HRD) using cytogenomic scar markers.
    • Saul D, Roytman M, Sherman W, Nasanovsky L.
    • Cancer Genet. 2022 Jun;264-265 (Suppl 1):2. doi: 10.1016/j.cancergen.2022.05.005.
    • Conference abstract
    • Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes.
    • Walsh EM, Mangini N, Fetting J, Armstrong D, Chan IS, Connolly RM, Fiallos K, Lehman J, Nunes R, Petry D, Reynolds J, Shah M, Smith KL, Visvanathan K, Lauring J, Park BH, Stearns V, Wolff AC.
    • Clin Breast Cancer. 2022 Jun;22(4):319-325. doi: 10.1016/j.clbc.2021.12.007. Epub 2021 Dec 30.
    • Appropriate Selection of PARP Inhibitors in Ovarian Cancer.
    • Smith M, Pothuri B.
    • Curr Treat Options Oncol. 2022 Jun;23(6):887-903. doi: 10.1007/s11864-022-00938-4. Epub 2022 Apr 12.
    • Review
    • Homologous recombination repair deficiency (HRD) testing in newly diagnosed advanced-stage epithelial ovarian cancer: A Belgian expert opinion.
    • Vergote I, Denys H, Altintas S, Kerger J, Baurain JF, Bours V, Henry S, Van de Vijver K, Lambrechts D, Gennigens C.
    • Facts Views Vis Obgyn. 2022 Jun;14(2):111-120. doi: 10.52054/FVVO.14.2.024.
    • PARP Inhibitor Insensitivity to BRCA1/2 Monoallelic Mutations in Microsatellite Instability-High Cancers.
    • Sokol ES, Jin DX, Fine A, Trabucco SE, Maund S, Frampton G, Molinero L, Antonarakis ES.
    • JCO Precis Oncol. 2022 Jun;6:e2100531. doi: 10.1200/PO.21.00531.

    Research news: Oncologists Seeing Lack of PARP Inhibitor Response in MSI-High, BRCA-Mutant Prostate Cancer Patients. (Precision Oncology News)

    • Colorectal leiomyosarcoma with BRCA2 mutation benefit from treatment with olaparib: a case report.
    • Hong L, Wang YN, Zhang X, Zhou X, Fan S, Xu M, Zhang S, Jiang D.
    • J Gastrointest Oncol. 2022 Jun;13(3):1499-1504. doi: 10.21037/jgo-22-419.
    • Veliparib for the treatment of solid malignancies.
    • George RR, Thomas R, Davice A, Mathew MS.
    • J Oncol Pharm Pract. 2022 Jun;28(4):924-934. doi: 10.1177/10781552221073990. Epub 2022 Jan 17.
    • Review
    • Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests.
    • Meijer TG, Nguyen L, Van Hoeck A, Sieuwerts AM, Verkaik NS, Ladan MM, Ruigrok-Ritstier K, van Deurzen CHM, van de Werken HJG, Lips EH, Linn SC, Memari Y, Davies H, Nik-Zainal S, Kanaar R, Martens JWM, Cuppen E, Jager A, van Gent DC.
    • Oncogene. 2022 Jun;41(26):3498-3506. doi: 10.1038/s41388-022-02363-1. Epub 2022 Jun 3.
    • Evolution in adjuvant treatment of ovarian carcinoma [Évolution des traitements adjuvants des cancers de l'ovaire].
    • Pautier P.
    • Rev Prat. 2022 Jun;72(6):633-637. French.
    • Homologous Recombination Deficiency and Ovarian Cancer Treatment Decisions: Practical Implications for Pathologists for Tumor Typing and Reporting.
    • Rabban JT, Chen LM, Devine WP.
    • Surg Pathol Clin. 2022 Jun;15(2):219-234. doi: 10.1016/j.path.2022.02.003. Epub 2022 May 18.
    • Review
    • Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort.
    • Leibowitz BD, Dougherty BV, Bell JSK, Kapilivsky J, Michuda J, Sedgewick AJ, Munson WA, Chandra TA, Dry JR, Beaubier N, Igartua C, Taxter T.
    • BMC Cancer. 2022 May 28;22(1):587. doi: 10.1186/s12885-022-09669-z.
    • Pharmacologic Induction of BRCAness in BRCA-Proficient Cancers: Expanding PARP Inhibitor Use.
    • Abbotts R, Dellomo AJ, Rassool FV.
    • Cancers (Basel). 2022 May 26;14(11):2640. doi: 10.3390/cancers14112640.
    • How to improve metastatic pancreatic ductal adenocarcinoma patients' selection: Between clinical trials and the real-world.
    • Pretta A, Spanu D, Mariani S, Liscia N, Ziranu P, Pusceddu V, Puzzoni M, Massa E, Scartozzi M, Lai E.
    • World J Clin Oncol. 2022 May 24;13(5):417-422. doi: 10.5306/wjco.v13.i5.417.
    • Homologous Recombination Repair in Biliary Tract Cancers: A Prime Target for PARP Inhibition?
    • Yin C, Kulasekaran M, Roy T, Decker B, Alexander S, Margolis M, Jha RC, Kupfer GM, He AR.
    • Cancers (Basel). 2022 May 23;14(10):2561. doi: 10.3390/cancers14102561.
    • Olaparib for Chinese metastatic castration-resistant prostate cancer: A real-world study of efficacy and gene predictive analysis.
    • Dong B, Yang B, Chen W, Du X, Fan L, Yao X, Xue W.
    • Med Oncol. 2022 May 23;39(5):96. doi: 10.1007/s12032-022-01648-5.
    • Clinical Landscape of PARP Inhibitors in Ovarian Cancer: Molecular Mechanisms and Clues to Overcome Resistance.
    • Kyo S, Kanno K, Takakura M, Yamashita H, Ishikawa M, Ishibashi T, Sato S, Nakayama K.
    • Cancers (Basel). 2022 May 19;14(10):2504. doi: 10.3390/cancers14102504.
    • Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor.
    • Tymon-Rosario JR, Manara P, Manavella DD, Bellone S, Hartwich TMP, Harold J, Yang-Hartwich Y, Zipponi M, Choi J, Jeong K, Mutlu L, Yang K, Altwerger G, Menderes G, Ratner E, Huang GS, Clark M, Andikyan V, Azodi M, Schwartz PE, Alexandrov LB, Santin AD.
    • Gynecol Oncol. 2022 May 19:S0090-8258(22)00305-5. doi: 10.1016/j.ygyno.2022.05.005. Epub ahead of print.
    • Therapeutic pattern and progress of neoadjuvant treatment for triple-negative breast cancer.
    • Xiao Y, Gao W.
    • Oncol Lett. 2022 May 19;24(1):219. doi: 10.3892/ol.2022.13340.
    • Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer.
    • Wen H, Feng Z, Ma Y, Liu R, Ou Q, Guo Q, Shen Y, Wu X, Shao Y, Bao H, Wu X.
    • BMC Cancer. 2022 May 16;22(1):550. doi: 10.1186/s12885-022-09602-4.
    • Computational Screening of Anti-Cancer Drugs Identifies a New BRCA Independent Gene Expression Signature to Predict Breast Cancer Sensitivity to Cisplatin.
    • Berthelet J, Foroutan M, Bhuva DD, Whitfield HJ, El-Saafin F, Cursons J, Serrano A, Merdas M, Lim E, Charafe-Jauffret E, Ginestier C, Ernst M, Hollande F, Anderson RL, Pal B, Yeo B, Davis MJ, Merino D.
    • Cancers (Basel). 2022 May 13;14(10):2404. doi: 10.3390/cancers14102404.
    • Ovarian cancer recurrence: is the definition of platinum resistance modified by PARPi and other intervening treatments? The evolving landscape in the management of platinum-resistant ovarian cancer.
    • Flynn MJ, Ledermann JA.
    • Cancer Drug Resist. 2022 May 12;5(2):424-435. doi: 10.20517/cdr.2022.13.
    • Homologous recombination deficiency predicts the response to platinum-based neoadjuvant chemotherapy in early-stage triple-negative breast cancer patients: a systematic review and meta-analysis.
    • Zhang L, Chen Y, Cheng MY, Zhuang X, Zou J, Wei D, Lin YY, Zhang Y, Wang K.
    • Ther Adv Med Oncol. 2022 May 7;14:17588359221096253. doi: 10.1177/17588359221096253.
    • BRCA status and platinum sensitivity in advanced ovarian cancer according to Chemotherapy Response Score.
    • Ergasti R, Marchetti C, Tudisco R, Iervolino A, Naldini A, Oliva R, Inzani F, Scambia G, Fagotti A.
    • Int J Gynecol Cancer. 2022 May 3;32(5):639-645. doi: 10.1136/ijgc-2021-003116.
    • Alterations in homologous recombination repair genes in prostate cancer brain metastases.
    • Rodriguez-Calero A, Gallon J, Akhoundova D, Maletti S, Ferguson A, Cyrta J, Amstutz U, Garofoli A, Paradiso V, Tomlins SA, Hewer E, Genitsch V, Fleischmann A, Vassella E, Rushing EJ, Grobholz R, Fischer I, Jochum W, Cathomas G, Osunkoya AO, Bubendorf L, Moch H, Thalmann G, Ng CKY, Gillessen S, Piscuoglio S, Rubin MA.
    • Nat Commun. 2022 May 3;13(1):2400. doi: 10.1038/s41467-022-30003-5.
    • High RAD51 gene expression is associated with aggressive biology and with poor survival in breast cancer.
    • Wu R, Patel A, Tokumaru Y, Asaoka M, Oshi M, Yan L, Ishikawa T, Takabe K.
    • Breast Cancer Res Treat. 2022 May;193(1):49-63. doi: 10.1007/s10549-022-06552-0. Epub 2022 Mar 6.
    • BRCA1 and RAD51C promotor methylation in human resectable pancreatic adenocarcinoma.
    • Abdallah R, Zhao S, Garinet S, Hormigos K, Le Corre D, Cros J, Perez Toralla K, Bats AS, Augustin J, Bachet JB, Taly V, Blons H, Taieb J, Laurent-Puig P.
    • Clin Res Hepatol Gastroenterol. 2022 May;46(5):101880. doi: 10.1016/j.clinre.2022.101880. Epub 2022 Feb 11.
    • Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors.
    • Paulet L, Trecourt A, Leary A, Peron J, Descotes F, Devouassoux-Shisheboran M, Leroy K, You B, Lopez J.
    • Eur J Cancer. 2022 May;166:87-99. doi: 10.1016/j.ejca.2022.01.037. Epub 2022 Mar 10.
    • Review
    • Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types.
    • Takamatsu S, Brown JB, Yamaguchi K, Hamanishi J, Yamanoi K, Takaya H, Kaneyasu T, Mori S, Mandai M, Matsumura N.
    • JCO Precis Oncol. 2022 May;6:e2200085. doi: 10.1200/PO.22.00085.
    • PARP inhibitors in ovarian cancer: overcoming resistance with combination strategies.
    • Miller RE, El-Shakankery KH, Lee JY.
    • J Gynecol Oncol. 2022 May;33(3):e44. doi: 10.3802/jgo.2022.33.e44. Epub 2022 Mar 8.
    • Whole-genome and transcriptome analysis of advanced adrenocortical cancer highlights multiple alterations affecting epigenome and DNA repair pathways.
    • Lavoie JM, Csizmok V, Williamson LM, Culibrk L, Wang G, Marra MA, Laskin J, Jones SJM, Renouf DJ, Kollmannsberger CK.
    • Cold Spring Harb Mol Case Stud. 2022 Apr 28;8(3):a006148. doi: 10.1101/mcs.a006148.
    • Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR.
    • Ueno T, Kitano S, Masuda N, Ikarashi D, Yamashita M, Chiba T, Kadoya T, Bando H, Yamanaka T, Ohtani S, Nagai S, Nakayama T, Takahashi M, Saji S, Aogi K, Velaga R, Kawaguchi K, Morita S, Haga H, Ohno S, Toi M.
    • BMC Med. 2022 Apr 25;20(1):136. doi: 10.1186/s12916-022-02332-1.
    • Improving ovarian cancer treatment decision using a novel risk predictive tool.
    • Xu Z, Song J, Cao L, Rong Z, Zhang W, He J, Li K, Hou Y.
    • Aging (Albany NY). 2022 Apr 19;14(8):3464-3483. doi: 10.18632/aging.204023. Epub 2022 Apr 19.
    • Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification.
    • Pellegrino B, Herencia-Ropero A, Llop-Guevara A, Pedretti F, Moles-Fernández A, Viaplana C, Villacampa G, Guzmán M, Rodríguez O, Grueso J, Jiménez J, Arenas EJ, Degasperi A, Dias JML, Forment JV, O'Connor MJ, Déas O, Cairo S, Zhou Y, Musolino A, Caldas C, Nik-Zainal S, Clarke RB, Nuciforo P, Díez O, Serres-Créixams X, Peg V, Espinosa-Bravo M, Macarulla T, Oaknin A, Mateo J, Arribas J, Dienstmann R, Bellet M, Oliveira M, Saura C, Gutiérrez-Enríquez S, Balmaña J, Serra V.
    • Cancer Res. 2022 Apr 15;82(8):1646-1657. doi: 10.1158/0008-5472.CAN-21-2409.
    • Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib).
    • Hussain M, Corcoran C, Sibilla C, Fizazi K, Saad F, Shore N, Sandhu S, Mateo J, Olmos D, Mehra N, Kolinsky MP, Roubaud G, Özgüroglu M, Matsubara N, Gedye C, Choi YD, Padua C, Kohlmann A, Huisden R, Elvin JA, Kang J, Adelman CA, Allen A, Poehlein C, de Bono J.
    • Clin Cancer Res. 2022 Apr 14;28(8):1518-1530. doi: 10.1158/1078-0432.CCR-21-3940.
    • Prediction of breast cancer risk based on flow variant analysis of circulating peripheral blood mononuclear cells.
    • Loke J, Alim I, Yam S, Klugman S, Xia LC, Gruber D, Tegay D, LaBella A, Onel K, Ostrer H.
    • HGG Adv. 2022 Jan 8 [eCollection 2022 Apr 14];3(2):100085. doi: 10.1016/j.xhgg.2022.100085.
    • Role of Homologous Recombination Repair (HRR) Genes in Uterine Leiomyosarcomas: A Retrospective Analysis.
    • Ciccarone F, Bruno M, De Paolis E, Piermattei A, De Bonis M, Lorusso D, Zannoni GF, Normanno N, Minucci A, Scambia G, Ferrandina G.
    • Cancers (Basel). 2022 Apr 12;14(8):1934. doi: 10.3390/cancers14081934.
    • PARP inhibition in breast cancer: progress made and future hopes.
    • Tung N, Garber JE.
    • NPJ Breast Cancer. 2022 Apr 8;8(1):47. doi: 10.1038/s41523-022-00411-3.
    • Incidence and impact of brain metastasis in patients with hereditary BRCA1 or BRCA2 mutated invasive breast cancer.
    • Garber HR, Raghavendra AS, Lehner M, Qiao W, Gutierrez-Barrera AM, Tripathy D, Arun B, Ibrahim NK.
    • NPJ Breast Cancer. 2022 Apr 7;8(1):46. doi: 10.1038/s41523-022-00407-z.
    • Predicting Response to Anthracyclines in Ovarian Cancer.
    • Ferrero A, Borghese M, Restaino S, Puppo A, Vizzielli G, Biglia N.
    • Int J Environ Res Public Health. 2022 Apr 2;19(7):4260. doi: 10.3390/ijerph19074260.
    • Examining the prevalence of homologous recombination repair defects in ER+ breast cancers.
    • Moore GM, Powell SN, Higginson DS, Khan AJ.
    • Breast Cancer Res Treat. 2022 Apr;192(3):649-653. doi: 10.1007/s10549-022-06529-z. Epub 2022 Jan 29.
    • Somatic loss of the remaining allele occurs approximately in half of CHEK2-driven breast cancers and is accompanied by a border-line increase of chromosomal instability.
    • Iyevleva AG, Aleksakhina SN, Sokolenko AP, Baskina SV, Venina AR, Anisimova EI, Bizin IV, Ivantsov AO, Belysheva YV, Chernyakova AP, Togo AV, Imyanitov EN.
    • Breast Cancer Res Treat. 2022 Apr;192(2):283-291. doi: 10.1007/s10549-022-06517-3. Epub 2022 Jan 12.
    • Considerations on the identification and management of metastatic prostate cancer patients with DNA repair gene alterations in the Canadian context.
    • Kolinsky MP, Niederhoffer KY, Kwan EM, Hotte SJ, Hamilou Z, Yip SM, Chi KN, Wyatt AW, Saad F.
    • Can Urol Assoc J. 2022 Apr;16(4):132-143. doi: 10.5489/cuaj.7621.
    • BRCA2 promoter hypermethylation as a biomarker for the leukemic transformation of myeloproliferative neoplasms.
    • Yang C, Zhang Q, Tang X, Wang B, Guan M, Tang G, Wu Z.
    • Epigenomics. 2022 Apr;14(7):391-403. doi: 10.2217/epi-2022-0025. Epub 2022 Mar 9.
    • The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy.
    • Maiorano BA, Lorusso D, Maiorano MFP, Ciardiello D, Parrella P, Petracca A, Cormio G, Maiello E.
    • Int J Mol Sci. 2022 Mar 31;23(7):3871. doi: 10.3390/ijms23073871.
    • Associations with response to Poly(ADP-ribose) Polymerase (PARP) inhibitors in patients with metastatic breast cancer.
    • Desnoyers A, Nadler M, Wilson BE, Stajer S, Amir E.
    • NPJ Breast Cancer. 2022 Mar 31;8(1):43. doi: 10.1038/s41523-022-00405-1.
    • Bevacizumab versus PARP-inhibitors in women with newly diagnosed ovarian cancer: a network meta-analysis.
    • Suh YJ, Lee B, Kim K, Jeong Y, Choi HY, Hwang SO, Kim YB.
    • BMC Cancer. 2022 Mar 30;22(1):346. doi: 10.1186/s12885-022-09455-x.
    • Next Generation Sequencing and Molecular Biomarkers in Ovarian Cancer-An Opportunity for Targeted Therapy.
    • Harbin LM, Gallion HH, Allison DB, Kolesar JM.
    • Diagnostics (Basel). 2022 Mar 29;12(4):842. doi: 10.3390/diagnostics12040842.
    • Establish of an Initial Platinum-Resistance Predictor in High-Grade Serous Ovarian Cancer Patients Regardless of Homologous Recombination Deficiency Status.
    • Li Y, Nie Y, Guo H, Guo H, Ha C, Li Y.
    • Front Oncol. 2022 Mar 18;12:847085. doi: 10.3389/fonc.2022.847085.
    • Molecular Pathology of Pancreatic Cancer.
    • Karamitopoulou E.
    • Cancers (Basel). 2022 Mar 16;14(6):1523. doi: 10.3390/cancers14061523.
    • Homologous Recombination Deficiency: Concepts, Definitions, and Assays.
    • Stewart MD, Merino Vega D, Arend RC, Baden JF, Barbash O, Beaubier N, Collins G, French T, Ghahramani N, Hinson P, Jelinic P, Marton MJ, McGregor K, Parsons J, Ramamurthy L, Sausen M, Sokol ES, Stenzinger A, Stires H, Timms KM, Turco D, Wang I, Williams JA, Wong-Ho E, Allen J.
    • Oncologist. 2022 Mar 11;27(3):167-174. doi: 10.1093/oncolo/oyab053.
    • Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal Cancer.
    • Catalano F, Borea R, Puglisi S, Boutros A, Gandini A, Cremante M, Martelli V, Sciallero S, Puccini A.
    • Cancers (Basel). 2022 Mar 9;14(6):1388. doi: 10.3390/cancers14061388.
    • The Clinical Utility and Impact of Next Generation Sequencing in Gynecologic Cancers.
    • Maruthi VK, Khazaeli M, Jeyachandran D, Desouki MM.
    • Cancers (Basel). 2022 Mar 7;14(5):1352. doi: 10.3390/cancers14051352.
    • Efficacy of platinum-based chemotherapy in metastatic breast cancer and HRD biomarkers: utility of exome sequencing.
    • Galland L, Ballot E, Mananet H, Boidot R, Lecuelle J, Albuisson J, Arnould L, Desmoulins I, Mayeur D, Kaderbhai C, Ilie S, Hennequin A, Bergeron A, Derangère V, Ghiringhelli F, Truntzer C, Ladoire S.
    • NPJ Breast Cancer. 2022 Mar 4;8(1):28. doi: 10.1038/s41523-022-00395-0.
    • Sequencing of BRCA1/2-alterations using NGS-based technology: annotation as a challenge.
    • Ebner S, Winkelmann R, Martin S, Köllermann J, Wild PJ, Demes M.
    • Oncotarget. 2022 Mar 3;13:464-475. doi: 10.18632/oncotarget.28213.
    • European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer.
    • Vergote I, González-Martín A, Ray-Coquard I, Harter P, Colombo N, Pujol P, Lorusso D, Mirza MR, Brasiuniene B, Madry R, Brenton JD, Ausems MGEM, Büttner R, Lambrechts D; European experts’ consensus group.
    • Ann Oncol. 2022 Mar;33(3):276-287. doi: 10.1016/j.annonc.2021.11.013. Epub 2021 Dec 1.

    Commentary:

    Homologous recombination deficiency testing in first-line ovarian cancer.

    • Biomarkers for characterization and therapeutic orientation in castration-resistant prostate cancer.
    • Plata Bello A, Tamayo Jover MA, Gutierrez Nicolas F, Acosta López S, Concepción Masip T, Plata Bello J.
    • Arch Esp Urol. 2022 Mar;75(2):195-202. English, Spanish.
    • Review
    • Predictive and prognostic significance of BRCAness in HER2-negative breast cancer.
    • Sueta A, Yamamoto-Ibusuki M, Tomiguchi M, Fujiki Y, Goto-Yamaguchi L, Iwase H, Yamamoto Y.
    • Breast Cancer. 2022 Mar;29(2):368-376. doi: 10.1007/s12282-021-01319-9. Epub 2022 Jan 5.
    • PARP inhibitors for metastatic castration-resistant prostate cancer: Biological rationale and current evidence.
    • Bienkowski M, Tomasik B, Braun M, Jassem J.
    • Cancer Treat Rev. 2022 Mar;104:102359. doi: 10.1016/j.ctrv.2022.102359.Epub 2022 Feb 11.
    • Review
    • The role of PARP inhibitors in gastrointestinal cancers.
    • Hanna D, Chopra N, Hochhauser D, Khan K.
    • Crit Rev Oncol Hematol. 2022 Mar;171:103621. doi: 10.1016/j.critrevonc.2022.103621. Epub 2022 Feb 3.
    • Review
    • DNA damage-induced sumoylation of Sp1 induces its interaction with RNF4 and degradation in S phase to remove 53BP1 from DSBs and permit HR.
    • Swift ML, Azizkhan-Clifford J.
    • DNA Repair (Amst). 2022 Mar;111:103289. doi: 10.1016/j.dnarep.2022.103289. Epub 2022 Feb 1.
    • Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis.
    • Poveda A, Lheureux S, Colombo N, Cibula D, Lindemann K, Weberpals J, Bjurberg M, Oaknin A, Sikorska M, González-Martín A, Madry R, Pérez MJR, Ledermann J, Davidson R, Blakeley C, Bennett J, Barnicle A, Škof E.
    • Gynecol Oncol. 2022 Mar;164(3):498-504. doi: 10.1016/j.ygyno.2021.12.025. Epub 2022 Jan 19.
    • Molecular analysis of endometrial serous carcinoma reveals distinct clinicopathologic and genomic subgroups.
    • Lin DI, Fine A, Danziger NA, Huang RSP, Mata DA, Decker B, Killian JK, Ramkissoon SH, Lechpammer M, Janovitz T, Ross JS, Sokol ES, Elvin JA.
    • Gynecol Oncol. 2022 Mar;164(3):558-565. doi: 10.1016/j.ygyno.2021.12.030. Epub 2022 Jan 5.
    • A New Landscape of Testing and Therapeutics in Metastatic Breast Cancer.
    • Jagannathan G, White MJ, Xian RR, Emens LA, Cimino-Mathews A.
    • Surg Pathol Clin. 2022 Mar;15(1):105-120. doi: 10.1016/j.path.2021.11.007. Epub 2022 Jan 31.
    • Review
    • The BRCA Gene in Epithelial Ovarian Cancer.
    • Sánchez-Lorenzo L, Salas-Benito D, Villamayor J, Patiño-García A, González-Martín A.
    • Cancers (Basel). 2022 Feb 27;14(5):1235. doi: 10.3390/cancers14051235.
    • Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial.
    • Fumet JD, Lardenois E, Ray-Coquard I, Harter P, Joly F, Canzler U, Truntzer C, Tredan O, Liebrich C, Lortholary A, Pissaloux D, Leary A, Pfisterer J, Eeckhoutte A, Hilpert F, Fabbro M, Caux C, Alexandre J, Houlier A, Sehouli J, Sohier E, Kimmig R, Dubois B, Spaeth D, Treilleux I, Frenel JS, Herwig U, Le Saux O, Bendriss-Vermare N, du Bois A.
    • Cancers (Basel). 2022 Feb 25;14(5):1189. doi: 10.3390/cancers14051189.
    • Clinical Benefit With PARP Inhibitor for Pathogenic Germline FANCA-Mutated Relapsed Epithelial Ovarian Cancer: A Case Report.
    • Qian B, Leng W, Yan Z, Lu J, Chen S, Yi H, Jiang Z.
    • Front Oncol. 2022 Feb 25;12:778545. doi: 10.3389/fonc.2022.778545.
    • Status of the Current Treatment Options and Potential Future Targets in Uterine Leiomyosarcoma: A Review.
    • Asano H, Isoe T, Ito YM, Nishimoto N, Watanabe Y, Yokoshiki S, Watari H.
    • Cancers (Basel). 2022 Feb 24;14(5):1180. doi: 10.3390/cancers14051180.
    • Case Report Series: Aggressive HR Deficient Colorectal Cancers Related to BRCA1 Pathogenic Germline Variants.
    • Freire MV, Martin M, Thissen R, Van Marcke C, Segers K, Sépulchre E, Leroi N, Lété C, Fasquelle C, Radermacher J, Gokburun Y, Collignon J, Sacré A, Josse C, Palmeira L, Bours V.
    • Front Oncol. 2022 Feb 24;12:835581. doi: 10.3389/fonc.2022.835581.
    • PARP Inhibitor Applicability: Detailed Assays for Homologous Recombination Repair Pathway Components.
    • O'Sullivan Coyne G, Karlovich C, Wilsker D, Voth AR, Parchment RE, Chen AP, Doroshow JH.
    • Onco Targets Ther. 2022 Feb 24;15:165-180. doi: 10.2147/OTT.S278092.
    • Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer, Part 1: Technical Considerations.
    • Quesada S, Fabbro M, Solassol J.
    • Cancers (Basel). 2022 Feb 23;14(5):1132. doi: 10.3390/cancers14051132.
    • Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical Perspectives.
    • Quesada S, Fabbro M, Solassol J.
    • Cancers (Basel). 2022 Feb 21;14(4):1098. doi: 10.3390/cancers14041098.
    • Homologous Recombination Deficiency (HRD) and BRCA 1/2 Gene Mutation for Predicting the Effect of Platinum-Based Neoadjuvant Chemotherapy of Early-Stage Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis.
    • Chai Y, Chen Y, Zhang D, Wei Y, Li Z, Li Q, Xu B.
    • J Pers Med. 2022 Feb 21;12(2):323. doi: 10.3390/jpm12020323.
    • RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer.
    • Miao C, Tsujino T, Takai T, Gui F, Tsutsumi T, Sztupinszki Z, Wang Z, Azuma H, Szallasi Z, Mouw KW, Zou L, Kibel AS, Jia L.
    • Sci Adv. 2022 Feb 18;8(7):eabl9794. doi: 10.1126/sciadv.abl9794. Epub 2022 Feb 18.
    • PARP Inhibitors Show Frontline Prostate Cancer Benefit; Conflicting Biomarker Data Raise Questions.
    • Hopkins C.
    • Precision Oncology News. Disease Areas. Cancer. 2022 Feb 17.
    • Conference report
    • Mass General, Lunaphore Technologies to Develop Test to Predict PARP Inhibitor Response.
    • [No author given]
    • Precision Oncology News. Disease Areas. Cancer. 2022 Feb 17.
    • Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
    • Tattersall A, Ryan N, Wiggans AJ, Rogozinska E, Morrison J.
    • Cochrane Database Syst Rev. 2022 Feb 16;2:CD007929. doi: 10.1002/14651858.CD007929.pub4.
    • Review
    • Co-Relation of Hormonal Profile and BRCA1 in Sporadic Breast Carcinoma: A Single Institutional Experience of 303 Patients.
    • Agarwal P, Khan F, Gupta S, Bhalla S, Thomas A, Anand A, Singh K, Sonkar AA.
    • Clin Pathol. 2022 Feb 14;15:2632010X221076379. doi: 10.1177/2632010X221076379.
    • Phase 2 Trial (POLA Study) of Lurbinectedin plus Olaparib in Patients with Advanced Solid Tumors: Results of Efficacy, Tolerability, and the Translational Study.
    • Poveda A, Lopez-Reig R, Oaknin A, Redondo A, Rubio MJ, Guerra E, Fariñas-Madrid L, Gallego A, Rodriguez-Freixinos V, Fernandez-Serra A, Juan O, Romero I, Lopez-Guerrero JA.
    • Cancers (Basel). 2022 Feb 12;14(4):915. doi: 10.3390/cancers14040915.
    • Clinicopathological Significance of BRCAness in Resectable Pancreatic Ductal Adenocarcinoma and Its Association With Anticancer Drug Sensitivity in Pancreatic Cancer Cells.
    • Tadehara M, Kato T, Adachi K, Tamaki A, Kesen Y, Sakurai Y, Ichinoe M, Koizumi W, Murakumo Y.
    • Pancreas. 2022 Feb 1;51(2):183-189. doi: 10.1097/MPA.0000000000001975.
    • RAD51 as a functional biomarker for homologous recombination deficiency in cancer: a promising addition to the HRD toolbox?
    • van Wijk LM, Nilas AB, Vrieling H, Vreeswijk MPG.
    • Expert Rev Mol Diagn. 2022 Feb;22(2):185-199. doi: 10.1080/14737159.2022.2020102. Epub 2022 Feb 16.
    • Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.
    • Swisher EM, Aghajanian C, O'Malley DM, Fleming GF, Kaufmann SH, Levine DA, Birrer MJ, Moore KN, Spirtos NM, Shahin MS, Reid TJ, Friedlander M, Steffensen KD, Okamoto A, Sehgal V, Ansell PJ, Dinh MH, Bookman MA, Coleman RL.
    • Gynecol Oncol. 2022 Feb;164(2):245-253. doi: 10.1016/j.ygyno.2021.12.003. Epub 2021 Dec 11.

    Commentary:

    Testing for homologous recombination deficiency - does it provide new insights for the use of veliparib?

    Podcast:

    February 2022 Editor’s Choice: HRD: What does it really mean and are we looking at this the right way?

    • Identifying Transcripts with Tandem Duplications from RNA-Sequencing Data to Predict BRCA1-Type Primary Breast Cancer.
    • Qu S, Martens JWM, Hollestelle A, Smid M.
    • Cancers (Basel). 2022 Jan 31;14(3):753. doi: 10.3390/cancers14030753.
    • Genomic landscape and immune-related gene expression profiling of epithelial ovarian cancer after neoadjuvant chemotherapy.
    • Lodewijk I, Bernardini A, Suárez-Cabrera C, Bernal E, Sánchez R, Garcia JL, Rojas K, Morales L, Wang S, Han X, Dueñas M, Paramio JM, Manso L.
    • NPJ Precis Oncol. 2022 Jan 27;6(1):7. doi: 10.1038/s41698-021-00247-3.
    • Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities.
    • Cosgrove N, Varešlija D, Keelan S, Elangovan A, Atkinson JM, Cocchiglia S, Bane FT, Singh V, Furney S, Hu C, Carter JM, Hart SN, Yadav S, Goetz MP, Hill ADK, Oesterreich S, Lee AV, Couch FJ, Young LS.
    • Nat Commun. 2022 Jan 26;13(1):514. doi: 10.1038/s41467-022-27987-5.
    • Expression Profiling in Ovarian Cancer Reveals Coordinated Regulation of BRCA1/2 and Homologous Recombination Genes.
    • Custódio N, Savisaar R, Carvalho C, Bak-Gordon P, Ribeiro MI, Tavares J, Nunes PB, Peixoto A, Pinto C, Escudeiro C, Teixeira MR, Carmo-Fonseca M.
    • Biomedicines. 2022 Jan 18;10(2):199. doi: 10.3390/biomedicines10020199.
    • Clinical benefit with PARP inhibitor for pathogenic germline FANCA-mutated relapsed epithelial ovarian cancer: a case report.
    • Qian B, Lu J, Leng W, Yan Z, Chen S, Yi H, Jiang Z.
    • Front Oncol. 2022 Jan 18;10:778545. doi: 10.3389/fonc.2022.778545.
    • Value of the loss of heterozygosity to BRCA1 variant classification.
    • Santana Dos Santos E, Spurdle AB, Carraro DM, Briaux A, Southey M, Torrezan G, Petitalot A, Leman R, Lafitte P; kConFab Investigators, Meseure D, Driouch K, Side L, Brewer C, Beck S, Melville A, Callaway A, Revillion F, Folgueira MAAK, Parsons MT, Thorne H, Vincent-Salomon A, Stoppa-Lyonnet D, Bieche I, Caputo SM, Rouleau E.
    • NPJ Breast Cancer. 2022 Jan 17;8(1):9. doi: 10.1038/s41523-021-00361-2.
    • Homologous Recombination Deficiency Associated With Response to Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer Patients: The First Real-World Evidence From China.
    • Ni J, Guo W, Zhao Q, Cheng X, Xu X, Zhou R, Gu H, Chen C, Chen X.
    • Front Oncol. 2022 Jan 6;11:746571. doi: 10.3389/fonc.2021.746571.
    • Platinum-Based Neoadjuvant Chemotherapy Before Radical Prostatectomy for Locally Advanced Prostate Cancer With Homologous Recombination Deficiency: A Case Report.
    • Zhuang J, Zhang S, Qiu X, Fu Y, Ai S, Zhao T, Yang Y, Guo H.
    • Front Oncol. 2022 Jan 5;11:777318. doi: 10.3389/fonc.2021.777318.
    • Complete Response of a Mutated BRCA2 Metastatic Clear Cell Endometrial Adenocarcinoma to the Poly (ADP ribose) Polymerase (PARP) Inhibitor Olaparib.
    • Anzellini D, Arcangeli G, Del Bianco S.
    • Cancer Diagn Progn. 2022 Jan 3;2(1):84-86. doi: 10.21873/cdp.10080.
    • Aberrant Transcript Usage Is Associated with Homologous Recombination Deficiency and Predicts Therapeutic Response.
    • Kang HG, Hwangbo H, Kim MJ, Kim S, Lee EJ, Park MJ, Kim JW, Kim BG, Cho EH, Chang S, Lee JY, Choi JK.
    • Cancer Res. 2022 Jan 1;82(1):142-154. doi: 10.1158/0008-5472.CAN-21-2023. Epub 2021 Oct 28.
    • Platinum-based systematic therapy in triple-negative breast cancer.
    • Zhu Y, Hu Y, Tang C, Guan X, Zhang W.
    • Biochim Biophys Acta Rev Cancer. 2022 Jan;1877(1):188678. doi: 10.1016/j.bbcan.2022.188678. Epub 2022 Jan 10.
    • Review
    • Molecular targeted drugs resistance impairs double-strand break repair and sensitizes ER-positive breast cancer to PARP inhibitors.
    • Suzuki Y, Wenwen W, Ohta T, Hayashi SI.
    • Breast Cancer. 2022 Jan;29(1):77-91. doi: 10.1007/s12282-021-01282-5. Epub 2021 Aug 3.
    • Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts.
    • Guffanti F, Alvisi MF, Anastasia A, Ricci F, Chiappa M, Llop-Guevara A, Serra V, Fruscio R, Degasperi A, Nik-Zainal S, Bani MR, Lupia M, Giavazzi R, Rulli E, Damia G.
    • Br J Cancer. 2022 Jan;126(1):120-128. doi: 10.1038/s41416-021-01609-1. Epub 2021 Nov 3.
    • Défauts de la recombinaison homologue et inhibiteurs de PARP en thérapeutique [Homologous recombination deficiency and PARP inhibitors in therapeutics].
    • Salaün H, Saint-Ghislain M, Bellesoeur A, Beuzeboc P, Neuzillet C, Diéras V, Stern MH, Rodrigues M.
    • Bull Cancer. 2022 Jan;109(1):76-82. French. doi: 10.1016/j.bulcan.2021.09.015. Epub 2021 Nov 17.
    • Review, [Article in French]
    • Alterations in BRCA2 as Determinants of Therapy Response in Prostate Cancer.
    • Hofstad M, Huang EY, Woods A, Yin Y, Desai NB, Raj GV.
    • Crit Rev Oncog. 2022;27(1):81-96. doi: 10.1615/CritRevOncog.2022043233.
    • Review
    • DNA Damage Repair: Predictor of Platinum Efficacy in Ovarian Cancer?
    • Stefanou DT, Souliotis VL, Zakopoulou R, Liontos M, Bamias A.
    • Biomedicines. 2021 Dec 31;10(1):82. doi: 10.3390/biomedicines10010082.
    • Homologous Recombination Deficiencies and Hereditary Tumors.
    • Yamamoto H, Hirasawa A.
    • Int J Mol Sci. 2021 Dec 29;23(1):348. doi: 10.3390/ijms23010348.
    • Preventing and Overcoming Resistance to PARP Inhibitors: A Focus on the Clinical Landscape.
    • Prados-Carvajal R, Irving E, Lukashchuk N, Forment JV.
    • Cancers (Basel). 2021 Dec 23;14(1):44. doi: 10.3390/cancers14010044.
    • Evaluation of the Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis.
    • Wu K, Liang J, Shao Y, Xiong S, Feng S, Li X.
    • Front Pharmacol. 2021 Dec 17;12:777663. doi: 10.3389/fphar.2021.777663.
    • Inferring Homologous Recombination Deficiency of Ovarian Cancer From the Landscape of Copy Number Variation at Subchromosomal and Genetic Resolutions.
    • Zhang M, Ma SC, Tan JL, Wang J, Bai X, Dong ZY, Zhang QX.
    • Front Oncol. 2021 Dec 16;11:772604. doi: 10.3389/fonc.2021.772604.
    • Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancer.
    • De Sarkar N, Dasgupta S, Chatterjee P, Coleman I, Ha G, Ang LS, Kohlbrenner EA, Frank SB, Nunez TA, Salipante SJ, Corey E, Morrissey C, Van Allen E, Schweizer MT, Haffner MC, Patel R, Hanratty B, Lucas JM, Dumpit RF, Pritchard CC, Montgomery RB, Nelson PS.
    • JCI Insight. 2021 Dec 8;6(23):e152789. doi: 10.1172/jci.insight.152789.
    • Case Report: Niraparib as Maintenance Therapy in A Patient With Ovarian Carcinosarcoma.
    • Zhang JQ, Zhao BB, Wang MM, Li L.
    • Front Oncol. 2021 Dec 6;11:603591. doi: 10.3389/fonc.2021.603591.
    • Filling in the gaps in PARP inhibitor-induced synthetic lethality.
    • Paes Dias M, Jonkers J.
    • Mol Cell Oncol. 2021 Dec 6;8(6):2010512. doi: 10.1080/23723556.2021.2010512.
    • Expanding the Use of PARP Inhibitors as Monotherapy and in Combination in Triple-Negative Breast Cancer.
    • Yordanova M, Hubert A, Hassan S.
    • Pharmaceuticals (Basel). 2021 Dec 6;14(12):1270. doi: 10.3390/ph14121270.
    • Race-Specific Genetic Profiles of Homologous Recombination Deficiency in Multiple Cancers.
    • Hsiao YW, Lu TP.
    • J Pers Med. 2021 Dec 3;11(12):1287. doi: 10.3390/jpm11121287.
    • Ovarian Cancer-Specific BRCA-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial.
    • Schouten PC, Richters L, Vis DJ, Kommoss S, van Dijk E, Ernst C, Kluin RJC, Marmé F, Lips EH, Schmidt S, Scheerman E, Prieske K, van Deurzen CHM, Burges A, Ewing-Graham PC, Dietrich D, Jager A, de Gregorio N, Hauke J, du Bois A, Nederlof PM, Wessels LF, Hahnen E, Harter P, Linn SC, Schmutzler RK.
    • Clin Cancer Res. 2021 Dec 1;27(23):6559-6569. doi: 10.1158/1078-0432.CCR-21-1673. Epub 2021 Sep 30.
    • Association of RAD51 with Homologous Recombination Deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial.
    • Llop-Guevara A, Loibl S, Villacampa G, Vladimirova V, Schneeweiss A, Karn T, Zahm DM, Herencia-Ropero A, Jank P, van Mackelenbergh M, Fasching PA, Marmé F, Stickeler E, Schem C, Dienstmann R, Florian S, Nekljudova V, Balmaña J, Hahnen E, Denkert C, Serra V.
    • Ann Oncol. 2021 Dec;32(12):1590-1596. doi: 10.1016/j.annonc.2021.09.003. Epub 2021 Sep 11.
    • Diagnostic histologique et moléculaire des cancers de l'ovaire - recommandations pour la pratique clinique Saint-Paul 2021: Histological and molecular diagnosis of ovarian.
    • Genestie C, Gladieff L, Frère-Belda ML, Lortholary A, Vaur D, Treilleux I, Lyonnet DS.
    • Bull Cancer. 2021 Dec;108(9S1):S33-S38. doi: 10.1016/S0007-4551(21)00585-3.
    • Guideline
    • Cabazitaxel activity in men with metastatic castration-resistant prostate cancer with and without DNA damage repair defects.
    • Aldea M, Lam L, Orillard E, Llacer Perez C, Saint-Ghislain M, Gravis G, Fléchon A, Roubaud G, Barthelemy P, Ricci F, Priou F, Neviere Z, Beaufils M, Laguerre B, Hardy AC, Helissey C, Ratta R, Borchiellini D, Pobel C, Joly F, Castro E, Thiery-Vuillemin A, Baciarello G, Fizazi K.
    • Eur J Cancer. 2021 Dec;159:87-97. doi: 10.1016/j.ejca.2021.09.029. Epub 2021 Nov 2.
    • Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutation.
    • Patsouris A, Diop K, Tredan O, Nenciu D, Gonçalves A, Arnedos M, Sablin MP, Jézéquel P, Jimenez M, Droin N, Bièche I, Callens C, Loehr A, Vicier C, Guerin C, Filleron T, André F.
    • Eur J Cancer. 2021 Dec;159:283-295. doi: 10.1016/j.ejca.2021.09.028. Epub 2021 Nov 25.
    • Concordance of BRCA mutation detection in tumor versus blood, and frequency of bi-allelic loss of BRCA in tumors from patients in the phase III SOLO2 trial.
    • Hodgson DR, Brown JS, Dearden SP, Lai Z, Elks CE, Milenkova T, Dougherty BA, Lanchbury JS, Perry M, Timms KM, Harrington EA, Barrett JC, Leary A, Pujade-Lauraine E.
    • Gynecol Oncol. 2021 Dec;163(3):563-568. doi: 10.1016/j.ygyno.2021.10.002. Epub 2021 Nov 4.
    • Understanding and overcoming resistance to PARP inhibitors in cancer therapy.
    • Dias MP, Moser SC, Ganesan S, Jonkers J.
    • Nat Rev Clin Oncol. 2021 Dec;18(12):773-791. doi: 10.1038/s41571-021-00532-x. Epub 2021 Jul 20.
    • Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations.
    • Xu Q, Li Z.
    • Front Pharmacol. 2021 Nov 29;12:743073. doi: 10.3389/fphar.2021.743073.
    • Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives.
    • Barchiesi G, Roberto M, Verrico M, Vici P, Tomao S, Tomao F.
    • Front Oncol. 2021 Nov 25;11:769280. doi: 10.3389/fonc.2021.769280.
    • GSA: an independent development algorithm for calling copy number and detecting homologous recombination deficiency (HRD) from target capture sequencing.
    • Chen D, Shao M, Meng P, Wang C, Li Q, Cai Y, Song C, Wang X, Shi T.
    • BMC Bioinformatics. 2021 Nov 23;22(1):562. doi: 10.1186/s12859-021-04487-9.
    • Regional and temporal heterogeneity of epithelial ovarian cancer tumor biopsies: implications for therapeutic strategies.
    • Paracchini L, Mannarino L, Craparotta I, Romualdi C, Fruscio R, Grassi T, Fotia V, Caratti G, Perego P, Calura E, Clivio L, D'Incalci M, Beltrame L, Marchini S.
    • Oncotarget. 2016 Jul 9;12(24):2404-2417. doi: 10.18632/oncotarget.10505. eCollection 2021 Nov 23.
    • Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer.
    • Carr TH, Adelman C, Barnicle A, Kozarewa I, Luke S, Lai Z, Hollis S, Dougherty B, Harrington EA, Kang J, Saad F, Sala N, Thiery-Vuillemin A, Clarke NW, Hodgson D, Barrett JC.
    • Cancers (Basel). 2021 Nov 20;13(22):5830. doi: 10.3390/cancers13225830.
    • Dynamically Accumulating Homologous Recombination Deficiency Score Served as an Important Prognosis Factor in High-Grade Serous Ovarian Cancer.
    • Su R, Liu Y, Wu X, Xiang J, Xi X.
    • Front Mol Biosci. 2021 Nov 19;8:762741. doi: 10.3389/fmolb.2021.762741.
    • Maintenance Treatment of Newly Diagnosed Advanced Ovarian Cancer: Time for a Paradigm Shift?
    • DiSilvestro P, Colombo N, Harter P, González-Martín A, Ray-Coquard I, Coleman RL.
    • Cancers (Basel). 2021 Nov 17;13(22):5756. doi: 10.3390/cancers13225756.
    • Inhibition of poly (ADP-Ribose) polymerase: A promising strategy targeting pancreatic cancer with BRCAness phenotype.
    • Jeong KY, Lee H.
    • World J Gastrointest Oncol. 2021 Nov 15;13(11):1544-1550. doi: 10.4251/wjgo.v13.i11.1544.
    • DNA methylation-based classifier and gene expression signatures detect BRCAness in osteosarcoma.
    • Barenboim M, Kovac M, Ameline B, Jones DTW, Witt O, Bielack S, Burdach S, Baumhoer D, Nathrath M.
    • PLoS Comput Biol. 2021 Nov 11;17(11):e1009562. doi: 10.1371/journal.pcbi.1009562.
    • Quantitative Analysis of the Efficacy of PARP Inhibitors as Maintenance Therapy in Recurrent Ovarian Cancer.
    • Gao L, Chen R, Li T, Li L, Zheng Q.
    • Front Pharmacol. 2021 Nov 8;12:771836. doi: 10.3389/fphar.2021.771836.
    • Examining the Prevalence of Homologous Recombination Repair Defects in ER+ Breast Cancers.
    • Moore GM, Powell SN, Higginson DS, Khan AJ.
    • Int J Radiat Oncol Biol Phys. 2021 Nov 1;111(3S):S35-S36. doi: 10.1016/j.ijrobp.2021.07.106.
    • Integrated, Integral, and Exploratory Biomarkers in the Development of Poly(ADP-Ribose) Polymerase Inhibitors.
    • Konecny GE, Chander C, Zhang L.
    • Cancer J. 2021 Nov-Dec 01;27(6):482-490. doi: 10.1097/PPO.0000000000000564.
    • Review
    • High BRCA2 Gene Expression is Associated with Aggressive and Highly Proliferative Breast Cancer.
    • Satyananda V, Oshi M, Endo I, Takabe K.
    • Ann Surg Oncol. 2021 Nov;28(12):7356-7365. doi: 10.1245/s10434-021-10063-5. Epub 2021 May 8.

    Commentary:

    ASO Author Reflections: High BRCA2 Gene Expression is Associated with Aggressive and Highly Proliferative Breast Cancer.

    Commentary:

    ASO Visual Abstract: High BRCA2 Gene Expression is Associated with Aggressive and Highly Proliferative Breast Cancer.

    • Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial.
    • Carreira S, Porta N, Arce-Gallego S, Seed G, Llop-Guevara A, Bianchini D, Rescigno P, Paschalis A, Bertan C, Baker C, Goodall J, Miranda S, Riisnaes R, Figueiredo I, Ferreira A, Pereira R, Crespo M, Gurel B, Nava Rodrigues D, Pettitt SJ, Yuan W, Serra V, Rekowski J, Lord CJ, Hall E, Mateo J, de Bono JS.
    • Cancer Discov. 2021 Nov;11(11):2812-2827. doi: 10.1158/2159-8290.CD-21-0007. Epub 2021 May 27.
    • The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas.
    • You B, Freyer G, Gonzalez-Martin A, Lheureux S, McNeish I, Penson RT, Pignata S, Pujade-Lauraine E.
    • Cancer Treat Rev. 2021 Nov;100:102294. doi: 10.1016/j.ctrv.2021.102294. Epub 2021 Sep 15.
    • Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer.
    • Shah PD, Wethington SL, Pagan C, Latif N, Tanyi J, Martin LP, Morgan M, Burger RA, Haggerty A, Zarrin H, Rodriguez D, Domchek S, Drapkin R, Shih IM, Smith SA, Dean E, Gaillard S, Armstrong D, Torigian DA, Hwang WT, Giuntoli R, Simpkins F.
    • Gynecol Oncol. 2021 Nov;163(2):246-253. doi: 10.1016/j.ygyno.2021.08.024. Epub 2021 Oct 5.
    • Discordant Reporting of a Previously Undescribed Pathogenic Germline BRCA2 Variant in Blood and Tumor Tissue in a Patient With Pancreatic Adenocarcinoma.
    • Kordes M, Tamborero D, Lagerstedt-Robinson K, Yachnin J, Rosenquist R, Löhr JM, Gustafsson Liljefors M.
    • JCO Precis Oncol. 2021 Nov;5:974-980. doi: 10.1200/PO.21.00024.
    • Homologous recombination proficiency in ovarian and breast cancer patients.
    • Creeden JF, Nanavaty NS, Einloth KR, Gillman CE, Stanbery L, Hamouda DM, Dworkin L, Nemunaitis J.
    • BMC Cancer. 2021 Oct 28;21(1):1154. doi: 10.1186/s12885-021-08863-9.
    • Efficacy and Safety of PARP Inhibitors in Advanced or Metastatic Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis.
    • Liu X, Wu K, Zheng D, Luo C, Fan Y, Zhong X, Zheng H.
    • Front Oncol. 2021 Oct 28;11:742139. doi: 10.3389/fonc.2021.742139.
    • The role of patient-derived ovarian cancer organoids in the study of PARP inhibitors sensitivity and resistance: from genomic analysis to functional testing.
    • Tao M, Wu X.
    • J Exp Clin Cancer Res. 2021 Oct 26;40(1):338. doi: 10.1186/s13046-021-02139-7.
    • PARP Inhibition in Prostate Cancer With Homologous Recombination Repair Alterations.
    • von Werdt A, Brandt L, Schärer OD, Rubin MA.
    • JCO Precis Oncol. 2021 Oct 22;5:PO.21.00152. doi: 10.1200/PO.21.00152.
    • First successful case of platinum-based chemotherapy for neuroendocrine prostate cancer with BRCA2 and PTEN alterations.
    • Omura M, Kosaka T, Aimono E, Nakamura K, Hongo H, Mikami S, Nishihara H, Oya M.
    • IJU Case Rep. 2021 Oct 20;5(1):41-44. doi: 10.1002/iju5.12383.
    • Targeting DNA Damage Response Pathway in Ovarian Clear Cell Carcinoma.
    • Wong OGW, Li J, Cheung ANY.
    • Front Oncol. 2021 Oct 19;11:666815. doi: 10.3389/fonc.2021.666815.
    • Homologous Recombination Deficiency Assays in Epithelial Ovarian Cancer: Current Status and Future Direction.
    • Chiang YC, Lin PH, Cheng WF.
    • Front Oncol. 2021 Oct 14;11:675972. doi: 10.3389/fonc.2021.675972.
    • CRISPR screens guide the way for PARP and ATR inhibitors biomarker discovery.
    • Schleicher EM, Moldovan GL.
    • FEBS J. 2021 Oct 3. doi: 10.1111/febs.16217. Epub ahead of print.
    • Response to rucaparib in BRCA-mutant metastatic castration-resistant prostate cancer identified by genomic testing in the TRITON2 study.
    • Loehr A, Patnaik A, Campbell D, Shapiro J, Bryce AH, McDermott R, Sautois B, Vogelzang NJ, Bambury RM, Voog E, Zhang J, Piulats JM, Hussain A, Ryan CJ, Merseburger AS, Daugaard G, Heidenreich A, Fizazi K, Higano CS, Krieger LE, Sternberg C, Watkins SP, Despain D, Simmons AD, Dowson M, Golsorkhi T, Chowdhury S, Abida W.
    • Clin Cancer Res. 2021 Oct 1:clincanres.2199.2021. doi: 10.1158/1078-0432.CCR-21-2199. Epub ahead of print.
    • Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer.
    • Clark CA, Yang ES.
    • Front Oncol. 2021 Sep 24;11:703802. doi: 10.3389/fonc.2021.703802.
    • Determinants of Homologous Recombination Deficiency in Pancreatic Cancer.
    • Wattenberg MM, Reiss KA.
    • Cancers (Basel). 2021 Sep 21;13(18):4716. doi: 10.3390/cancers13184716.
    • Let-7i Reduces Aggressive Phenotype and Induces BRCAness in Ovarian Cancer Cells.
    • Chirshev E, Suzuki T, Wang H, Nguyen A, Hojo N, Sanderman L, Mirshahidi S, Ioffe YJ, Unternaehrer JJ.
    • Cancers (Basel). 2021 Sep 15;13(18):4617. doi: 10.3390/cancers13184617.
    • Preclinical Studies on the Effect of Rucaparib in Ovarian Cancer: Impact of BRCA2 Status.
    • Saravi S, Alizzi Z, Tosi S, Hall M, Karteris E.
    • Cells. 2021 Sep 15;10(9):2434. doi: 10.3390/cells10092434.
    • Phase 1b dose expansion and translational analyses of olaparib in combination with capivasertib in recurrent endometrial, triple negative breast, and ovarian cancer.
    • Westin SN, Labrie M, Litton JK, Blucher A, Fang Y, Vellano CP, Marszalek JR, Feng N, Ma X, Creason A, Fellman B, Yuan Y, Lee S, Kim T, Liu J, Chelariu-Raicu A, Chen TH, Kabil N, Soliman PT, Frumovitz M, Schmeler KM, Jazaeri A, Lu KH, Murthy R, Meyer L, Sun C, Sood AK, Coleman RL, Mills GB.
    • Clin Cancer Res. 2021 Sep 13:clincanres.1656.2021. doi: 10.1158/1078-0432.CCR-21-1656. Epub ahead of print.
    • Genomic Determinants of Homologous Recombination Deficiency across Human Cancers.
    • Qing T, Wang X, Jun T, Ding L, Pusztai L, Huang KL.
    • Cancers (Basel). 2021 Sep 12;13(18):4572. doi: 10.3390/cancers13184572.
    • The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors.
    • Kim H, Ahn S, Kim H, Hong JY, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim KM, Kim ST.
    • J Cancer Res Clin Oncol. 2021 Sep 12. doi: 10.1007/s00432-021-03781-6. Epub ahead of print.
    • Illumina, Merck Partner to Advance Homologous Recombination Deficiency CDx, Research Assay.
    • [No author given]
    • GenomeWeb. 2021 Sep 7.
    • Patients with bi-allelic BRCA1/2 inactivation respond to olaparib treatment across histologic tumor types.
    • van der Wijngaart H, Hoes LR, van Berge Henegouwen JM, van der Velden DL, Zeverijn LJ, Roepman P, van Werkhoven E, de Leng WWJ, Jansen AML, Mehra N, Robbrecht DGJ, Labots M, de Groot DJA, Hoeben A, Hamberg P, Gelderblom H, Voest EE, Verheul HMW.
    • Clin Cancer Res. 2021 Sep 2:clincanres.1104.2021. doi: 10.1158/1078-0432.CCR-21-1104. Epub ahead of print.
    • Olaparib effectively treats local recurrence of extrahepatic cholangiocarcinoma in a patient harboring a BRCA2-inactivating mutation: a case report.
    • Li W, Ma Z, Fu X, Hao Z, Shang H, Shi J, Lei M, Xu M, Ning S, Hua X.
    • Ann Transl Med. 2021 Sep;9(18):1487. doi: 10.21037/atm-21-3681.
    • Hedgehog/GLI1 Transcriptionally Regulates FANCD2 in Ovarian Tumor Cells: Its Inhibition Induces HR-Deficiency and Synergistic Lethality with PARP Inhibition.
    • Mani C, Tripathi K, Chaudhary S, Somasagara RR, Rocconi RP, Crasto C, Reedy M, Athar M, Palle K.
    • Neoplasia. 2021 Sep;23(9):1002-1015. doi: 10.1016/j.neo.2021.06.010. Epub 2021 Aug 8.
    • Cytotoxic and targeted therapy for BRCA1/2-driven cancers.
    • Imyanitov EN.
    • Hered Cancer Clin Pract. 2021 Aug 28;19(1):36. doi: 10.1186/s13053-021-00193-y.
    • Uncovering cancer vulnerabilities by machine learning prediction of synthetic lethality.
    • Benfatto S, Serçin Ö, Dejure FR, Abdollahi A, Zenke FT, Mardin BR.
    • Mol Cancer. 2021 Aug 28;20(1):111. doi: 10.1186/s12943-021-01405-8.
    • Current gene panels account for nearly all homologous recombination repair-associated multiple-case breast cancer families.
    • Matis TS, Zayed N, Labraki B, de Ladurantaye M, Matis TA, Camacho Valenzuela J, Hamel N, Atayan A, Rivera B, Tabach Y, Tonin PN, Orthwein A, Mes-Masson AM, El Haffaf Z, Foulkes WD, Polak P.
    • NPJ Breast Cancer. 2021 Aug 25;7(1):109. doi: 10.1038/s41523-021-00315-8.
    • BRCAness as a Biomarker of Susceptibility to PARP Inhibitors in Glioblastoma Multiforme.
    • Xavier MA, Rezende F, Titze-de-Almeida R, Cornelissen B.
    • Biomolecules. 2021 Aug 11;11(8):1188. doi: 10.3390/biom11081188.
    • Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types.
    • Takamatsu S, Brown JB, Yamaguchi K, Hamanishi J, Yamanoi K, Takaya H, Kaneyasu T, Mori S, Mandai M, Matsumura N.
    • JCO Precis Oncol. 2021 Aug 11;5:PO.21.00141. doi: 10.1200/PO.21.00141.
    • Revealing biomarkers associated with PARP inhibitors based on genetic interactions in cancer genome.
    • Dong Q, Liu M, Chen B, Zhao Z, Chen T, Wang C, Zhuang S, Li Y, Wang Y, Ai L, Liu Y, Liang H, Qi L, Gu Y.
    • Comput Struct Biotechnol J. 2021 Aug 10;19:4435-4446. doi: 10.1016/j.csbj.2021.08.007.
    • Guardians of the Genome: BRCA2 and Its Partners.
    • Le HP, Heyer WD, Liu J.
    • Genes (Basel). 2021 Aug 10;12(8):1229. doi: 10.3390/genes12081229.
    • Acquired RAD51C promoter methylation loss causes PARP inhibitor resistance in high grade serous ovarian carcinoma.
    • Nesic K, Kondrashova O, Hurley RM, McGehee CD, Vandenberg CJ, Ho GY, Lieschke E, Dall G, Bound N, Shield-Artin K, Radke M, Musafer A, Chai ZQ, Eftekhariyan Ghamsari MR, Harrell MI, Kee D, Olesen I, McNally O, Traficante N, Cancer Study AO, DeFazio A, Bowtell DDL, Swisher EM, Weroha SJ, Nones K, Waddell N, Kaufmann SH, Dobrovic A, Wakefield MJ, Scott CL.
    • Cancer Res. 2021 Jul 28:canres.0774.2021. doi: 10.1158/0008-5472.CAN-21-0774. Epub ahead of print.
    • Rapid progression of metastatic pancreatic adenocarcinoma during platinum-based therapy in a patient harboring a pathogenic BRCA2 germline variant.
    • Sorscher S, Ramkissoon S.
    • Oncologist. 2021 Jul 26. doi: 10.1002/onco.13912. Epub ahead of print.
    • Missense Variants of Uncertain Significance: A Powerful Genetic Tool for Function Discovery with Clinical Implications.
    • Sessa G, Ehlén Å, von Nicolai C, Carreira A.
    • Cancers (Basel). 2021 Jul 23;13(15):3719. doi: 10.3390/cancers13153719.
    • Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants.
    • Macchini M, Centonze F, Peretti U, Orsi G, Militello AM, Valente MM, Cascinu S, Reni M.
    • Cancer Treat Rev. 2021 Jul 23;100:102262. doi: 10.1016/j.ctrv.2021.102262. Epub ahead of print.
    • Review
    • Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis.
    • Lee CK, Friedlander ML, Tjokrowidjaja A, Ledermann JA, Coleman RL, Mirza MR, Matulonis UA, Pujade-Lauraine E, Bloomfield R, Goble S, Wang P, Glasspool RM, Scott CL; Gynecologic Cancer Intergroup Meta-Analysis Committee.
    • Cancer. 2021 Jul 15;127(14):2432-2441. doi: 10.1002/cncr.33517. Epub 2021 Mar 19.
    • Meta-Analysis
    • Multi-Gene Testing Overview with a Clinical Perspective in Metastatic Triple-Negative Breast Cancer.
    • Dameri M, Ferrando L, Cirmena G, Vernieri C, Pruneri G, Ballestrero A, Zoppoli G.
    • Int J Mol Sci. 2021 Jul 1;22(13):7154. doi: 10.3390/ijms22137154.
    • Molecular Features and Functional Implications of Germline Variants in Triple-Negative Breast Cancer.
    • Ma D, Chen SY, Ren JX, Pei YC, Jiang CW, Zhao S, Xiao Y, Xu XE, Liu GY, Hu X, Liang XZ, Yu KD, Li DQ, Jiang YZ, Shao ZM.
    • J Natl Cancer Inst. 2021 Jul 1;113(7):884-892. doi: 10.1093/jnci/djaa175. Erratum in: J Natl Cancer Inst. 2021 Aug 17.
    • Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial.
    • Masuda N, Bando H, Yamanaka T, Kadoya T, Takahashi M, Nagai SE, Ohtani S, Aruga T, Suzuki E, Kikawa Y, Yasojima H, Kasai H, Ishiguro H, Kawabata H, Morita S, Haga H, Kataoka TR, Uozumi R, Ohno S, Toi M.
    • Breast Cancer Res Treat. 2021 Jul;188(1):117-131. doi: 10.1007/s10549-021-06184-w. Epub 2021 Mar 25.
    • Defizienz der homologen Rekombinationsreparatur als prädiktiver Marker : Grundlagen und Nachweis [Homologous recombination repair deficiency as a predictive biomarker : Basic mechanisms and detection methods].
    • Pfarr N, Merkelbach-Bruse S.
    • Pathologe. 2021 Jul;42(4):391-398. German. doi: 10.1007/s00292-021-00950-9. Epub 2021 Jun 21.
    • Review, Article in German
    • Remarkable Response to Olaparib in a Patient with Combined Hepatocellular-Cholangiocarcinoma Harboring a Biallelic BRCA2 Mutation.
    • Su YL, Ng CT, Jan YH, Hsieh YL, Wu CL, Tan KT.
    • Onco Targets Ther. 2021 Jun 29;14:3895-3901. doi: 10.2147/OTT.S317514.
    • Biomarkers for Homologous Recombination Deficiency in Cancer.
    • Wagener-Ryczek S, Merkelbach-Bruse S, Siemanowski J.
    • J Pers Med. 2021 Jun 28;11(7):612. doi: 10.3390/jpm11070612.
    • An Algorithm Combining Patient Performance Status, Second Hit Analysis, PROVEAN and Dann Prediction Tools Could Foretell Sensitization to PARP Inhibitors in Digestive, Skin, Ovarian and Breast Cancers.
    • Chevrier S, Richard C, Collot T, Mananet H, Arnould L, Boidot R.
    • Cancers (Basel). 2021 Jun 22;13(13):3113. doi: 10.3390/cancers13133113.
    • A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signatures.
    • Diossy M, Sztupinszki Z, Borcsok J, Krzystanek M, Tisza V, Spisak S, Rusz O, Timar J, Csabai I, Fillinger J, Moldvay J, Pedersen AG, Szuts D, Szallasi Z.
    • NPJ Precis Oncol. 2021 Jun 18;5(1):55. doi: 10.1038/s41698-021-00199-8.
    • Phase 1 Combination Study of the CHK1 inhibitor prexasertib, and the PARP inhibitor olaparib, in high-grade serous ovarian cancer and other solid tumors.
    • Do K, Kochupurakkal BS, Kelland S, de Jonge A, Hedglin J, Powers A, Quinn N, Gannon C, Vuong L, Parmar K, Lazaro JB, D'Andrea AD, Shapiro GI.
    • Clin Cancer Res. 2021 Jun 15:clincanres.1279.2021. doi: 10.1158/1078-0432.CCR-21-1279. Epub ahead of print.
    • Helicobacter pylori CagA elicits BRCAness to induce genome instability that may underlie bacterial gastric carcinogenesis.
    • Imai S, Ooki T, Murata-Kamiya N, Komura D, Tahmina K, Wu W, Takahashi-Kanemitsu A, Knight CT, Kunita A, Suzuki N, Del Valle AA, Tsuboi M, Hata M, Hayakawa Y, Ohnishi N, Ueda K, Fukayama M, Ushiku T, Ishikawa S, Hatakeyama M.
    • Cell Host Microbe. 2021 Jun 9;29(6):941-958.e10. doi: 10.1016/j.chom.2021.04.006. Epub 2021 May 13.
    • Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3.
    • Clamp AR, Lorusso D, Oza AM, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Scambia G, Leary A, Holloway RW, Amenedo Gancedo M, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Cameron T, Goble S, Coleman RL, Ledermann JA.
    • Int J Gynecol Cancer. 2021 Jun 8:ijgc-2020-002240. doi: 10.1136/ijgc-2020-002240. Epub ahead of print.
    • Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial.
    • Aghajanian C, Bookman MA, Fleming GF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Jackson CG, Sullivan D, Ratajczak CK, Coleman RL.
    • Gynecol Oncol. 2021 Jun 7:S0090-8258(21)00437-6. doi: 10.1016/j.ygyno.2021.05.031. Epub ahead of print.
    • Molecular predictors of the outcome of paclitaxel plus carboplatin neoadjuvant therapy in high-grade serous ovarian cancer patients.
    • Sokolenko AP, Gorodnova TV, Bizin IV, Kuligina ES, Kotiv KB, Romanko AA, Ermachenkova TI, Ivantsov AO, Preobrazhenskaya EV, Sokolova TN, Broyde RV, Imyanitov EN.
    • Cancer Chemother Pharmacol. 2021 Jun 2. doi: 10.1007/s00280-021-04301-6. Epub ahead of print.
    • Ex vivo analysis of DNA repair targeting in extreme rare cutaneous apocrine sweat gland carcinoma.
    • Mäkelä R, Härmä V, Fajardo NB, Wells G, Lygerou Z, Sangfelt O, Kononen J, Rantala JK.
    • Oncotarget. 2021 May 25;12(11):1100-1109. doi: 10.18632/oncotarget.27961.
    • Homologous recombination deficiency: cancer predispositions and treatment implications.
    • Toh MR, Ngeow J.
    • Oncologist. 2021 May 22. doi: 10.1002/onco.13829. Epub ahead of print.
    • DNA Damage Repair Inhibitor for Breast Cancer Treatment.
    • Min A, Lee KH, Im SA.
    • Adv Exp Med Biol. 2021 [First Online: 14 May 2021];1187:159-179. doi: 10.1007/978-981-32-9620-6_8.
    • Review, eBook chapter
    • Use of Circulating Tumor DNA for the Clinical Management of Metastatic Castration-Resistant Prostate Cancer: A Multicenter, Real-World Study.
    • Dong B, Fan L, Yang B, Chen W, Li Y, Wu K, Zhang F, Dong H, Cheng H, Pan J, Zhu Y, Chi C, Dong L, Sha J, Li L, Yao X, Xue W.
    • J Natl Compr Canc Netw. 2021 May 14;19(8):905-914. doi: 10.6004/jnccn.2020.7663.
    • C/EBPß promotes poly(ADP-ribose) polymerase inhibitor resistance by enhancing homologous recombination repair in high-grade serous ovarian cancer.
    • Tan J, Zheng X, Li M, Ye F, Song C, Xu C, Zhang X, Li W, Wang Y, Zeng S, Li H, Chen G, Huang X, Ma D, Liu D, Gao Q.
    • Oncogene. 2021 May 8. doi: 10.1038/s41388-021-01788-4. Epub ahead of print.
    • BRCA mutated pancreatic cancer: A change is coming.
    • Rosen MN, Goodwin RA, Vickers MM.
    • World J Gastroenterol. 2021 May 7;27(17):1943-1958. doi: 10.3748/wjg.v27.i17.1943.
    • Detection of Molecular Signatures of Homologous Recombination Deficiency in Bladder Cancer.
    • Börcsök J, Diossy M, Sztupinski Z, Prosz A, Tisza V, Spisak S, Rusz O, Stormoen DR, Pappot H, Csabai I, Brunak S, Mouw KW, Szallasi Z.
    • Clin Cancer Res. 2021 May 4:clincanres.5037.2020. doi: 10.1158/1078-0432.CCR-20-5037. Epub ahead of print.
    • Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2).
    • Swisher EM, Kwan TT, Oza AM, Tinker AV, Ray-Coquard I, Oaknin A, Coleman RL, Aghajanian C, Konecny GE, O'Malley DM, Leary A, Provencher D, Welch S, Chen LM, Wahner Hendrickson AE, Ma L, Ghatage P, Kristeleit RS, Dorigo O, Musafer A, Kaufmann SH, Elvin JA, Lin DI, Chambers SK, Dominy E, Vo LT, Goble S, Maloney L, Giordano H, Harding T, Dobrovic A, Scott CL, Lin KK, McNeish IA.
    • Nat Commun. 2021 May 3;12(1):2487. doi: 10.1038/s41467-021-22582-6.
    • Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Phase 2 Nonrandomized Clinical Trials.
    • Javle M, Shacham-Shmueli E, Xiao L, Varadhachary G, Halpern N, Fogelman D, Boursi B, Uruba S, Margalit O, Wolff RA, Golan T.
    • JAMA Oncol. 2021 May 1;7(5):693-699. doi: 10.1001/jamaoncol.2021.0006.
    • Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis.
    • Schettini F, Giudici F, Bernocchi O, Sirico M, Corona SP, Giuliano M, Locci M, Paris I, Scambia G, De Placido S, Rescigno P, Prat A, Curigliano G, Generali D.
    • Eur J Cancer. 2021 May;149:134-152. doi: 10.1016/j.ejca.2021.02.035. Epub 2021 Apr 13. Erratum in: Eur J Cancer. 2021 Aug;153:274.
    • Meta-Analysis
    • Poly (ADP-ribose) polymerase (PARP) as target for the treatment of epithelial ovarian cancer: what to know.
    • Della Corte L, Foreste V, Di Filippo C, Giampaolino P, Bifulco G.
    • Expert Opin Investig Drugs. 2021 May;30(5):543-554. doi: 10.1080/13543784.2021.1901882. Epub 2021 Mar 24.
    • Review
    • Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women.
    • Filippova OT, Selenica P, Pareja F, Vahdatinia M, Zhu Y, Pei X, Riaz N, Long Roche K, Chi DS, Abu-Rustum NR, Ellenson LH, Reis-Filho JS, Zamarin D, Weigelt B.
    • Gynecol Oncol. 2021 May;161(2):545-552. doi: 10.1016/j.ygyno.2021.02.028. Epub 2021 Mar 3.
    • An Overview of PARP Inhibitors for the Treatment of Breast Cancer.
    • Cortesi L, Rugo HS, Jackisch C.
    • Target Oncol. 2021 May;16(3):255-282. doi: 10.1007/s11523-021-00796-4. Epub 2021 Mar 12.
    • WNT inhibition creates a BRCA-like state in Wnt-addicted cancer.
    • Kaur A, Lim JYS, Sepramaniam S, Patnaik S, Harmston N, Lee MA, Petretto E, Virshup DM, Madan B.
    • EMBO Mol Med. 2021 Apr 9;13(4):e13349. doi: 10.15252/emmm.202013349. Epub 2021 Mar 4.
    • Treatment Strategies for ARID1A-Deficient Ovarian Clear Cell Carcinoma.
    • Takahashi K, Takenaka M, Okamoto A, Bowtell DDL, Kohno T.
    • Cancers (Basel). 2021 Apr 7;13(8):1769. doi: 10.3390/cancers13081769.
    • Changing the History of Prostate Cancer with New Targeted Therapies.
    • Hernando Polo S, Moreno Muñoz D, Rosero Rodríguez AC, Silva Ruiz J, Rosero Rodríguez DI, Couñago F.
    • Biomedicines. 2021 Apr 6;9(4):392. doi: 10.3390/biomedicines9040392.
    • Olaparib in hormone receptor-positive, HER2-negative metastatic breast cancer with a somatic BRCA2 mutation.
    • Schwartzberg LS, Kiedrowski LA.
    • Ther Adv Med Oncol. 2021 Apr 5;13:17588359211006962. doi: 10.1177/17588359211006962.
    • Synthetic Lethality in Cancer Therapeutics: The Next Generation.
    • Setton J, Zinda M, Riaz N, Durocher D, Zimmermann M, Koehler M, Reis-Filho JS, Powell SN.
    • Cancer Discov. 2021 Apr 1. doi: 10.1158/2159-8290.CD-20-1503. Epub ahead of print.
    • Review
    • Targeting Replicative Stress and DNA Repair by Combining PARP and Wee1 Kinase Inhibitors Is Synergistic in Triple Negative Breast Cancers with Cyclin E or BRCA1 Alteration.
    • Chen X, Yang D, Carey JPW, Karakas C, Albarracin C, Sahin AA, Arun BK, Guray Durak M, Li M, Kohansal M, Bui TN, Ha MJ, Hunt KK, Keyomarsi K.
    • Cancers (Basel). 2021 Apr 1;13(7):1656. doi: 10.3390/cancers13071656.
    • Decreased expression of the translation factor eIF3e induces senescence in breast cancer cells via suppression of PARP1 and activation of mTORC1.
    • Morris C, Durand S, Jalinot P.
    • Oncotarget. 2021 Mar 30;12(7):649-664. doi: 10.18632/oncotarget.27923.
    • Intermountain Gets National Stage, Myriad Adds Tumor Profiling Panel With Combined Test Offering.
    • Ray T.
    • GenomeWeb. Business & Policy. Business News. 2021 Mar 24.
    • News
    • Prolonged response to treatment based on cell-free DNA analysis and molecular profiling in three patients with metastatic cancer: a case series.
    • Naqvi MF, Vo HH, Vining D, Tsimberidou AM.
    • Ther Adv Med Oncol. 2021 Mar 24;13:17588359211001538. doi: 10.1177/17588359211001538.
    • Shaping the BRCAness mutational landscape by alternative double-strand break repair, replication stress and mitotic aberrancies.
    • Stok C, Kok YP, van den Tempel N, van Vugt MATM.
    • Nucleic Acids Res. 2021 Mar 21:gkab151. doi: 10.1093/nar/gkab151. Epub ahead of print.
    • Structural variants at the BRCA1/2 loci are a common source of homologous repair deficiency in high grade serous ovarian carcinoma.
    • Ewing A, Meynert A, Churchman M, Grimes G, Hollis RL, Herrington CS, Rye T, Bartos C, Croy I, Ferguson MJ, Lennie M, McGoldrick T, McPhail N, Siddiqui N, Dowson S, Glasspool R, Mackean M, Nussey F, McDade B, Ennis D, Genomes Partnership TS, McMahon L, Matakidou A, Dougherty BA, March R, Barrett JC, McNeish IA, Biankin AV, Roxburgh P, Gourley C, Semple CA.
    • Clin Cancer Res. 2021 Mar 19:clincanres.CCR-20-4068-A.2020. doi: 10.1158/1078-0432.CCR-20-4068. Epub ahead of print.
    • NICE Recommends Lynparza, Avastin Combination in Ovarian Cancer Through Cancer Drugs Fund.
    • [No author given]
    • Precision Oncology News. Business & Policy. 2021 Mar 19.
    • Replication Gaps Underlie BRCA Deficiency and Therapy Response.
    • Panzarino NJ, Krais JJ, Cong K, Peng M, Mosqueda M, Nayak SU, Bond SM, Calvo JA, Doshi MB, Bere M, Ou J, Deng B, Zhu LJ, Johnson N, Cantor SB.
    • Cancer Res. 2021 Mar 1;81(5):1388-1397. doi: 10.1158/0008-5472.CAN-20-1602. Epub 2020 Nov 12.

    Commentary:

    Which Holds the Key to BRCAness: Inability to Repair the Break, Protect the Fork, or Prevent the Gap?

    • Homologous Recombination Deficiency Testing for BRCA-Like Tumors: The Road to Clinical Validation.
    • Ladan MM, van Gent DC, Jager A.
    • Cancers (Basel). 2021 Feb 28;13(5):1004. doi: 10.3390/cancers13051004.
    • Blocking Fra-1 sensitizes triple-negative breast cancer to PARP inhibitor.
    • Song D, He H, Sinha I, Hases L, Yan F, Archer A, Haldosen LA, Zhao C, Williams C.
    • Cancer Lett. 2021 Feb 27:S0304-3835(21)00092-6. doi: 10.1016/j.canlet.2021.02.018. Epub ahead of print.
    • Loss of BRCA1 expression and morphological features associated with BRCA1 promoter methylation status in triple-negative breast cancer.
    • Morizono A, Tanabe M, Ikemura M, Sasaki T, Ushiku T, Seto Y.
    • J Hum Genet. 2021 Feb 27. doi: 10.1038/s10038-021-00911-3. Epub ahead of print.
    • BKM120 sensitizes BRCA-proficient triple negative breast cancer cells to olaparib through regulating FOXM1 and Exo1 expression.
    • Li Y, Wang Y, Zhang W, Wang X, Chen L, Wang S.
    • Sci Rep. 2021 Feb 26;11(1):4774. doi: 10.1038/s41598-021-82990-y.
    • Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer.
    • How JA, Jazaeri AA, Fellman B, Daniels MS, Penn S, Solimeno C, Yuan Y, Schmeler K, Lanchbury JS, Timms K, Lu KH, Yates MS.
    • Cancers (Basel). 2021 Feb 24;13(5):946. doi: 10.3390/cancers13050946.
    • Benefit of AstraZeneca's Cediranib Plus Lynparza May Be Limited to HRR-Deficient Prostate Cancers.
    • Hopkins C.
    • Precision Oncology News. Cancer Specialties. 2021 Feb 12.
    • Conference news
    • Clinical significance of homologous recombination deficiency score testing in endometrial Cancer.
    • Siedel JH, Ring KL, Hu W, Dood RL, Wang Y, Baggerly K, Darcy KM, Conrads TP, Gallagher S, Tshiaba P, Neff C, Timms KM, Mangala S, Westin SN, Broaddus R, Lopez-Berestein G, Lu KH, Coleman RL, Maxwell GL, Sood AK.
    • Gynecol Oncol. 2021 Feb 6:S0090-8258(20)34181-0. doi: 10.1016/j.ygyno.2020.12.010. Epub ahead of print.
    • DNA damage response inhibitors: An avenue for TNBC treatment.
    • Jin J, Tao Z, Cao J, Li T, Hu X.
    • Biochim Biophys Acta Rev Cancer. 2021 Feb 5:188521. doi: 10.1016/j.bbcan.2021.188521. Epub ahead of print.
    • Review
    • Clinical impact of BRCA2 mRNA expression in high-grade serous ovarian cancer: validation using the TCGA cohort.
    • Tsibulak I, Wieser V, Welponer H, Leitner K, Hackl H, Marth C, Fiegl H, Zeimet AG.
    • Acta Oncol. 2021 Feb;60(2):187-190. doi: 10.1080/0284186X.2020.1841288. Epub 2020 Nov 4.
    • Comprehensive Genomic Profiling-Guided Niraparib Treatment of Triple-Negative Breast Cancer in a Patient With Extensive Brain Metastasis: Case Report and Literature Review.
    • Lam TC.
    • J Immunother Precis Oncol. 2021 Jan 29 [eCollection 2021 Feb];4(1):16-20. doi: 10.36401/JIPO-20-24.
    • Promoter methylation of DNA homologous recombination genes is predictive of the responsiveness to PARP inhibitor treatment in testicular germ cell tumors.
    • Lobo J, Constâncio V, Guimarães-Teixeira C, Leite-Silva P, Miranda-Gonçalves V, Sequeira JP, Pistoni L, Guimarães R, Cantante M, Braga I, Maurício J, Looijenga LH, Henrique R, Jerónimo C.
    • Mol Oncol. 2021 Jan 29. doi: 10.1002/1878-0261.12909. Epub ahead of print.
    • Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial.
    • Fennell DA, King A, Mohammed S, Branson A, Brookes C, Darlison L, Dawson AG, Gaba A, Hutka M, Morgan B, Nicholson A, Richards C, Wells-Jordan P, Murphy GJ, Thomas A; MiST1 study group.
    • Lancet Respir Med. 2021 Jan 27:S2213-2600(20)30390-8. doi: 10.1016/S2213-2600(20)30390-8. Epub ahead of print.
    • ASCO 2020: highlights in breast cancer.
    • Bartsch R.
    • Memo. 2021 Jan 24:1-4. doi: 10.1007/s12254-021-00674-9. Epub ahead of print.
    • The Prognostic Relevance of Poly (ADP-Ribose) Polymerase Expression in Ovarian Cancer Tissue of Wild Type and BRCA-Mutation Carrier Patients.
    • Molnár S, Vida B, Beke L, Méhes G, Póka R.
    • Diagnostics (Basel). 2021 Jan 19;11(1):E144. doi: 10.3390/diagnostics11010144.
    • Clinical application of liquid biopsies to detect somatic BRCA1/2 mutations and guide potential therapeutic intervention for patients with metastatic breast cancer.
    • Vidula N, Ellisen LW, Bardia A.
    • Oncotarget. 2021 Jan 19;12(2):63-65. doi: 10.18632/oncotarget.27863.
    • Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer.
    • Lotan TL, Kaur HB, Salles DC, Murali S, Schaeffer EM, Lanchbury JS, Isaacs WB, Brown R, Richardson AL, Cussenot O, Cancel-Tassin G, Timms KM, Antonarakis ES.
    • Mod Pathol. 2021 Jan 18. doi: 10.1038/s41379-020-00731-4. Epub ahead of print.
    • Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer.
    • Chiappa M, Guffanti F, Bertoni F, Colombo I, Damia G.
    • Drug Resist Updat. 2021 Jan 16:100744. doi: 10.1016/j.drup.2021.100744. Epub ahead of print.
    • Review
    • Homologous Recombination Repair Mechanisms in Serous Endometrial Cancer.
    • Jönsson JM, Bååth M, Björnheden I, Sahin ID, Måsbäck A, Hedenfalk I.
    • Cancers (Basel). 2021 Jan 12;13(2):E254. doi: 10.3390/cancers13020254.
    • Pathogenicity Assessment of Variants for Breast Cancer Susceptibility Genes Based on BRCAness of Tumor Sample.
    • Yoshida R, Hagio T, Kaneyasu T, Gotoh O, Osako T, Tanaka N, Amino S, Yaguchi N, Nakashima E, Kitagawa D, Ueno T, Ohno S, Nakajima T, Nakamura S, Miki Y, Hirota T, Takahashi S, Matsuura M, Noda T, Mori S.
    • Cancer Sci. 2021 Jan 9. doi: 10.1111/cas.14803. Epub ahead of print.
    • Generating real-world evidence from unstructured clinical notes to examine clinical utility of genetic tests: use case in BRCAness.
    • Zhao Y, Weroha SJ, Goode EL, Liu H, Wang C.
    • BMC Med Inform Decis Mak. 2021 Jan 6;21(1):3. doi: 10.1186/s12911-020-01364-y.
    • The current landscape of molecular profiling in the treatment of epithelial ovarian cancer.
    • Haunschild CE, Tewari KS.
    • Gynecol Oncol. 2021 Jan;160(1):333-345. doi: 10.1016/j.ygyno.2020.09.043. Epub 2020 Oct 11.
    • Review
    • PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports.
    • Collot T, Niogret J, Carnet M, Chevrier S, Humblin E, Favier L, Bengrine-Lefevre L, Desmoulins I, Arnould L, Boidot R.
    • Mol Med Rep. 2021 Jan;23(1):75. doi: 10.3892/mmr.2020.11713. Epub 2020 Nov 25.
    • Case report
    • PARP inhibitors in ovarian cancer: an overview of the practice-changing trials.
    • Foo T, George A, Banerjee S.
    • Genes Chromosomes Cancer. 2020 Dec 31. doi: 10.1002/gcc.22935. Epub ahead of print.
    • Review
    • Poly(ADP-ribose) polymerase inhibition in pancreatic cancer.
    • Singh HM, Bailey P, Hübschmann D, Berger AK, Neoptolemos J, Jäger D, Siveke J, Springfeld C.
    • Genes Chromosomes Cancer. 2020 Dec 20. doi: 10.1002/gcc.22932. Epub ahead of print.
    • Review
    • TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.
    • Tung NM, Robson ME, Ventz S, Santa-Maria CA, Nanda R, Marcom PK, Shah PD, Ballinger TJ, Yang ES, Vinayak S, Melisko M, Brufsky A, DeMeo M, Jenkins C, Domchek S, D'Andrea A, Lin NU, Hughes ME, Carey LA, Wagle N, Wulf GM, Krop IE, Wolff AC, Winer EP, Garber JE.
    • J Clin Oncol. 2020 Dec 20;38(36):4274-4282. doi: 10.1200/JCO.20.02151. Epub 2020 Oct 29.

    Commentary, Review:

    Germline Mutations in Other Homologous Recombination Repair-Related Genes Than BRCA1/2: Predictive or Prognostic Factors?

    • BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor.
    • Sahnane N, Carnevali I, Formenti G, Casarin J, Facchi S, Bombelli R, Di Lauro E, Memoli D, Salvati A, Rizzo F, Sessa F, Tibiletti MG.
    • Int J Mol Sci. 2020 Dec 19;21(24):E9708. doi: 10.3390/ijms21249708.
    • Enhanced Efficacy of Combined Therapy with Checkpoint Kinase 1 Inhibitor and Rucaparib Via Regulation of Rad-51 Expression in BRCA Wild-Type Epithelial Ovarian Cancer Cells.
    • Cho HY, Kim YB, Park WH, No JH.
    • Cancer Res Treat. 2020 Dec 16. doi: 10.4143/crt.2020.1013. Epub ahead of print.
    • Clinical Outcome-Related Mutational Signatures Identified by Integrative Genomic Analysis in Nasopharyngeal Carcinoma.
    • Dai W, Chung DL, Chow LK, Yu VZ, Lei LC, Leong MM, Chan CK, Ko JM, Lung ML.
    • Clin Cancer Res. 2020 Dec 15;26(24):6494-6504. doi: 10.1158/1078-0432.CCR-20-2854. Epub 2020 Sep 28.
    • BRCAness as a prognostic indicator in patients with early breast cancer.
    • Liu L, Matsunaga Y, Tsurutani J, Akashi-Tanaka S, Masuda H, Ide Y, Hashimoto R, Inuzuka M, Watanabe C, Taruno K, Sawada T, Okuyama H, Ata A, Kuwayama T, Nakayama S, Tonouchi Y, Nakamura S.
    • Sci Rep. 2020 Dec 3;10(1):21173. doi: 10.1038/s41598-020-78016-8.
    • Patient selection biomarker strategies for PARP inhibitor therapy.
    • Pilié PG, George A, Yap TA.
    • Ann Oncol. 2020 Dec;31(12):1603-1605. doi: 10.1016/j.annonc.2020.09.017. Epub 2020 Oct 1.
    • Editorial
    • The effect of the triazene compound CT913 on ovarian cancer cells in vitro and its synergistic interaction with the PARP-inhibitor olaparib.
    • Wichmann C, Klotz DM, Zeiler HJ, Hilger RA, Grützmann K, Krüger A, Aust D, Wimberger P, Kuhlmann JD.
    • Gynecol Oncol. 2020 Dec;159(3):850-859. doi: 10.1016/j.ygyno.2020.09.018. Epub 2020 Sep 23.
    • Homologous recombination deficiency real-time clinical assays, ready or not?
    • Fuh K, Mullen M, Blachut B, Stover E, Konstantinopoulos P, Liu J, Matulonis U, Khabele D, Mosammaparast N, Vindigni A.
    • Gynecol Oncol. 2020 Dec;159(3):877-886. doi: 10.1016/j.ygyno.2020.08.035. Epub 2020 Sep 20.
    • Review
    • New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer.
    • Han Y, Yu X, Li S, Tian Y, Liu C.
    • Front Oncol. 2020 Nov 25;10:578095. doi: 10.3389/fonc.2020.578095.
    • Olaparib Monotherapy as Primary Treatment in Unselected Triple Negative Breast Cancer.
    • Eikesdal HP, Yndestad S, Elzawahry A, Llop-Guevara A, Gilje B, Blix ES, Espelid H, Lundgren S, Geisler J, Vagstad G, Venizelos A, Minsaas L, Leirvaag B, Gudlaugsson EG, Vintermyr OK, Aase HS, Aas T, Balmaña J, Serra V, Janssen EAM, Knappskog S, Lønning PE.
    • Ann Oncol. 2020 Nov 23:S0923-7534(20)43164-3. doi: 10.1016/j.annonc.2020.11.009. Epub ahead of print.
    • Tumor BRCA Testing in High Grade Serous Carcinoma: Mutation Rates and Optimal Tissue Requirements.
    • Turashvili G, Lazaro C, Ying S, Charames G, Wong A, Hamilton K, Yee D, Agro E, Chang M, Pollett A, Lerner-Ellis J.
    • Cancers (Basel). 2020 Nov 21;12(11):3468. doi: 10.3390/cancers12113468.
    • Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.
    • Sheta R, Bachvarova M, Plante M, Renaud MC, Sebastianelli A, Gregoire J, Navarro JM, Perez RB, Masson JY, Bachvarov D.
    • J Transl Med. 2020 Nov 19;18(1):439. doi: 10.1186/s12967-020-02613-4.
    • Frequency and prognostic value of mutations associated with the homologous recombination DNA repair pathway in a large pan cancer cohort.
    • Principe DR, Narbutis M, Koch R, Rana A.
    • Sci Rep. 2020 Nov 19;10(1):20223. doi: 10.1038/s41598-020-76975-6.
    • Pan-cancer landscape of homologous recombination deficiency.
    • Nguyen L, W M Martens J, Van Hoeck A, Cuppen E.
    • Nat Commun. 2020 Nov 4;11(1):5584. doi: 10.1038/s41467-020-19406-4.
    • Update Breast Cancer 2020 Part 4 - Advanced Breast Cancer.
    • Tesch H, Müller V, Wöckel A, Ettl J, Belleville E, Schütz F, Hartkopf A, Thill M, Huober J, Fasching PA, Kolberg HC, Schulmeyer CE, Welslau M, Overkamp F, Fehm TN, Lux MP, Schneeweiss A, Lüftner D, Janni W.
    • Geburtshilfe Frauenheilkd. 2020 Nov;80(11):1115-1122. doi: 10.1055/a-1270-7481. Epub 2020 Nov 6.
    • PARP Inhibitor in Advanced Endometrial Carcinoma Beyond BRCA and Related Genetic Mutations.
    • Alexandre J, Ray-Coquard I, Joly F.
    • JCO Precis Oncol. 2020 Nov;4:1025-1026. doi: 10.1200/PO.20.00177.
    • RAD51-Mediated DNA Homologous Recombination Is Independent of PTEN Mutational Status.
    • Sinha A, Saleh A, Endersby R, Yuan SH, Chokshi CR, Brown KR, Kuzio B, Kauppinen T, Singh SK, Baker SJ, McKinnon PJ, Katyal S.
    • Cancers (Basel). 2020 Oct 29;12(11):3178. doi: 10.3390/cancers12113178.
    • Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study.
    • O'Shaughnessy J, Brezden-Masley C, Cazzaniga M, Dalvi T, Walker G, Bennett J, Ohsumi S.
    • Breast Cancer Res. 2020 Oct 27;22(1):114. doi: 10.1186/s13058-020-01349-9.
    • Poly(ADP-Ribose) Polymerase Inhibitors in Prostate Cancer: Molecular Mechanisms, and Preclinical and Clinical Data.
    • Sigorski D, Izycka-Swieszewska E, Bodnar L.
    • Target Oncol. 2020 Oct 12. doi: 10.1007/s11523-020-00756-4. Epub ahead of print.
    • Newly diagnosed ovarian cancer: Which first-line treatment?
    • Lorusso D, Ceni V, Daniele G, Salutari V, Pietragalla A, Muratore M, Nero C, Ciccarone F, Scambia G.
    • Cancer Treat Rev. 2020 Oct 9;91:102111. doi: 10.1016/j.ctrv.2020.102111. Epub ahead of print.
    • Review
    • Clinical assays for assessment of homologous recombination DNA repair deficiency.
    • Stover EH, Fuh K, Konstantinopoulos PA, Matulonis UA, Liu JF.
    • Gynecol Oncol. 2020 Oct 1:S0090-8258(20)33922-6. doi: 10.1016/j.ygyno.2020.09.029. Epub ahead of print.
    • Review
    • Effects of germline and somatic events in candidate BRCA-like genes on breast-tumor signatures.
    • Bodily WR, Shirts BH, Walsh T, Gulsuner S, King MC, Parker A, Roosan M, Piccolo SR.
    • PLoS One. 2020 Sep 30;15(9):e0239197. doi: 10.1371/journal.pone.0239197.
    • The RECAP Test Rapidly and Reliably Identifies Homologous Recombination-Deficient Ovarian Carcinomas.
    • van Wijk LM, Vermeulen S, Meijers M, van Diest MF, Ter Haar NT, de Jonge MM, Solleveld-Westerink N, van Wezel T, van Gent DC, Kroep JR, Bosse T, Gaarenstroom KN, Vrieling H, Vreeswijk MPG.
    • Cancers (Basel). 2020 Sep 29;12(10):2805. doi: 10.3390/cancers12102805.
    • Exploiting Chromosomal Instability of PTEN-Deficient Triple-Negative Breast Cancer Cell Lines for the Sensitization against PARP1 Inhibition in a Replication-Dependent Manner.
    • Rieckhoff J, Meyer F, Classen S, Zielinski A, Riepen B, Wikman H, Petersen C, Rothkamm K, Borgmann K, Parplys AC.
    • Cancers (Basel). 2020 Sep 29;12(10):2809. doi: 10.3390/cancers12102809.
    • ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.
    • Miller RE, Leary A, Scott CL, Serra V, Lord CJ, Bowtell D, Chang DK, Garsed DW, Jonkers J, Ledermann JA, Nik-Zainal S, Ray-Coquard I, Shah SP, Matias-Guiu X, Swisher EM, Yates LR.
    • Ann Oncol. 2020 Sep 28:S0923-7534(20)42164-7. doi: 10.1016/j.annonc.2020.08.2102. Epub ahead of print.
    • Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy.
    • Gou R, Dong H, Lin B.
    • Life Sci. 2020 Sep 14:118434. doi: 10.1016/j.lfs.2020.118434. Epub ahead of print.
    • What is the role of PARP inhibitors in pancreatic cancer?
    • Halder R, T Shroff R.
    • Expert Rev Anticancer Ther. 2020 Sep 11:1-6. doi: 10.1080/14737140.2020.1816174. Epub ahead of print.
    • Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancer.
    • Kalachand RD, O'Riain C, Toomey S, Carr A, Timms KM, O'Toole S, Madden S, Bates M, O'Leary JJ, Gleeson N, O'Donnell D, Grogan L, Breathnach O, Farrelly A, Stordal B, Hennessy BT.
    • Obstet Gynecol Sci. 2020 Sep 2. doi: 10.5468/ogs.20030. Epub ahead of print.
    • Somatic mutation profiling in BRCA-negative breast and ovarian cancer patients by multigene panel sequencing.
    • Kwong A, Cheuk IW, Shin VY, Ho CY, Au CH, Ho DN, Wong EY, Yu SW, Chen J, Chan KK, Ngan HY, Chan TL, Ma ES.
    • Am J Cancer Res. 2020 Sep 1;10(9):2919-2932.
    • Recent advancements in PARP inhibitors-based targeted cancer therapy.
    • Zhou P, Wang J, Mishail D, Wang CY.
    • Precis Clin Med. 2020 Sep;3(3):187-201. doi: 10.1093/pcmedi/pbaa030. Epub 2020 Aug 31.
    • PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?
    • Ricci AD, Rizzo A, Bonucci C, Tober N, Palloni A, Mollica V, Maggio I, Deserti M, Tavolari S, Brandi G.
    • Medicines (Basel). 2020 Aug 31;7(9):E54. doi: 10.3390/medicines7090054.
    • Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer.
    • Onstad M, Coleman RL, Westin SN.
    • Drugs. 2020 Aug 27. doi: 10.1007/s40265-020-01382-0. Epub ahead of print.
    • Review
    • DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives.
    • Perkhofer L, Gout J, Roger E, Kude de Almeida F, Baptista Simões C, Wiesmüller L, Seufferlein T, Kleger A.
    • Gut. 2020 Aug 27:gutjnl-2019-319984. doi: 10.1136/gutjnl-2019-319984. Epub ahead of print.
    • Breast cancer (BRCA) gene testing in ovarian cancer.
    • Chelariu-Raicu A, Coleman RL.
    • Chin Clin Oncol. 2020 Aug 19:cco-20-4. doi: 10.21037/cco-20-4. Epub ahead of print.
    • TBCRC 030: A phase II study of preoperative cisplatin vs. paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker.
    • Mayer EL, Abramson V, Jankowitz R, Falkson C, Marcom PK, Traina T, Carey L, Rimawi M, Specht J, Miller K, Stearns V, Tung N, Perou C, Richardson AL, Componeschi K, Trippa L, Tan-Wasielewski Z, Timms K, Krop I, Wolff AC, Winer EP.
    • Ann Oncol. 2020 Aug 13:S0923-7534(20)42061-7. doi: 10.1016/j.annonc.2020.08.2064. Epub ahead of print.
    • Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway.
    • Heeke AL, Xiu J, Elliott A, Korn WM, Lynce F, Pohlmann PR, Isaacs C, Swain SM, Vidal G, Schwartzberg LS, Tan AR.
    • Breast Cancer Res Treat. 2020 Aug 10. doi: 10.1007/s10549-020-05849-2. Epub ahead of print.
    • BReast CAncer (BRCA) gene mutations as an emerging biomarker for the treatment of gastrointestinal malignancies.
    • Premnath N, O'Reilly EM.
    • Chin Clin Oncol. 2020 Aug 10:cco-2019-ddp-05. doi: 10.21037/cco-2019-ddp-05. Epub ahead of print.
    • Using whole-genome sequencing data to derive the homologous recombination deficiency scores.
    • de Luca XM, Newell F, Kazakoff SH, Hartel G, McCart Reed AE, Holmes O, Xu Q, Wood S, Leonard C, Pearson JV, Lakhani SR, Waddell N, Nones K, Simpson PT.
    • NPJ Breast Cancer. 2020 Aug 7;6(1):33. doi: 10.1038/s41523-020-0172-0.
    • Using whole-genome sequencing data to derive the homologous recombination deficiency scores.
    • de Luca XM, Newell F, Kazakoff SH, Hartel G, McCart Reed AE, Holmes O, Xu Q, Wood S, Leonard C, Pearson JV, Lakhani SR, Waddell N, Nones K, Simpson PT.
    • NPJ Breast Cancer. 2020 Aug 7;6:33. doi: 10.1038/s41523-020-0172-0.
    • Niraparib maintenance in frontline management of ovarian cancer: a cost effectiveness analysis.
    • Barrington DA, Tubbs C, Smith HJ, Straughn JM Jr, Senter L, Cohn DE.
    • Int J Gynecol Cancer. 2020 Aug 4:ijgc-2020-001550. doi: 10.1136/ijgc-2020-001550. Epub ahead of print.
    • Promoter Hypermethylation and Expression Changes of BRCA1 Gene in a Cohort of Sporadic Breast Cancer Cases among Pakistani Population.
    • Arif T, Anwar N.
    • Asian Pac J Cancer Prev. 2020 Aug 1;21(8):2395-2401. doi: 10.31557/APJCP.2020.21.8.2395.
    • Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers.
    • Glodzik D, Bosch A, Hartman J, Aine M, Vallon-Christersson J, Reuterswärd C, Karlsson A, Mitra S, Niméus E, Holm K, Häkkinen J, Hegardt C, Saal LH, Larsson C, Malmberg M, Rydén L, Ehinger A, Loman N, Kvist A, Ehrencrona H, Nik-Zainal S, Borg Å, Staaf J.
    • Nat Commun. 2020 Jul 27;11(1):3747. doi: 10.1038/s41467-020-17537-2.
    • Homologous repair deficiency score for identifying breast cancers with defective DNA damage response.
    • Min A, Kim K, Jeong K, Choi S, Kim S, Suh KJ, Lee KH, Kim S, Im SA.
    • Sci Rep. 2020 Jul 27;10(1):12506. doi: 10.1038/s41598-020-68176-y.
    • BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer.
    • Lips EH, Benard-Slagter A, Opdam M, Scheerman CE, Wesseling J, Hogervorst FBL, Linn SC, Savola S, Nederlof PM.
    • Breast Cancer Res. 2020 Jul 25;22(1):79. doi: 10.1186/s13058-020-01313-7.
    • PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies.
    • Lee EK, Matulonis UA.
    • Cancers (Basel). 2020 Jul 25;12(8):2054. doi: 10.3390/cancers12082054.
    • Enhance PARPi Application beyond BRCA-Mutant Breast Cancer (BC): Facts Are Facts.
    • Di Raimo T, Angelini F.
    • J Clin Med. 2020 Jul 25;9(8):E2377. doi: 10.3390/jcm9082377.
    • Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas.
    • Li H, Tu J, Zhao Z, Chen L, Qu Y, Li H, Yao H, Wang X, Lee DF, Shen J, Wen L, Huang G, Xie X.
    • Theranostics. 2020 Jul 25;10(21):9477-9494. doi: 10.7150/thno.45763.
    • Olaparib for metastatic breast cancer in a patient with a germline PALB2 variant.
    • Kuemmel S, Harrach H, Schmutzler RK, Kostara A, Ziegler-Löhr K, Dyson MH, Chiari O, Reinisch M.
    • NPJ Breast Cancer. 2020 Jul 24;6:31. doi: 10.1038/s41523-020-00174-9.
    • BRCA1-associated structural variations are a consequence of polymerase theta-mediated end-joining.
    • Kamp JA, van Schendel R, Dilweg IW, Tijsterman M.
    • Nat Commun. 2020 Jul 17;11(1):3615. doi: 10.1038/s41467-020-17455-3.
    • Inhibition of the ATR kinase enhances 5-FU sensitivity independently of non-homologous end-joining and homologous recombination repair pathways.
    • Ito SS, Nakagawa Y, Matsubayashi M, Sakaguchi YM, Kobashigawa S, Matsui TK, Nanaura H, Nakanishi M, Kitayoshi F, Kikuchi S, Kajihara A, Tamaki S, Sugie K, Kashino G, Takahashi A, Hasegawa M, Mori E, Kirita T.
    • J Biol Chem. 2020 Jul 16:jbc.RA120.013726. doi: 10.1074/jbc.RA120.013726. Epub ahead of print.
    • Inactivation of the Prolyl Isomerase Pin1 Sensitizes BRCA1-Proficient Breast Cancer to PARP Inhibition.
    • Luo ML, Zheng F, Chen W, Liang ZM, Chandramouly G, Tan J, Willis NA, Chen CH, Taveira MO, Zhou XZ, Lu KP, Scully R, Wulf GM, Hu H.
    • Cancer Res. 2020 Jul 15;80(14):3033-3045. doi: 10.1158/0008-5472.CAN-19-2739. Epub 2020 Mar 19.

    Commentary:

    A Novel Mechanism to Induce BRCAness in Cancer Cells.

    • The Landscape and Therapeutic Implications of Molecular Profiles in Epithelial Ovarian Cancer.
    • Dion L, Carton I, Jaillard S, Nyangoh Timoh K, Henno S, Sardain H, Foucher F, Levêque J, de la Motte Rouge T, Brousse S, Lavoué V.
    • J Clin Med. 2020 Jul 15;9(7):E2239. doi: 10.3390/jcm9072239.
    • PARP inhibitors as maintenance therapy in newly diagnosed advanced ovarian cancer: A meta-analysis.
    • Lin Q, Liu W, Xu S, Shang H, Li J, Guo Y, Tong J.
    • BJOG. 2020 Jul 12. doi: 10.1111/1471-0528.16411. Epub ahead of print.
    • Meta-Analysis
    • Molecular Features of Metaplastic Breast Carcinoma: An Infrequent Subtype of Triple Negative Breast Carcinoma.
    • González-Martínez S, Pérez-Mies B, Carretero-Barrio I, Palacios-Berraquero ML, Perez-García J, Cortés J, Palacios J.
    • Cancers (Basel). 2020 Jul 8;12(7):E1832. doi: 10.3390/cancers12071832.
    • Zebrafish Xenografts Unveil Sensitivity to Olaparib beyond BRCA Status.
    • Varanda AB, Martins-Logrado A, Ferreira MG, Fior R.
    • Cancers (Basel). 2020 Jul 2;12(7):E1769. doi: 10.3390/cancers12071769.
    • Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer.
    • van der Doelen MJ, Isaacsson Velho P, Slootbeek PHJ, Pamidimarri Naga S, Bormann M, van Helvert S, Kroeze LI, van Oort IM, Gerritsen WR, Antonarakis ES, Mehra N.
    • Eur J Cancer. 2020 Jul 4;136:16-24. doi: 10.1016/j.ejca.2020.05.001. Epub ahead of print.
    • The efficacy and safety of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for ovarian cancer: a systematic review and meta-analysis.
    • Yang Y, Du N, Xie L, Jiang J, Mo J, Hong J, Mao D, Ng DM, Shi H.
    • World J Surg Oncol. 2020 Jul 4;18(1):151. doi: 10.1186/s12957-020-01931-7.
    • Zebrafish Xenografts Unveil Sensitivity to Olaparib beyond BRCA Status.
    • Varanda AB, Martins-Logrado A, Ferreira MG, Fior R.
    • Cancers (Basel). 2020 Jul 2;12(7):E1769. doi: 10.3390/cancers12071769.
    • Integration of PARP-inhibitors in ovarian cancer therapy.
    • Pietragalla A, Ciccarone F, Nero C, Scambia G, Lorusso D, Daniele G.
    • Explor Target Antitumor Ther. 2020 [Jun 29];1(3):171-182. doi: 10.37349/etat.2020.00011. Epub 2020 Jun 29.
    • Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives.
    • Cocco S, Piezzo M, Calabrese A, Cianniello D, Caputo R, Lauro VD, Fusco G, Gioia GD, Licenziato M, Laurentiis M.
    • Int J Mol Sci. 2020 Jun 27;21(13):E4579. doi: 10.3390/ijms21134579.
    • Identification of somatically acquired BRCA1/2 mutations by cfDNA analysis in patients with metastatic breast cancer.
    • Vidula N, Dubash TD, Lawrence MS, Simoneau A, Niemierko A, Blouch EL, Nagy RJ, Roh W, Chirn B, Reeves B, Malvarosa G, Lennerz JK, Isakoff SJ, Juric D, Micalizzi DS, Wander SA, Spring LM, Moy B, Shannon KM, Younger J, Lanman RB, Toner M, Iafrate AJ, Getz G, Zou L, Ellisen LW, Maheswaran S, Haber DA, Bardia A.
    • Clin Cancer Res. 2020 Jun 22:clincanres.0638.2020. doi: 10.1158/1078-0432.CCR-20-0638. Epub ahead of print.
    • The forefront of ovarian cancer therapy: update on PARP inhibitors.
    • Mirza MR, Coleman RL, González-Martín A, Moore KN, Colombo N, Ray-Coquard I, Pignata S.
    • Ann Oncol. 2020 Jun 19:S0923-7534(20)39891-4. doi: 10.1016/j.annonc.2020.06.004. Epub ahead of print.
    • Review
    • Efficacy and Prognostic Factors for PARP Inhibitors in Patients With Ovarian Cancer.
    • Huang XZ, Jia H, Xiao Q, Li RZ, Wang XS, Yin HY, Zhou X.
    • Front Oncol. 2020 Jun 16;10:958. doi: 10.3389/fonc.2020.00958.
    • Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIR02-Lung Trial.
    • Remon J, Besse B, Leary A, Bièche I, Job B, Lacroix L, Auguste A, Mauduit M, Audigier-Valette C, Raimbourg J, Madroszyk A, Michels S, Bayar MA, Jimenez M, Soria JC, Rouleau E, Barlesi F.
    • JTO Clin Res Rep. 2020 Jun 11;1(3):100068. doi: 10.1016/j.jtocrr.2020.100068.
    • PARP Inhibitor Response Markers Still Key Consideration in Ovarian Cancer Despite Broad Indications.
    • Anderson A.
    • Precision Oncology News. 2020 Jun 4.
    • Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review.
    • Mohyuddin GR, Aziz M, Britt A, Wade L, Sun W, Baranda J, Al-Rajabi R, Saeed A, Kasi A.
    • BMC Cancer. 2020 Jun 3;20(1):507. doi: 10.1186/s12885-020-06948-5.
    • Genetic and epigenetic profiling of BRCA1/2 in ovarian tumors reveals additive diagnostic yield and evidence of a genomic BRCA1/2 DNA methylation signature.
    • Aref-Eshghi E, McGee JD, Pedro VP, Kerkhof J, Stuart A, Ainsworth PJ, Lin H, Volodarsky M, McLachlin CM, Sadikovic B.
    • J Hum Genet. 2020 Jun 1. doi: 10.1038/s10038-020-0780-4. Epub ahead of print.
    • Molecular profile of BRCA-mutated biliary tract cancers.
    • Spizzo G, Puccini A, Xiu J, Goldberg RM, Grothey A, Shields AF, Arora SP, Khushmann M, Salem ME, Battaglin F, Baca Y, El-Deiry WS, Philip PA, Nassem M, Hall M, Marshall JL, Kocher F, Amann A, Wolf D, Korn WM, Lenz H, Seeber A.
    • ESMO Open. 2020 Jun;5(3):e000682. doi: 10.1136/esmoopen-2020-000682.
    • Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer.
    • Chopra N, Tovey H, Pearson A, Cutts R, Toms C, Proszek P, Hubank M, Dowsett M, Dodson A, Daley F, Kriplani D, Gevensleben H, Davies HR, Degasperi A, Roylance R, Chan S, Tutt A, Skene A, Evans A, Bliss JM, Nik-Zainal S, Turner NC.
    • Nat Commun. 2020 May 29;11(1):2662. doi: 10.1038/s41467-020-16142-7.
    • Protein expression profiling identifies differential modulation of homologous recombination by platinum-based antitumor agents.
    • He G, Xie X, Siddik ZH.
    • Cancer Chemother Pharmacol. 2020 May 28. doi: 10.1007/s00280-020-04085-1. Epub ahead of print.
    • HRness in Breast and Ovarian Cancers.
    • Santana Dos Santos E, Lallemand F, Petitalot A, Caputo SM, Rouleau E.
    • Int J Mol Sci. 2020 May 28;21(11):E3850. doi: 10.3390/ijms21113850.
    • First PARP Inhibitor Approved for Metastatic Prostate Cancer.
    • Nelson R.
    • Medscape. 2020 May 19.
    • Biomarker-Guided Development of DNA Repair Inhibitors.
    • Cleary JM, Aguirre AJ, Shapiro GI, D'Andrea AD.
    • Mol Cell. 2020 May 17:S1097-2765(20)30277-X. doi: 10.1016/j.molcel.2020.04.035. Epub ahead of print.
    • Review
    • Clovis Oncology's Rubraca Gets FDA Approval for BRCA-Mutated, Difficult-to-Treat Prostate Cancer.
    • [No author given]
    • Precision Oncology News. 2020 May 15.
    • Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase 2 study.
    • Lampert EJ, Zimmer AS, Padget MR, Cimino-Mathews A, Nair JR, Liu Y, Swisher EM, Hodge JW, Nixon AB, Nichols E, Bagheri M, Levy E, Radke MR, Lipkowitz S, Annunziata CM, Taube JM, Steinberg SM, Lee JM.
    • Clin Cancer Res. 2020 May 12:clincanres.0056.2020. doi: 10.1158/1078-0432.CCR-20-0056. Epub ahead of print.
    • Exploiting the Prevalence of Homologous Recombination Deficiencies in High-Grade Serous Ovarian Cancer.
    • Bouberhan S, Philp L, Hill S, Al-Alem LF, Rueda B.
    • Cancers (Basel). 2020 May 11;12(5):E1206. doi: 10.3390/cancers12051206.
    • The dynamic landscape of BRCA1 reversion mutations from indel to SNV in a patient with ovarian cancer treated with PARP-inhibitors and immunotherapy.
    • Jacob SL, Kiedrowski LA, Chae YK.
    • Heliyon. 2020 May 8;6(5):e03841. doi: 10.1016/j.heliyon.2020.e03841.
    • Neoantigen load and HLA-class I expression identify a subgroup of tumors with a T-cell-inflamed phenotype and favorable prognosis in homologous recombination-proficient high-grade serous ovarian carcinoma.
    • Matsushita H, Hasegawa K, Oda K, Yamamoto S, Asada K, Karasaki T, Yabuno A, Nishijima A, Nejo T, Kobayashi Y, Sato S, Ikeda Y, Miyai M, Takahashi Y, Yamaguchi R, Fujiwara K, Aburatani H, Kakimi K.
    • J Immunother Cancer. 2020 May;8(1):e000375. doi: 10.1136/jitc-2019-000375.
    • Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.
    • Ledermann JA, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Cameron T, Maloney L, Goble S, Coleman RL.
    • Lancet Oncol. 2020 May;21(5):710-722. doi: 10.1016/S1470-2045(20)30061-9.

    Commentary, Introductory article:

    Expanding use of rucaparib as maintenance therapy in recurrent ovarian cancer: updates from the ARIEL3 trial.

    • GSK Gets Broad Zejula Indication in Ovarian Cancer; FDA Deems Myriad Genetics' Test Complementary
    • [No author given.]
    • GenomeWeb. Business & Policy. 2020 Apr 30.

    Original research:

    Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.

    • Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity.
    • Sokol ES, Pavlick D, Khiabanian H, Frampton GM, Ross JS, Gregg JP, Lara PN, Oesterreich S, Agarwal N, Necchi A, Miller VA, Alexander B, Ali SM, Ganesan S, Chung JH.
    • JCO Precis Oncol. 2020;4:442-465. doi: 10.1200/po.19.00345. Epub 2020 Apr 30.
    • BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future Prospects.
    • Wong W, Raufi AG, Safyan RA, Bates SE, Manji GA.
    • Cancer Manag Res. 2020 Apr 23;12:2731-2742. doi: 10.2147/CMAR.S211151. eCollection 2020.
    • BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib/eribulin combination therapy.
    • Kawachi A, Yamashita S, Okochi-Takada E, Hirakawa A, Tsuda H, Shimomura A, Kojima Y, Yonemori K, Fujiwara Y, Kinoshita T, Ushijima T, Tamura K.
    • Breast Cancer Res Treat. 2020 Apr 20. doi: 10.1007/s10549-020-05647-w. [Epub ahead of print]
    • Genomic Landscape of Uterine Sarcomas Defined through Prospective Clinical Sequencing.
    • Hensley ML, Chavan SS, Solit DB, Murali R, Soslow R, Chiang S, Jungbluth AA, Bandlamudi C, Srinivasan P, Tap WD, Rosenbaum E, Taylor BS, Donoghue MTA, Hyman DM.
    • Clin Cancer Res. 2020 Apr 16. pii: clincanres.3959.2019. doi: 10.1158/1078-0432.CCR-19-3959. [Epub ahead of print]
    • Positron Emission Tomography Imaging of Poly-(Adenosine Diphosphate-Ribose) Polymerase 1 Expression in Breast Cancer: A Nonrandomized Clinical Trial.
    • McDonald ES, Doot RK, Pantel AR, Farwell MD, Mach RH, Maxwell KN, Mankoff DA.
    • JAMA Oncol. 2020 Apr 16. doi: 10.1001/jamaoncol.2020.0334. [Epub ahead of print]
    • Therapeutic Strategies and Biomarkers to Modulate PARP Activity for Targeted Cancer Therapy.
    • Singh N, Pay SL, Bhandare SB, Arimpur U, Motea EA.
    • Cancers (Basel). 2020 Apr 14;12(4). pii: E972. doi: 10.3390/cancers12040972.
    • CDK9 inhibitor CDKI-73 is synergetic lethal with PARP inhibitor olaparib in BRCA1 wide-type ovarian cancer.
    • Li J, Zhi X, Chen S, Shen X, Chen C, Yuan L, Guo J, Meng D, Chen M, Yao L.
    • Am J Cancer Res. 2020 Apr 1;10(4):1140-1155. eCollection 2020.
    • Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.
    • Lin PH, Chen M, Tsai LW, Lo C, Yen TC, Huang TY, Chen CK, Fan SC, Kuo SH, Huang CS.
    • Cancer Sci. 2020 Apr;111(4):1375-1384. doi: 10.1111/cas.14313. Epub 2020 Feb 19.
    • Pharmacological ascorbate induces 'BRCAness' and enhances the effects of Poly(ADP-Ribose) polymerase inhibitors against BRCA1/2 wild-type ovarian cancer.
    • Ma Y, Chen P, Drisko JA, Khabele D, Godwin AK, Chen Q.
    • Oncol Lett. 2020 Apr;19(4):2629-2638. doi: 10.3892/ol.2020.11364. Epub 2020 Jan 31.
    • BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer.
    • Jacot W, Lopez-Crapez E, Mollevi C, Boissière-Michot F, Simony-Lafontaine J, Ho-Pun-Cheung A, Chartron E, Theillet C, Lemoine A, Saffroy R, Lamy PJ, Guiu S.
    • Cancers (Basel). 2020 Mar 30;12(4). pii: E828. doi: 10.3390/cancers12040828.
    • Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status.
    • Keung MY, Wu Y, Badar F, Vadgama JV.
    • J Clin Med. 2020 Mar 30;9(4). pii: E940. doi: 10.3390/jcm9040940.
    • Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials.
    • Shao F, Liu J, Duan Y, Li L, Liu L, Zhang C, He S.
    • Biosci Rep. 2020 Mar 27;40(3). pii: BSR20192226. doi: 10.1042/BSR20192226.
    • Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond.
    • Boussios S, Abson C, Moschetta M, Rassy E, Karathanasi A, Bhat T, Ghumman F, Sheriff M, Pavlidis N.
    • Drugs R D. 2020 Mar 25. doi: 10.1007/s40268-020-00301-8. [Epub ahead of print]
    • An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
    • Przybytkowski E, Davis T, Hosny A, Eismann J, Matulonis UA, Wulf GM, Nabavi S.
    • BMC Cancer. 2020 Mar 12;20(1):197. doi: 10.1186/s12885-020-6605-1.
    • Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
    • Eoh KJ, Kim HM, Lee JY, Kim S, Kim SW, Kim YT, Nam EJ.
    • BMC Cancer. 2020 Mar 12;20(1):204. doi: 10.1186/s12885-020-6693-y.
    • The role of PARP inhibitors in germline BRCA-associated pancreatic ductal adenocarcinoma.
    • Moffat GT, O'Reilly EM.
    • Clin Adv Hematol Oncol. 2020 Mar;18(3):168-179.
    • A profile on the FoundationFocus CDxBRCA tests.
    • Ford L, Wolford JE, Brown SM, Randall LM.
    • Expert Rev Mol Diagn. 2020 Mar;20(3):285-292. doi: 10.1080/14737159.2020.1701438. Epub 2020 Feb 6.
    • Review
    • SGO Special Topic: PARP Inhibitor Maintenance Therapy after Initial Chemotherapy.
    • Armstrong DK, Eskander R, Cearbhaill R, Pothuri B.
    • Gynecologic Oncology. Podcasts. 2020 Mar.
    • Podcast
    • Both BRCA1-wild type and -mutant triple-negative breast cancers show sensitivity to the NAE inhibitor MLN4924 which is enhanced upon MLN4924 and cisplatin combination treatment.
    • Misra S, Zhang X, Wani NA, Sizemore S, Ray A.
    • Oncotarget. 2020 Feb 25;11(8):784-800. doi: 10.18632/oncotarget.27485. eCollection 2020 Feb 25.
    • BRCAness as an Important Prognostic Marker in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy: A Multicenter Retrospective Study.
    • Kosaka Y, Yamamoto Y, Tanino H, Nishimiya H, Yamamoto-Ibusuki M, Hirota Y, Iwase H, Nakamura S, Akashi-Tanaka S.
    • Diagnostics (Basel). 2020 Feb 21;10(2). pii: E119. doi: 10.3390/diagnostics10020119.
    • Association of BRCA Mutantations and BRCAness Status With Anticancer Drug Sensitivities in Triple-Negative Breast Cancer Cell Lines.
    • Teraoka S, Muguruma M, Takano N, Miyahara K, Kawate T, Kaise H, Yamada K, Miyazawa K, Ishikawa T.
    • J Surg Res. 2020 Feb 21;250:200-208. doi: 10.1016/j.jss.2019.12.040. [Epub ahead of print]
    • BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers.
    • Coussy F, El-Botty R, Château-Joubert S, Dahmani A, Montaudon E, Leboucher S, Morisset L, Painsec P, Sourd L, Huguet L, Nemati F, Servely JL, Larcher T, Vacher S, Briaux A, Reyes C, La Rosa P, Lucotte G, Popova T, Foidart P, Sounni NE, Noel A, Decaudin D, Fuhrmann L, Salomon A, Reyal F, Mueller C, Ter Brugge P, Jonkers J, Poupon MF, Stern MH, Bièche I, Pommier Y, Marangoni E.
    • Sci Transl Med. 2020 Feb 19;12(531). pii: eaax2625. doi: 10.1126/scitranslmed.aax2625.
    • Detection of molecular signatures of homologous recombination deficiency in prostate cancer with or without BRCA1/2 mutations.
    • Sztupinszki Z, Diossy M, Krzystanek M, Börcsök , Pomerantz MM, Tisza V, Spisák S, Rusz O, Csabai I, Freedman ML, Szallasi Z.
    • Clin Cancer Res. 2020 Feb 18. pii: clincanres.2135.2019. doi: 10.1158/1078-0432.CCR-19-2135. [Epub ahead of print]
    • Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma.
    • Takaya H, Nakai H, Takamatsu S, Mandai M, Matsumura N.
    • Sci Rep. 2020 Feb 17;10(1):2757. doi: 10.1038/s41598-020-59671-3.
    • Myriad Files sPMA With FDA for Test to ID Best Responders to Lynparza, Avastin Combination.
    • [No author given]
    • GenomeWeb. 2020 Feb 11.
    • Neoadjuvant Chemotherapy With Anthracycline-Based Regimen for BRCAness Tumors in Triple-Negative Breast Cancer.
    • Teraoka S, Sato E, Narui K, Yamada A, Fujita T, Yamada K, Oba M, Ishikawa T.
    • J Surg Res. 2020 Feb 7;250:143-147. doi: 10.1016/j.jss.2019.12.047. [Epub ahead of print]
    • Personalized Treatment Approach to Metastatic Castration-Resistant Prostate Cancer with BRCA2 and PTEN Mutations: A Case Report.
    • Julka PK, Verma A, Gupta K.
    • Case Rep Oncol. 2020 Feb 4;13(1):55-61. doi: 10.1159/000505182. eCollection 2020 Jan-Apr.
    • Are there clinical factors that can predict prolonged survival of patients receiving olaparib as maintenance therapy for BRCA-mutated ovarian cancer?
    • Lieberman HB.
    • Transl Cancer Res. 2020 Feb;9(2):418-420. doi: 10.21037/tcr.2019.12.102.

    Original research:

    Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers.

    • The metallo-intercalator [Ru(dppz)2(PIP)]2+ renders BRCA wild-type triple-negative breast cancer cells hypersensitive to PARP inhibition.
    • Yusoh NA, Leong SW, Chia SL, Harun SN, Abdul Rahman MB, Vallis KA, Gill MR, Ahmad H.
    • ACS Chem Biol. 2020 Jan 3. doi: 10.1021/acschembio.9b00843. [Epub ahead of print]
    • Triple negative breast cancer: A thorough review of biomarkers.
    • da Silva JL, Cardoso Nunes NC, Izetti P, de Mesquita GG, de Melo AC.
    • Crit Rev Oncol Hematol. 2019 Dec 20;145:102855. doi: 10.1016/j.critrevonc.2019.102855. [Epub ahead of print]
    • BRCA1 Promoter Methylation Status in 1031 Primary Breast Cancers Predicts Favorable Outcomes Following Chemotherapy.
    • Stefansson OA, Hilmarsdottir H, Olafsdottir K, Tryggvadottir L, Sverrisdottir A, Johannsson OT, Jonasson JG, Eyfjord JE, Sigurdsson S.
    • JNCI Cancer Spectr. 2019 Dec 11;4(2):pkz100. doi: 10.1093/jncics/pkz100. eCollection 2020 Apr.
    • Translational Highlights in Breast and Ovarian Cancer 2019 - Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy.
    • Hartkopf AD, Müller V, Wöckel A, Lux MP, Janni W, Ettl J, Belleville E, Schütz F, Fasching PA, Kolberg HC, Welslau M, Overkamp F, Taran FA, Brucker SY, Wallwiener M, Tesch H, Fehm TN, Schneeweiss A, Lüftner D.
    • Geburtshilfe Frauenheilkd. 2019 Dec;79(12):1309-1319. doi: 10.1055/a-1039-4458. Epub 2019 Dec 11.
    • Fluzoparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trials.
    • Luo J, Dai X, Hu H, Chen J, Zhao L, Yang C, Sun J, Zhang L, Wang Q, Xu S, Xu Y, Liu N, Ying G, Wang P.
    • J Cancer Res Clin Oncol. 2019 Nov 30. doi: 10.1007/s00432-019-03097-6. [Epub ahead of print]
    • Targeted Therapies for Triple-Negative Breast Cancer.
    • Lyons TG.
    • Curr Treat Options Oncol. 2019 Nov 21;20(11):82. doi: 10.1007/s11864-019-0682-x.
    • Review
    • The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact.
    • van Dessel LF, van Riet J, Smits M, Zhu Y, Hamberg P, van der Heijden MS, Bergman AM, van Oort IM, de Wit R, Voest EE, Steeghs N, Yamaguchi TN, Livingstone J, Boutros PC, Martens JWM, Sleijfer S, Cuppen E, Zwart W, van de Werken HJG, Mehra N, Lolkema MP.
    • Nat Commun. 2019 Nov 20;10(1):5251. doi: 10.1038/s41467-019-13084-7.
    • Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents.
    • Póti Á, Gyergyák H, Németh E, Rusz O, Tóth S, Kovácsházi C, Chen D, Szikriszt B, Spisák S, Takeda S, Szakács G, Szallasi Z, Richardson AL, Szüts D.
    • Genome Biol. 2019 Nov 14;20(1):240. doi: 10.1186/s13059-019-1867-0.
    • Advances and perspectives of PARP inhibitors.
    • Yi M, Dong B, Qin S, Chu Q, Wu K, Luo S.
    • Exp Hematol Oncol. 2019 Nov 11;8:29. doi: 10.1186/s40164-019-0154-9. eCollection 2019.
    • Metastatic Thymoma Harboring a Deleterious BRCA2 Mutation Derives Durable Clinical Benefit from Olaparib.
    • Principe DR, Kamath SD, Munshi HG, Mohindra NA.
    • Oncologist. 2019 Nov 1. pii: theoncologist.2019-0393. doi: 10.1634/theoncologist.2019-0393. [Epub ahead of print]
    • Case report, Review
    • Controversial issues in the neoadjuvant treatment of triple-negative breast cancer.
    • Fitzpatrick A, Tutt A.
    • Ther Adv Med Oncol. 2019 Nov 1;11:1758835919882581. doi: 10.1177/1758835919882581. eCollection 2019.
    • Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers.
    • Labidi-Galy SI, de La Motte Rouge T, Derbel O, Wolfer A, Kalbacher E, Olivier T, Combes JD, Heimgartner-Hu K, Tredan O, Guevara H, Heudel PE, Reverdy T, Bazan F, Heinzelmann-Schwarz V, Fehr M, de Castelbajac V, Vaflard P, Crivelli L, Bonadona V, Viassolo V, Buisson A, Golmard L, Rodrigues M, Ray-Coquard I.
    • Gynecol Oncol. 2019 Nov;155(2):262-269. doi: 10.1016/j.ygyno.2019.09.008. Epub 2019 Oct 8.

    Commentary:

    Are there clinical factors that can predict prolonged survival of patients receiving olaparib as maintenance therapy for BRCA-mutated ovarian cancer?

    • Outcomes in Patients With Pancreatic Adenocarcinoma With Genetic Mutations in DNA Damage Response Pathways: Results From the Know Your Tumor Program.
    • Pishvaian MJ, Blais EM, Brody JR, Rahib L, Lyons E, De Arbeloa P, Hendifar A, Mikhail S, Chung V, Sohal DPS, Leslie S, Mason K, Tibbets L, Madhavan S, Matrisian LM, Petricoin E 3rd.
    • JCO Precis Oncol. 2019 Dec [2019 Oct 23];3:1-10. doi: 10.1200/PO.19.00115.
    • Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations.
    • Veneris JT, Matulonis UA, Liu JF, Konstantinopoulos PA.
    • Gynecol Oncol. 2019 Oct 17. pii: S0090-8258(19)31549-5. doi: 10.1016/j.ygyno.2019.09.021. [Epub ahead of print]
    • Review
    • Patients resistant against PSMA-targeting alpha-radiation therapy often harbor mutations in DNA-repair associated genes.
    • Kratochwil C, Giesel FL, Heussel CP, Kazdal D, Endris V, Nientiedt C, Bruchertseifer F, Kippenberger M, Rathke H, Leichsenring J, Hohenfellner M, Morgenstern A, Haberkorn U, Duensing S, Stenzinger A.
    • J Nucl Med. 2019 Oct 10. pii: jnumed.119.234559. doi: 10.2967/jnumed.119.234559. [Epub ahead of print]
    • Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status.
    • Tomao F, Bardhi E, Di Pinto A, Sassu CM, Biagioli E, Petrella MC, Palaia I, Muzii L, Colombo N, Panici PB.
    • Cancer Treat Rev. 2019 Oct 9;80:101909. doi: 10.1016/j.ctrv.2019.101909. [Epub ahead of print]
    • Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer before olaparib maintenance: Still getting any benefit? A case-control study.
    • Marchetti C, Rosati A, Scaletta G, Pietragalla A, Arcieri M, Ergasti R, Palluzzi E, Scambia G, Fagotti A.
    • Gynecol Oncol. 2019 Oct 9. pii: S0090-8258(19)31545-8. doi: 10.1016/j.ygyno.2019.09.020. [Epub ahead of print]
    • ADP-ribosylation Levels and Patterns Correlate with Gene Expression and Clinical Outcomes in Ovarian Cancers.
    • Conrad LB, Lin KY, Nandu T, Gibson BA, Lea JS, Kraus WL.
    • Mol Cancer Ther. 2019 Oct 8. pii: molcanther.0569.2019. doi: 10.1158/1535-7163.MCT-19-0569. [Epub ahead of print]
    • Success for First-Line PARP Inhibition in Ovarian Cancer.
    • [No authors listed]
    • Cancer Discov. 2019 Oct 7. doi: 10.1158/2159-8290.CD-NB2019-121. [Epub ahead of print]
    • News
    • Epigenetic synthetic lethality approaches in cancer therapy.
    • Yang H, Cui W, Wang L.
    • Clin Epigenetics. 2019 Oct 7;11(1):136. doi: 10.1186/s13148-019-0734-x.
    • DNA methyltransferase inhibitors induce a BRCAness phenotype that sensitizes NSCLC to PARP inhibitor and ionizing radiation.
    • Abbotts R, Topper MJ, Biondi C, Fontaine D, Goswami R, Stojanovic L, Choi EY, McLaughlin L, Kogan AA, Xia L, Lapidus R, Mahmood J, Baylin SB, Rassool FV.
    • Proc Natl Acad Sci U S A. 2019 Oct 7. pii: 201903765. doi: 10.1073/pnas.1903765116. [Epub ahead of print]
    • 'Landmark' Trial in Prostate Cancer With Mutations.
    • Davenport L.
    • Medscape Oncology. 2019 Oct 4.
    • Update Breast Cancer 2019 Part 4 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer.
    • Schütz F, Fasching PA, Welslau M, Hartkopf AD, Wöckel A, Lux MP, Janni W, Ettl J, Lüftner D, Belleville E, Kolberg HC, Overkamp F, Taran FA, Brucker SY, Wallwiener M, Tesch H, Fehm TN, Schneeweiss A, Müller V.
    • Geburtshilfe Frauenheilkd. 2019 Oct;79(10):1079-1089. doi: 10.1055/a-1001-9925. Epub 2019 Oct 22.
    • [Synthetic Lethality - Its Current Application and Potential in Oncological Treatment.]
    • Bortlíková L, Müller P, Vojtěšek B, Rak V, Svoboda M.
    • Klin Onkol. 2019 Fall;32(Supplementum 3):19-24. doi: 10.14735/amko20193S.
    • Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints.
    • Ivy SP, Kunos CA, Arnaldez FI, Kohn EC.
    • Expert Opin Investig Drugs. 2019 Aug 26. doi: 10.1080/13543784.2019.1657403. [Epub ahead of print]
    • Case report, Review
    • The indenoisoquinoline TOP1 inhibitors selectively target homologous recombination deficient- and Schlafen 11-positive cancer cells and synergize with olaparib.
    • Marzi L, Szabova L, Gordon M, Weaver Ohler Z, Sharan SK, Beshiri ML, Etemadi M, Murai J, Kelly K, Pommier Y.
    • Clin Cancer Res. 2019 Aug 13. pii: clincanres.0419.2019. doi: 10.1158/1078-0432.CCR-19-0419. [Epub ahead of print]
    • Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers.
    • Przybycinski J, Nalewajska M, Marchelek-Mysliwiec M, Dziedziejko V, Pawlik A.
    • Expert Opin Ther Targets. 2019 Aug 8. doi: 10.1080/14728222.2019.1654458. [Epub ahead of print]
    • Review
    • Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy.
    • Shimomura A, Yonemori K, Yoshida M, Yoshida T, Yasojima H, Masuda N, Aogi K, Takahashi M, Naito Y, Shimizu S, Nakamura R, Hamada A, Michimae H, Hashimoto J, Yamamoto H, Kawachi A, Shimizu C, Fujiwara Y, Tamura K.
    • Transl Oncol. 2019 Aug 2;12(10):1386-1394. doi: 10.1016/j.tranon.2019.07.013. [Epub ahead of print]
    • Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review.
    • Boussios S, Karihtala P, Moschetta M, Karathanasi A, Sadauskaite A, Rassy E, Pavlidis N.
    • Diagnostics (Basel). 2019 Aug 1;9(3). pii: E87. doi: 10.3390/diagnostics9030087.
    • Defining and Modulating 'BRCAness'.
    • Byrum AK, Vindigni A, Mosammaparast N.
    • Trends Cell Biol. 2019 Jul 27. pii: S0962-8924(19)30104-7. doi: 10.1016/j.tcb.2019.06.005. [Epub ahead of print]
    • Review
    • Molecular Testing Identifies Determinants of Exceptional Response and Guides Precision Therapy in a Patient with Lethal, Treatment-emergent Neuroendocrine Prostate Cancer.
    • Turina CB, Coleman DJ, Thomas GV, Fung AW, Alumkal JJ.
    • Cureus. 2019 Jul 22;11(7):e5197. doi: 10.7759/cureus.5197.
    • Platinum Salts in Patients with Breast Cancer: A Focus on Predictive Factors.
    • Garutti M, Pelizzari G, Bartoletti M, Malfatti MC, Gerratana L, Tell G, Puglisi F.
    • Int J Mol Sci. 2019 Jul 10;20(14). pii: E3390. doi: 10.3390/ijms20143390.
    • Tumour lineage shapes BRCA-mediated phenotypes.
    • Jonsson P, Bandlamudi C, Cheng ML, Srinivasan P, Chavan SS, Friedman ND, Rosen EY, Richards AL, Bouvier N, Selcuklu SD, Bielski CM, Abida W, Mandelker D, Birsoy O, Zhang L, Zehir A, Donoghue MTA, Baselga J, Offit K, Scher HI, O'Reilly EM, Stadler ZK, Schultz N, Socci ND, Viale A, Ladanyi M, Robson ME, Hyman DM, Berger MF, Solit DB, Taylor BS.
    • Nature. 2019 Jul 10. doi: 10.1038/s41586-019-1382-1. [Epub ahead of print]
    • Targeting DNA repair in breast cancer.
    • Paluch-Shimon S, Evron E.
    • Breast. 2019 Jul 1;47:33-42. doi: 10.1016/j.breast.2019.06.007. [Epub ahead of print]
    • Review
    • The 34th Annual Meeting of the Korean Society of Gynecologic Oncology 2019: meeting report.
    • Yim GW, Suh DH, Kim JW, Kim SC, Kim YT.
    • J Gynecol Oncol. 2019 Jul;30(4):e91. doi: 10.3802/jgo.2019.30.e91.
    • BRCA1/2 Functional Loss Defines a Targetable Subset in Leiomyosarcoma.
    • Seligson ND, Kautto EA, Passen EN, Stets C, Toland AE, Millis SZ, Meyer CF, Hays JL, Chen JL.
    • Oncologist. 2019 Jul;24(7):973-979. doi: 10.1634/theoncologist.2018-0448. Epub 2018 Dec 12.
    • Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors.
    • Criscuolo D, Morra F, Giannella R, Cerrato A, Celetti A.
    • Int J Mol Sci. 2019 Jun 25;20(12). pii: E3100. doi: 10.3390/ijms20123100.
    • Clinical Utility of Real-Time Targeted Molecular Profiling in the Clinical Management of Ovarian Cancer: The ALLOCATE Study.
    • Kondrashova O, Ho GY, Au-Yeung G, Leas L, Boughtwood T, Alsop K, Zapparoli G, Dobrovic A, Ko YA, Hsu AL, Love CJ, Lunke S, Wakefield MJ, McNally O, Quinn M, Ananda S, Neesham D, Hamilton A, Grossi M, Freimund A, Kanjanapan Y, Rischin D, Traficante N, Bowtell D, Scott CL, Christie M, Taylor GR, Mileshkin L, Waring PM; Australian Ovarian Cancer Study Group.
    • JCO Precis Oncol. 2019 Dec [2019 Jun 20];3:1-18. doi: 10.1200/PO.19.00019.
    • Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor Therapy.
    • Park Y, Chui MH, Suryo Rahmanto Y, Yu ZC, Shamanna RA, Bellani MA, Gaillard S, Ayhan A, Viswanathan A, Seidman MM, Franco S, Leung AKL, Bohr VA, Shih IM, Wang TL.
    • Clin Cancer Res. 2019 Jun 13. doi: 10.1158/1078-0432.CCR-18-4222. [Epub ahead of print]
    • Exploiting DNA repair defects in breast cancer: from chemotherapy to immunotherapy.
    • Aktas BY, Guner G, Guven DC, Arslan C, Dizdar O.
    • Expert Rev Anticancer Ther. 2019 Jun 10. doi: 10.1080/14737140.2019.1631162. [Epub ahead of print]
    • Review
    • Significant Clinical Activity of Olaparib in a Somatic BRCA1-Mutated Triple-Negative Breast Cancer With Brain Metastasis.
    • Pascual T, Gonzalez-Farre B, Teixidó C, Oleaga L, Oses G, Ganau S, Chic N, Riu G, Adamo B, Galván P, Vidal M, Soy D, Urbano Á, Muñoz M, Prat A.
    • JCO Precis Oncol. 2019 Dec [2019 Jun 7];3:1-6. doi: 10.1200/PO.19.00012.
    • High EMSY expression defines a BRCA-like subgroup of high-grade serous ovarian carcinoma with prolonged survival and hypersensitivity to platinum.
    • Hollis RL, Churchman M, Michie CO, Rye T, Knight L, McCavigan A, Perren T, Williams ARW, McCluggage WG, Kaplan RS, Jayson GC, Oza A, Harkin DP, Herrington CS, Kennedy R, Gourley C.
    • Cancer. 2019 Jun 2. doi: 10.1002/cncr.32079. [Epub ahead of print]

    Commentary:

    Clarifying the role of EMSY in DNA repair in ovarian cancer

    • PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review.
    • Cook SA, Tinker AV.
    • BioDrugs. 2019 Jun;33(3):255-273. doi: 10.1007/s40259-019-00347-4.
    • Review
    • Homologous recombination deficiency in triple negative breast cancer.
    • Belli C, Duso BA, Ferraro E, Curigliano G.
    • Breast. 2019 Jun;45:15-21. doi: 10.1016/j.breast.2019.02.007. Epub 2019 Feb 20.
    • Review
    • Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer.
    • Ledermann JA, Pujade-Lauraine E.
    • Ther Adv Med Oncol. 2019 May 22;11:1758835919849753. doi: 10.1177/1758835919849753. eCollection 2019.
    • Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers.
    • Nones K, Johnson J, Newell F, Patch AM, Thorne H, Kazakoff SH, de Luca XM, Parsons MT, Ferguson K, Reid L, Reed AEM, Srihari S, Lakis V, Davidson AL, Mukhopadhyay P, Holmes O, Xu Q, Wood S, Leonard C; Kathleen Cuningham Foundation Consortium for Research into Familial Aspects of Breast Cancer (kConFab); Australian Breast Cancer Tissue Bank (ABCTB); Brisbane Breast Bank (BBB), Beesley J, Harris J, Barnes D, Degasperi A, Ragan MA, Spurdle AB, Khanna KK, Lakhani SR, Pearson JV, Nik-Zainal S, Chenevix-Trench G, Waddell N, Simpson PT.
    • Ann Oncol. 2019 May 15. pii: mdz132. doi: 10.1093/annonc/mdz132. [Epub ahead of print]

    Editorial:

    Journey's End: the quest for BRCA-like hereditary breast cancer genes is nearly over.

    • Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51.
    • Kaplan AR, Gueble SE, Liu Y, Oeck S, Kim H, Yun Z, Glazer PM.
    • Sci Transl Med. 2019 May 15;11(492). pii: eaav4508. doi: 10.1126/scitranslmed.aav4508.

    Research news:

    Mechanism of Cediranib/Olaparib Combo Revealed.

    • A Comparison of DNA Mutation and Copy Number Profiles of Primary Breast Cancers and Paired Brain Metastases for Identifying Clinically Relevant Genetic Alterations in Brain Metastases.
    • Tyran M, Carbuccia N, Garnier S, Guille A, Adelaïde J, Finetti P, Toulzian J, Viens P, Tallet A, Goncalves A, Metellus P, Birnbaum D, Chaffanet M, Bertucci F.
    • Cancers (Basel). 2019 May 13;11(5):665. doi: 10.3390/cancers11050665.
    • Universal tumor DNA BRCA1/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition.
    • Vos JR, Fakkert IE, de Hullu JA, van Altena AM, Sie AS, Ouchene H, Willems RW, Nagtegaal ID, Jongmans MCJ, Mensenkamp AR, Woldringh GH, Bulten J, Leter EM, Kets CM, Simons M, Ligtenberg MJL, Hoogerbrugge N.
    • J Natl Cancer Inst. 2019 May 11. pii: djz080. doi: 10.1093/jnci/djz080. [Epub ahead of print]

    Letter, Comment:

    RE: Universal tumor DNA BRCA1/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition.

    • Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes.
    • da Costa AABA, do Canto LM, Larsen SJ, Ribeiro ARG, Stecca CE, Petersen AH, Aagaard MM, de Brot L, Baumbach J, Baiocchi G, Achatz MI, Rogatto SR.
    • BMC Cancer. 2019 May 6;19(1):422. doi: 10.1186/s12885-019-5622-4.
    • ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers.
    • Mesquita KA, Alabdullah M, Griffin M, Toss MS, Fatah TMAA, Alblihy A, Moseley P, Chan SYT, Rakha EA, Madhusudan S.
    • Gynecol Oncol. 2019 May;153(2):416-424. doi: 10.1016/j.ygyno.2019.02.014. Epub 2019 Feb 20.
    • EZH2 is overexpressed in BRCA1-like breast tumors and predictive for sensitivity to high-dose platinum-based chemotherapy.
    • Puppe J, Opdam M, Schouten PC, Jóźwiak K, Lips EH, Severson T, van de Ven M, Brambillasca CS, Bouwman P, van Tellingen O, Bernards R, Wesseling J, Eichler C, Thangarajah F, Malter W, Pandey GK, Ozretić L, Caldas C, van Lohuizen M, Hauptmann M, Rhiem K, Hahnen E, Reinhardt HC, Büttner R, Mallmann P, Schömig-Markiefka B, Schmutzler RK, Linn SC, Jonkers J.
    • Clin Cancer Res. 2019 Apr 29. pii: clincanres.4024.2018. doi: 10.1158/1078-0432.CCR-18-4024. [Epub ahead of print]
    • Detecting the mutational signature of homologous recombination deficiency in clinical samples.
    • Gulhan DC, Lee JJ, Melloni GEM, Cortés-Ciriano I, Park PJ.
    • Nat Genet. 2019 Apr 15. doi: 10.1038/s41588-019-0390-2. [Epub ahead of print]
    • Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883).
    • Hauke J, Hahnen E, Schneider S, Reuss A, Richters L, Kommoss S, Heimbach A, Marmé F, Schmidt S, Prieske K, Gevensleben H, Burges A, Borde J, De Gregorio N, Nürnberg P, El-Balat A, Thiele H, Hilpert F, Altmüller J, Meier W, Dietrich D, Kimmig R, Schoemig-Markiefka B, Kast K, Braicu E, Baumann K, Jackisch C, Park-Simon TW, Ernst C, Hanker L, Pfisterer J, Schnelzer A, du Bois A, Schmutzler RK, Harter P.
    • J Med Genet. 2019 Apr 12. pii: jmedgenet-2018-105930. doi: 10.1136/jmedgenet-2018-105930. [Epub ahead of print]
    • Multi-region sequencing unveils novel actionable targets and spatial heterogeneity in esophageal squamous cell carcinoma.
    • Yan T, Cui H, Zhou Y, Yang B, Kong P, Zhang Y, Liu Y, Wang B, Cheng Y, Li J, Guo S, Xu E, Liu H, Cheng C, Zhang L, Chen L, Zhuang X, Qian Y, Yang J, Ma Y, Li H, Wang F, Liu J, Liu X, Su D, Wang Y, Sun R, Guo S, Li Y, Cheng X, Liu Z, Zhan Q, Cui Y.
    • Nat Commun. 2019 Apr 11;10(1):1670. doi: 10.1038/s41467-019-09255-1.
    • Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
    • Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, Wahner Hendrickson AE, Azodi M, DiSilvestro P, Oza AM, Cristea M, Berek JS, Chan JK, Rimel BJ, Matei DE, Li Y, Sun K, Luptakova K, Matulonis UA, Monk BJ.
    • Lancet Oncol. 2019 Apr 1. pii: S1470-2045(19)30029-4. doi: 10.1016/S1470-2045(19)30029-4. [Epub ahead of print]

    Commentary:

    Fighting against the challenge of treating patients with late-line ovarian cancer: are we there yet?

    • Exploiting DNA repair defects in colorectal cancer.
    • Reilly NM, Novara L, Di Nicolantonio F, Bardelli A.
    • Mol Oncol. 2019 Apr;13(4):681-700. doi: 10.1002/1878-0261.12467. Epub 2019 Mar 2.
    • Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition.
    • Gabbasov R, Benrubi ID, O'Brien SW, Krais JJ, Johnson N, Litwin S, Connolly DC.
    • Cancer Biol Ther. 2019 Mar 30:1-11. doi: 10.1080/15384047.2019.1595279. [Epub ahead of print]
    • PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers.
    • Keung MYT, Wu Y, Vadgama JV.
    • J Clin Med. 2019 Mar 30;8(4). pii: E435. doi: 10.3390/jcm8040435.
    • BRCAness in prostate cancer.
    • Bednarz-Knoll N, Eltze E, Semjonow A, Brandt B.
    • Oncotarget. 2019 Mar 29;10(25):2421-2422. doi: 10.18632/oncotarget.26818. eCollection 2019 Mar 29.
    • Polo-like Kinase 1 inhibition as a therapeutic approach to selectively target BRCA1-deficient cancer cells by synthetic lethality induction.
    • Carbajosa S, Pansa MF, Paviolo NS, Castellaro AM, Andino DL, Nigra AD, García IA, Racca AC, Rodriguez-Berdini L, Angiolini V, Guantay L, Villafañez F, Federico MB, Rodríguez-Baili MC, Caputto BL, Drewes G, Madauss KP, Gloger I, Fernandez E, Gil GA, Bocco JL, Gottifredi V, Soria G.
    • Clin Cancer Res. 2019 Mar 19. pii: clincanres.3516.2018. doi: 10.1158/1078-0432.CCR-18-3516. [Epub ahead of print]
    • The deubiquitylating enzyme USP15 regulates homologous recombination repair and cancer cell response to PARP inhibitors.
    • Peng Y, Liao Q, Tan W, Peng C, Hu Z, Chen Y, Li Z, Li J, Zhen B, Zhu W, Li X, Yao Y, Song Q, Liu C, Qi X, He F, Pei H.
    • Nat Commun. 2019 Mar 15;10(1):1224. doi: 10.1038/s41467-019-09232-8.

    Press: New Biomarker Could Expand Effective PARP Inhibitor Treatment Options. (Clinical OMICs)

    • Exploring the Frequency of Homologous Recombination DNA Repair Dysfunction in Multiple Cancer Types.
    • Gentles L, Goranov B, Matheson E, Herriott A, Kaufmann A, Hall S, Mukhopadhyay A, Drew Y, Curtin NJ, O'Donnell RL.
    • Cancers (Basel). 2019 Mar 13;11(3). pii: E354. doi: 10.3390/cancers11030354.
    • Direct Ex Vivo Observation of Homologous Recombination Defect Reversal After DNA-Damaging Chemotherapy in Patients With Metastatic Breast Cancer.
    • Meijer TG, Verkaik NS, van Deurzen CHM, Dubbink HJ, den Toom TD, Sleddens HFBM, De Hoop EO, Dinjens WNM, Kanaar R, van Gent DC, Jager A.
    • JCO Precis Oncol. 2019 Dec [2019 Mar 11];3:1-12. doi: 10.1200/PO.18.00268.
    • Prospect for Application of PARP Inhibitor in Patients with HER2 Negative Breast Cancer.
    • Shao N, Shi Y, Yu L, Ye R, Shan Z, Zhang Z, Zhang Y, Lin Y.
    • Int J Biol Sci. 2019 Mar 10;15(5):962-972. doi: 10.7150/ijbs.30721. eCollection 2019.
    • Rad51/BRCA2 disruptors inhibit homologous recombination and synergize with olaparib in pancreatic cancer cells.
    • Roberti M, Schipani F, Bagnolini G, Milano D, Giacomini E, Falchi F, Balboni A, Manerba M, Farabegoli F, De Franco F, Robertson J, Minucci S, Pallavicini I, Di Stefano G, Girotto S, Pellicciari R, Cavalli A.
    • Eur J Med Chem. 2019 Mar 1;165:80-92. doi: 10.1016/j.ejmech.2019.01.008. Epub 2019 Jan 10.
    • Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer.
    • Foote JR, Secord AA, Liang MI, Ehrisman JA, Cohn DE, Jewell E, Havrilesky LJ.
    • Gynecol Oncol. 2019 Mar;152(3):445-451. doi: 10.1016/j.ygyno.2018.11.028.
    • PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper.
    • Liposits G, Loh KP, Soto-Perez-de-Celis E, Dumas L, Battisti NML, Kadambi S, Baldini C, Banerjee S, Lichtman SM.
    • J Geriatr Oncol. 2019 Mar;10(2):337-345. doi: 10.1016/j.jgo.2018.10.008. Epub 2018 Oct 14.
    • Review
    • BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy.
    • Mio C, Gerratana L, Bolis M, Caponnetto F, Zanello A, Barbina M, Di Loreto C, Garattini E, Damante G, Puglisi F.
    • Int J Cancer. 2019 Feb 15;144(4):755-766. doi: 10.1002/ijc.31898. Epub 2018 Dec 4.
    • PARP Inhibitors: Extending Benefit Beyond BRCA Mutant Cancers.
    • Pilie P, Gay CM, Byers LA, O'Connor MJ, Yap TA.
    • Clin Cancer Res. 2019 Feb 13. pii: clincanres.0968.2018. doi: 10.1158/1078-0432.CCR-18-0968. [Epub ahead of print]
    • Review
    • Evaluation of site-specific homologous recombination activity of BRCA1 by direct quantitation of gene editing efficiency.
    • Yoshino Y, Endo S, Chen Z, Qi H, Watanabe G, Chiba N.
    • Sci Rep. 2019 Feb 7;9(1):1644. doi: 10.1038/s41598-018-38311-x.
    • Evaluation of the BRCAness phenotype and its correlations with clinicopathological features in triple-negative breast cancers.
    • Tian T, Shan L, Yang W, Zhou X, Shui R.
    • Hum Pathol. 2019 Feb;84:231-238. doi: 10.1016/j.humpath.2018.10.004. Epub 2018 Oct 16.
    • Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro.
    • Borchert S, Wessolly M, Schmeller J, Mairinger E, Kollmeier J, Hager T, Mairinger T, Herold T, Christoph DC, Walter RFH, Eberhardt WEE, Plönes T, Wohlschlaeger J, Aigner C, Schmid KW, Mairinger FD.
    • BMC Cancer. 2019 Jan 30;19(1):108. doi: 10.1186/s12885-019-5314-0.
    • Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.
    • Gadducci A, Guarneri V, Peccatori FA, Ronzino G, Scandurra G, Zamagni C, Zola P, Salutari V.
    • J Ovarian Res. 2019 Jan 28;12(1):9. doi: 10.1186/s13048-019-0484-6.
    • Molecular and epigenetic profiles of BRCA1-like hormone-receptor-positive breast tumors identified with development and application of a copy-number-based classifier.
    • Chen Y, Wang Y, Salas LA, Miller TW, Mark K, Marotti JD, Kettenbach AN, Cheng C, Christensen BC.
    • Breast Cancer Res. 2019 Jan 25;21(1):14. doi: 10.1186/s13058-018-1090-z.
    • PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness.
    • Shen J, Zhao W, Ju Z, Wang L, Peng Y, Labrie M, Yap TA, Mills GB, Peng G.
    • Cancer Res. 2019 Jan 15;79(2):311-319. doi: 10.1158/0008-5472.CAN-18-1003. Epub 2018 Nov 27.
    • Targeting homologous repair deficiency in breast and ovarian cancers: Biological pathways, preclinical and clinical data.
    • Chartron E, Theillet C, Guiu S, Jacot W.
    • Crit Rev Oncol Hematol. 2019 Jan;133:58-73. doi: 10.1016/j.critrevonc.2018.10.012. Epub 2018 Nov 5.
    • Cyclin D1 silencing impairs DNA double strand break repair, sensitizes BRCA1 wildtype ovarian cancer cells to olaparib.
    • Zhong Q, Hu Z, Li Q, Yi T, Li J, Yang H.
    • Gynecol Oncol. 2019 Jan;152(1):157-165. doi: 10.1016/j.ygyno.2018.10.027. Epub 2018 Nov 7.
    • The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer.
    • Hjortkjær M, Malik Aagaard Jørgensen M, Waldstrøm M, Ørnskov D, Søgaard-Andersen E, Jakobsen A, Dahl-Steffensen K.
    • Int J Gynecol Cancer. 2019 Jan;29(1):166-173. doi: 10.1136/ijgc-2018-000017.
    • Functional Ex Vivo Assay Reveals Homologous Recombination Deficiency in Breast Cancer Beyond BRCA Gene Defects.
    • Meijer TG, Verkaik NS, Sieuwerts AM, van Riet J, Naipal KAT, van Deurzen CHM, den Bakker MA, Sleddens HFBM, Dubbink HJ, den Toom TD, Dinjens WNM, Lips E, Nederlof PM, Smid M, van de Werken HJG, Kanaar R, Martens JWM, Jager A, van Gent DC.
    • Clin Cancer Res. 2018 Dec 15;24(24):6277-6287. doi: 10.1158/1078-0432.CCR-18-0063. Epub 2018 Aug 23.
    • Kub5-Hera RPRD1B Deficiency Promotes "BRCAness" and Vulnerability to PARP Inhibition in BRCA-proficient Breast Cancers.
    • Motea EA, Fattah FJ, Xiao L, Girard L, Rommel A, Morales JC, Patidar P, Zhou Y, Porter A, Xie Y, Minna JD, Boothman DA.
    • Clin Cancer Res. 2018 Dec 15;24(24):6459-6470. doi: 10.1158/1078-0432.CCR-17-1118. Epub 2018 Aug 14.
    • Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives?
    • Nicolas E, Bertucci F, Sabatier R, Gonçalves A.
    • Cancers (Basel). 2018 Dec 11;10(12). pii: E506. doi: 10.3390/cancers10120506.
    • PARP-1 regulates DNA repair factor availability.
    • Schiewer MJ, Mandigo AC, Gordon N, Huang F, Gaur S, de Leeuw R, Zhao SG, Evans J, Han S, Parsons T, Birbe R, McCue P, McNair C, Chand SN, Cendon-Florez Y, Gallagher P, McCann JJ, Poudel Neupane N, Shafi AA, Dylgjeri E, Brand LJ, Visakorpi T, Raj GV, Lallas CD, Trabulsi EJ, Gomella LG, Dicker AP, Kelly WK, Leiby BE, Knudsen B, Feng FY, Knudsen KE.
    • EMBO Mol Med. 2018 Dec;10(12). pii: e8816. doi: 10.15252/emmm.201708816.
    • A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.
    • Castroviejo-Bermejo M, Cruz C, Llop-Guevara A, Gutiérrez-Enríquez S, Ducy M, Ibrahim YH, Gris-Oliver A, Pellegrino B, Bruna A, Guzmán M, Rodríguez O, Grueso J, Bonache S, Moles-Fernández A, Villacampa G, Viaplana C, Gómez P, Vidal M, Peg V, Serres-Créixams X, Dellaire G, Simard J, Nuciforo P, Rubio IT, Dientsmann R, Barrett JC, Caldas C, Baselga J, Saura C, Cortés J, Déas O, Jonkers J, Masson JY, Cairo S, Judde JG, O'Connor MJ, Díez O, Balmaña J, Serra V.
    • EMBO Mol Med. 2018 Dec;10(12). pii: e9172. doi: 10.15252/emmm.201809172.
    • Genome-wide DNA methylation assessment of 'BRCA1-like' early-onset breast cancer: Data from the Australian Breast Cancer Family Registry.
    • Scott CM, Wong EM, Joo JE, Dugué PA, Jung CH, O'Callaghan N, Dowty J, Giles GG, Hopper JL, Southey MC.
    • Exp Mol Pathol. 2018 Dec;105(3):404-410. doi: 10.1016/j.yexmp.2018.11.006. Epub 2018 Nov 10.
    • Targeted treatment of advanced ovarian cancer: spotlight on rucaparib.
    • Pearre DC, Tewari KS.
    • Ther Clin Risk Manag. 2018 Nov 2;14:2189-2201. doi: 10.2147/TCRM.S149248. eCollection 2018.
    • Defective DNA repair in hereditary ovarian cancers: Implications for therapy.
    • Burgess BT, Kolesar JM.
    • Am J Health Syst Pharm. 2018 Nov 1;75(21):1697-1707. doi: 10.2146/ajhp180124. Epub 2018 Sep 18.
    • Review
    • Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.
    • Hodgson DR, Dougherty BA, Lai Z, Fielding A, Grinsted L, Spencer S, O'Connor MJ, Ho TW, Robertson JD, Lanchbury JS, Timms KM, Gutin A, Orr M, Jones H, Gilks B, Womack C, Gourley C, Ledermann J, Barrett JC.
    • Br J Cancer. 2018 Nov;119(11):1401-1409. doi: 10.1038/s41416-018-0274-8. Epub 2018 Oct 24.
    • Clinical Activity of Olaparib in Urothelial Bladder Cancer With DNA Damage Response Gene Mutations.
    • Sweis RF, Heiss B, Segal J, Ritterhouse L, Kadri S, Churpek JE, Allen K, Conway D, Marinier C, Smith ND, Pitroda SP, Stadler WM.
    • JCO Precis Oncol. 2018 Nov;2:1-7. doi: 10.1200/PO.18.00264.
    • Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
    • Patel JN, Braicu I, Timms KM, Solimeno C, Tshiaba P, Reid J, Lanchbury JS, Darb-Esfahani S, Ganapathi MK, Sehouli J, Ganapathi RN.
    • Br J Cancer. 2018 Oct;119(9):1060-1066. doi: 10.1038/s41416-018-0268-6. Epub 2018 Oct 15.
    • Genetic Markers in Triple-Negative Breast Cancer.
    • Sporikova Z, Koudelakova V, Trojanec R, Hajduch M.
    • Clin Breast Cancer. 2018 Oct;18(5):e841-e850. doi: 10.1016/j.clbc.2018.07.023. Epub 2018 Aug 4.
    • BRCAness Combined With a Family History of Cancer Is Associated With a Poor Prognosis for Breast Cancer Patients With a High Risk of BRCA Mutations.
    • Mori H, Kubo M, Kai M, Velasquez VV, Kurata K, Yamada M, Okido M, Kuroki S, Oda Y, Nakamura M.
    • Clin Breast Cancer. 2018 Oct;18(5):e1217-e1227. doi: 10.1016/j.clbc.2018.05.008. Epub 2018 Jun 2.
    • Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors.
    • Diossy M, Reiniger L, Sztupinszki Z, Krzystanek M, Timms KM, Neff C, Solimeno C, Pruss D, Eklund AC, Tóth E, Kiss O, Rusz O, Cserni G, Zombori T, Székely B, Kulka J, Tímár J, Csabai I, Szallasi Z.
    • Ann Oncol. 2018 Sep 1;29(9):1948-1954. doi: 10.1093/annonc/mdy216.
    • Emerging PARP inhibitors for treating breast cancer.
    • Robert M, Patsouris A, Frenel JS, Gourmelon C, Augereau P, Campone M.
    • Expert Opin Emerg Drugs. 2018 Sep;23(3):211-221. doi: 10.1080/14728214.2018.1527900. Epub 2018 Sep 29.
    • Review
    • Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management.
    • da Cunha Colombo Bonadio RR, Fogace RN, Miranda VC, Diz MDPE.
    • Clinics (Sao Paulo). 2018 Aug 20;73(suppl 1):e450s. doi: 10.6061/clinics/2018/e450s.
    • Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness.
    • Holme H, Gulati A, Brough R, Fleuren EDG, Bajrami I, Campbell J, Chong IY, Costa-Cabral S, Elliott R, Fenton T, Frankum J, Jones SE, Menon M, Miller R, Pemberton HN, Postel-Vinay S, Rafiq R, Selfe JL, von Kriegsheim A, Munoz AG, Rodriguez J, Shipley J, van der Graaf WTA, Williamson CT, Ryan CJ, Pettitt S, Ashworth A, Strauss SJ, Lord CJ.
    • Sci Rep. 2018 Jul 13;8(1):10614. doi: 10.1038/s41598-018-29043-z.
    • Poly (ADP-Ribose) Polymerase Inhibitors for De Novo BRCA2-Null Small-Cell Prostate Cancer.
    • Chanez B, Chaffanet M, Adélaide J, Thomassin J, Garnier S, Carbuccia N, Guille A, Charrier N, Brenot-Rossi I, Walz J, Pignot G, Pakradouni J, Gonçalvès A, Eisinger F, Bertucci F, Birnbaum D, Gravis G.
    • JCO Precis Oncol. 2018 Nov [Epub 2018 Jul 10];2:1-8. doi: 10.1200/PO.18.00083.
    • BRCA Status Does Not Predict Synergism of a Carboplatin and Olaparib Combination in High-Grade Serous Ovarian Cancer Cell Lines.
    • Shen YT, Evans JC, Zafarana G, Allen C, Piquette-Miller M.
    • Mol Pharm. 2018 Jul 2;15(7):2742-2753. doi: 10.1021/acs.molpharmaceut.8b00246. Epub 2018 Jun 1.
    • Biomarkers for Homologous Recombination Deficiency in Cancer.
    • Hoppe MM, Sundar R, Tan DSP, Jeyasekharan AD.
    • J Natl Cancer Inst. 2018 Jul 1;110(7):704-713. doi: 10.1093/jnci/djy085.
    • Review
    • A systematic review on the frequency of BRCA promoter methylation in breast and ovarian carcinomas of BRCA germline mutation carriers: Mutually exclusive, or not?
    • Vos S, van Diest PJ, Moelans CB.
    • Crit Rev Oncol Hematol. 2018 Jul;127:29-41. doi: 10.1016/j.critrevonc.2018.05.008. Epub 2018 May 14.
    • Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent.
    • Sizemore ST, Mohammad R, Sizemore GM, Nowsheen S, Yu H, Ostrowski MC, Chakravarti A, Xia F.
    • Mol Cancer Res. 2018 Jul;16(7):1092-1102. doi: 10.1158/1541-7786.MCR-18-0106. Epub 2018 Mar 28.
    • Olaparib-induced Adaptive Response Is Disrupted by FOXM1 Targeting that Enhances Sensitivity to PARP Inhibition.
    • Fang P, Madden JA, Neums L, Moulder RK, Forrest ML, Chien J.
    • Mol Cancer Res. 2018 Jun;16(6):961-973. doi: 10.1158/1541-7786.MCR-17-0607. Epub 2018 Mar 15.
    • Biomarkers for Homologous Recombination Deficiency in Cancer.
    • Hoppe MM, Sundar R, Tan DSP, Jeyasekharan AD.
    • J Natl Cancer Inst. 2018 May 18. doi: 10.1093/jnci/djy085. [Epub ahead of print]
    • Review
    • Complete response to orally administered melphalan in malignant pleural effusion from an occult female genital organ primary neoplasm with BRCA1/2 mutations: a case report.
    • Fan FS, Yang CF.
    • J Med Case Rep. 2018 May 6;12(1):122. doi: 10.1186/s13256-018-1674-3.
    • Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.
    • Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, Owen J, Abraham J, Barrett S, Barrett-Lee P, Brown R, Chan S, Dowsett M, Flanagan JM, Fox L, Grigoriadis A, Gutin A, Harper-Wynne C, Hatton MQ, Hoadley KA, Parikh J, Parker P, Perou CM, Roylance R, Shah V, Shaw A, Smith IE, Timms KM, Wardley AM, Wilson G, Gillett C, Lanchbury JS, Ashworth A, Rahman N, Harries M, Ellis P, Pinder S, Bliss JM.v
    • Nat Med. 2018 May;24(5):628-637. doi: 10.1038/s41591-018-0009-7. Epub 2018 Apr 30.
    • Update on the Treatment of Early-Stage Triple-Negative Breast Cancer.
    • Sharma P.
    • Curr Treat Options Oncol. 2018 Apr 14;19(5):22. doi: 10.1007/s11864-018-0539-8.
    • Review
    • Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
    • Telli ML, Hellyer J, Audeh W, Jensen KC, Bose S, Timms KM, Gutin A, Abkevich V, Peterson RN, Neff C, Hughes E, Sangale Z, Jones J, Hartman AR, Chang PJ, Vinayak S, Wenstrup R, Ford JM.
    • Breast Cancer Res Treat. 2018 Apr;168(3):625-630. doi: 10.1007/s10549-017-4624-7. Epub 2017 Dec 23.
    • EWS-FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma.
    • Gorthi A, Romero JC, Loranc E, Cao L, Lawrence LA, Goodale E, Iniguez AB, Bernard X, Masamsetti VP, Roston S, Lawlor ER, Toretsky JA, Stegmaier K, Lessnick SL, Chen Y, Bishop AJR.
    • Nature. 2018 Mar 15;555(7696):387-391. doi: 10.1038/nature25748. Epub 2018 Mar 7.

    Research news:

    Ewing Sarcomas Phenocopy BRCA1-Deficient Tumors.

    • Negative regulation of BRCA1 by transforming acidic coiled-coil protein 3 (TACC3).
    • Kim JL, Ha GH, Campo L, Breuer EK.
    • Biochem Biophys Res Commun. 2018 Feb 5;496(2):633-640. doi: 10.1016/j.bbrc.2018.01.101. Epub 2018 Jan 19.
    • The development of PARP as a successful target for cancer therapy.
    • Ferrara R, Simionato F, Ciccarese C, Grego E, Cingarlini S, Iacovelli R, Bria E, Tortora G, Melisi D.
    • Expert Rev Anticancer Ther. 2018 Feb;18(2):161-175. doi: 10.1080/14737140.2018.1419870. Epub 2017 Dec 26.
    • Review
    • Gynaecological neoplasms in common familial syndromes (Lynch and HBOC).
    • Bartosch C, Clarke B, Bosse T.
    • Pathology. 2018 Feb;50(2):222-237. doi: 10.1016/j.pathol.2017.10.010. Epub 2017 Dec 26.
    • Review
    • DNA repair and cell cycle checkpoint defects in a mouse model of 'BRCAness' are partially rescued by 53BP1 deletion.
    • Misenko SM, Patel DS, Her J, Bunting SF.
    • Cell Cycle. 2018;17(7):881-891. doi: 10.1080/15384101.2018.1456295. Epub 2018 May 15.
    • PARP Inhibitors for the Treatment of Ovarian Cancer.
    • Cortesi L, Toss A, Cucinotto I.
    • Curr Cancer Drug Targets. 2018;18(9):877-893. doi: 10.2174/1568009618666180308104646.
    • Review
    • Gene aberration profile of tumors of adolescent and young adult females.
    • Kanke Y, Shimomura A, Saito M, Honda T, Shiraishi K, Shimada Y, Watanabe R, Yoshida H, Yoshida M, Shimizu C, Takahashi K, Totsuka H, Ogiwara H, Hirose S, Kono K, Tamura K, Okamoto A, Kinoshita T, Kato T, Kohno T.
    • Oncotarget. 2017 Dec 29;9(5):6228-6237. doi: 10.18632/oncotarget.23765. eCollection 2018 Jan 19.
    • Metabolomics reveals novel blood plasma biomarkers associated to the BRCA1-mutated phenotype of human breast cancer.
    • Roig B, Rodríguez-Balada M, Samino S, Lam EW, Guaita-Esteruelas S, Gomes AR, Correig X, Borràs J, Yanes O, Gumà J.
    • Sci Rep. 2017 Dec 19;7(1):17831. doi: 10.1038/s41598-017-17897-8.
    • BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial.
    • van Rossum AGJ, Schouten PC, Weber KE, Nekljudova V, Denkert C, Solbach C, Köhne CH, Thomssen C, Forstbauer H, Hoffmann G, Kohls A, Schmatloch S, Schem C, von Minckwitz G, Karn T, Möbus VJ, Linn SC, Loibl S, Marmé F.
    • Breast Cancer Res Treat. 2017 Dec;166(3):775-785. doi: 10.1007/s10549-017-4444-9. Epub 2017 Aug 18.
    • Impact of Etoposide on BRCA1 Expression in Various Breast Cancer Cell Lines.
    • Zhang X, Hofmann S, Harbeck N, Jeschke U, Sixou S.
    • Drugs R D. 2017 Dec;17(4):569-583. doi: 10.1007/s40268-017-0208-6.
    • Characterization, Detection, and Treatment Approaches for Homologous Recombination Deficiency in Cancer.
    • O'Kane GM, Connor AA, Gallinger S.
    • Trends Mol Med. 2017 Dec;23(12):1121-1137. doi: 10.1016/j.molmed.2017.10.007. Epub 2017 Nov 10.
    • Review
    • Detection of BRCA1/2 mutations in circulating tumor DNA from patients with ovarian cancer.
    • Ratajska M, Koczkowska M, Żuk M, Gorczyński A, Kuźniacka A, Stukan M, Biernat W, Limon J, Wasąg B.
    • Oncotarget. 2017 Sep 8;8(60):101325-101332. doi: 10.18632/oncotarget.20722. eCollection 2017 Nov 24.
    • Computational Investigation of Homologous Recombination DNA Repair Deficiency in Sporadic Breast Cancer.
    • Wang Y, Ung MH, Cantor S, Cheng C.
    • Sci Rep. 2017 Nov 16;7(1):15742. doi: 10.1038/s41598-017-16138-2.
    • Judy Garber on PARP Inhibitors for Triple-Negative Breast Cancer.
    • Garber J.
    • OncoTherapy Network. 2017 Nov 15.
    • A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors.
    • Evans KW, Yuca E, Akcakanat A, Scott SM, Arango NP, Zheng X, Chen K, Tapia C, Tarco E, Eterovic AK, Black DM, Litton JK, Yap TA, Tripathy D, Mills GB, Meric-Bernstam F.
    • Clin Cancer Res. 2017 Nov 1;23(21):6468-6477. doi: 10.1158/1078-0432.CCR-17-0615.
    • Drugging the Cancers Addicted to DNA Repair.
    • Nickoloff JA, Jones D, Lee SH, Williamson EA, Hromas R.
    • J Natl Cancer Inst. 2017 Nov 1;109(11). doi: 10.1093/jnci/djx059.
    • [DNA repair as a therapeutic target].
    • Eberst L, Brahmi M, Cassier PA.
    • Bull Cancer. 2017 Nov;104(11):988-998. doi: 10.1016/j.bulcan.2017.09.005. Epub 2017 Nov 11.
    • Review, [Article in French]
    • Homologous Recombination Deficiency in Breast Cancer: A Clinical Review.
    • den Brok WD, Schrader KA, Sun S, Tinker AV, Zhao EY, Aparicio S, Gelmon KA.
    • JCO Precis Oncol. 2017 Nov;1:1-13. doi: 10.1200/PO.16.00031.
    • Biallelic Deletion of PALB2 Occurs Across Multiple Tumor Types and Suggests Responsiveness to Poly (ADP-ribose) Polymerase Inhibition.
    • Bhangoo MS, Costantini C, Clifford BT, Chung JH, Schrock AB, Ali SM, Klempner SJ.
    • JCO Precis Oncol. 2017 Nov;1:1-7. doi: 10.1200/PO.17.00043.
    • Combining Enzalutamide with PARP inhibitors: Pharmaceutically induced BRCAness.
    • Thompson TC, Li L, Broom BM.
    • Oncotarget. 2017 Oct 25. doi: 10.18632/oncotarget.22074. [Epub ahead of print]
    • Niraparib in ovarian cancer: results to date and clinical potential.
    • Caruso D, Papa A, Tomao S, Vici P, Panici PB, Tomao F.
    • Ther Adv Med Oncol. 2017 Sep;9(9):579-588. doi: 10.1177/1758834017718775. Epub 2017 Jul 12.
    • The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting.
    • Severson TM, Wolf DM, Yau C, Peeters J, Wehkam D, Schouten PC, Chin SF, Majewski IJ, Michaut M, Bosma A, Pereira B, Bismeijer T, Wessels L, Caldas C, Bernards R, Simon IM, Glas AM, Linn S, van 't Veer L.
    • Breast Cancer Res. 2017 Aug 25;19(1):99. doi: 10.1186/s13058-017-0861-2.
    • DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial.
    • Wolf DM, Yau C, Sanil A, Glas A, Petricoin E, Wulfkuhle J, Severson TM, Linn S, Brown-Swigart L, Hirst G, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, Paoloni M, Esserman L, Berry D, Rugo H, Olopade O, van 't Veer L.
    • NPJ Breast Cancer. 2017 Aug 25;3:31. doi: 10.1038/s41523-017-0025-7. eCollection 2017.
    • TGFbeta and miRNA regulation in familial and sporadic breast cancer.
    • Danza K, Summa S, Pinto R, Pilato B, Palumbo O, Carella M, Popescu O, Digennaro M, Lacalamita R, Tommasi S.
    • Oncotarget. 2017 Jan 30;8(31):50715-50723. doi: 10.18632/oncotarget.14899. eCollection 2017 Aug 1.
    • Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics.
    • Engert F, Kovac M, Baumhoer D, Nathrath M, Fulda S.
    • Oncotarget. 2017 Jul 25;8(30):48794-48806. doi: 10.18632/oncotarget.10720.
    • Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA Repair.
    • Piacente F, Caffa I, Ravera S, Sociali G, Passalacqua M, Vellone VG, Becherini P, Reverberi D, Monacelli F, Ballestrero A, Odetti P, Cagnetta A, Cea M, Nahimana A, Duchosal MA, Bruzzone S, Nencioni A.
    • Cancer Res. 2017 Jul 15;77(14):3857-3869. doi: 10.1158/0008-5472.CAN-16-3079. Epub 2017 May 15.
    • The effect of thermal dose on hyperthermia-mediated inhibition of DNA repair through homologous recombination.
    • van den Tempel N, Laffeber C, Odijk H, van Cappellen WA, van Rhoon GC, Franckena M, Kanaar R.
    • Oncotarget. 2017 Jul 4;8(27):44593-44604. doi: 10.18632/oncotarget.17861.
    • Development of PARP inhibitors in gynecological malignancies.
    • Ang YLE, Tan DSP.
    • Curr Probl Cancer. 2017 Jul - Aug;41(4):273-286. doi: 10.1016/j.currproblcancer.2017.02.008. Epub 2017 Mar 14.
    • Review
    • Acquired cross-linker resistance associated with a novel spliced BRCA2 protein variant for molecular phenotyping of BRCA2 disruption.
    • Meyer S, Stevens A, Paredes R, Schneider M, Walker MJ, Williamson AJK, Gonzalez-Sanchez MB, Smetsers S, Dalal V, Teng HY, White DJ, Taylor S, Muter J, Pierce A, de Leonibus C, Rockx DAP, Rooimans MA, Spooncer E, Stauffer S, Biswas K, Godthelp B, Dorsman J, Clayton PE, Sharan SK, Whetton AD.
    • Cell Death Dis. 2017 Jun 15;8(6):e2875. doi: 10.1038/cddis.2017.264.
    • Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy.
    • Jin J, Zhang W, Ji W, Yang F, Guan X.
    • Cancer Biol Ther. 2017 Jun 3;18(6):369-378. doi: 10.1080/15384047.2017.1323582. Epub 2017 May 11.
    • Whence High-Grade Serous Ovarian Cancer.
    • Kohn EC, Ivy SP.
    • Am Soc Clin Oncol Educ Book. [Presented Friday, June 2, 2017.] 2017;37:443-448. doi: 10.14694/EDBK_174718.
    • The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.
    • Rimar KJ, Tran PT, Matulewicz RS, Hussain M, Meeks JJ.
    • Cancer. 2017 Jun 1;123(11):1912-1924. doi: 10.1002/cncr.30631. Epub 2017 Mar 21.
    • Review
    • Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma.
    • Connor AA, Denroche RE, Jang GH, Timms L, Kalimuthu SN, Selander I, McPherson T, Wilson GW, Chan-Seng-Yue MA, Borozan I, Ferretti V, Grant RC, Lungu IM, Costello E, Greenhalf W, Palmer D, Ghaneh P, Neoptolemos JP, Buchler M, Petersen G, Thayer S, Hollingsworth MA, Sherker A, Durocher D, Dhani N, Hedley D, Serra S, Pollett A, Roehrl MH, Bavi P, Bartlett JM, Cleary S, Wilson JM, Alexandrov LB, Moore M, Wouters BG, McPherson JD, Notta F, Stein LD, Gallinger S.
    • JAMA Oncol. 2017 Jun 1;3(6):774-783. doi: 10.1001/jamaoncol.2016.3916.
    • Analysis Suggests Wider Use for PARP Inhibitors.
    • [No authors listed]
    • Cancer Discov. 2017 Jun;7(6):OF7. doi: 10.1158/2159-8290.CD-NB2017-049. Epub 2017 Apr 12.
    • News
    • PARP inhibitors alone and in combination with other biological agents in homologous recombination deficient epithelial ovarian cancer: From the basic research to the clinic.
    • Gadducci A, Guerrieri ME.
    • Crit Rev Oncol Hematol. 2017 Jun;114:153-165. doi: 10.1016/j.critrevonc.2017.04.006. Epub 2017 Apr 20.

    Commentary: 'Clear Role' for PARP Inhibitors in Advanced Ovarian Cancer. (Medscape Oncology)

    • PARP Inhibitors in Prostate Cancer.
    • Ramakrishnan Geethakumari P, Schiewer MJ, Knudsen KE, Kelly WK.
    • Curr Treat Options Oncol. 2017 Jun;18(6):37. doi: 10.1007/s11864-017-0480-2.
    • Review
    • Olaparib for the treatment of breast cancer.
    • Robert M, Frenel JS, Gourmelon C, Patsouris A, Augereau P, Campone M.
    • Expert Opin Investig Drugs. 2017 Jun;26(6):751-759. doi: 10.1080/13543784.2017.1318847. Epub 2017 Apr 21.
    • Review
    • Bi-allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer.
    • Mutter RW, Riaz N, Ng CK, Delsite R, Piscuoglio S, Edelweiss M, Martelotto LG, Sakr RA, King TA, Giri DD, Drobnjak M, Brogi E, Bindra R, Bernheim G, Lim RS, Blecua P, Desrichard A, Higginson D, Towers R, Jiang R, Lee W, Weigelt B, Reis-Filho JS, Powell SN.
    • J Pathol. 2017 Jun;242(2):165-177. doi: 10.1002/path.4890. Epub 2017 Apr 27.
    • BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers.
    • Vos S, Moelans CB, van Diest PJ.
    • Breast Cancer Res. 2017 May 31;19(1):64. doi: 10.1186/s13058-017-0856-z.
    • Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers.
    • Sun C, Fang Y, Yin J, Chen J, Ju Z, Zhang D, Chen X, Vellano CP, Jeong KJ, Ng PK, Eterovic AKB, Bhola NH, Lu Y, Westin SN, Grandis JR, Lin SY, Scott KL, Peng G, Brugge J, Mills GB.
    • Sci Transl Med. 2017 May 31;9(392). pii: eaal5148. doi: 10.1126/scitranslmed.aal5148.

    Research news: Expanding the use of PARP inhibitors. (Nature Reviews Cancer)

    • Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer.
    • Li L, Karanika S, Yang G, Wang J, Park S, Broom BM, Manyam GC, Wu W, Luo Y, Basourakos S, Song JH, Gallick GE, Karantanos T, Korentzelos D, Azad AK, Kim J, Corn PG, Aparicio AM, Logothetis CJ, Troncoso P, Heffernan T, Toniatti C, Lee HS, Lee JS, Zuo X, Chang W, Yin J, Thompson TC.
    • Sci Signal. 2017 May 23;10(480). pii: eaam7479. doi: 10.1126/scisignal.aam7479.

    Research news: Expanding the use of PARP inhibitors. (Nature Reviews Cancer)

    • Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer.
    • Hollis RL, Churchman M, Gourley C.
    • Onco Targets Ther. 2017 May 11;10:2539-2551. doi: 10.2147/OTT.S102569. eCollection 2017.
    • Somatic BRCA2 bi-allelic loss in the primary prostate cancer was associated to objective response to PARPi in a sporadic CRPC patient.
    • Romero-Laorden N, Piñeiro-Yañez E, Gutierrez-Pecharroman A, Pacheco MI, Calvo E, Al-Shahrour F, Castro E, Olmos D1.
    • Ann Oncol. 2017 May 1;28(5):1158-1159. doi: 10.1093/annonc/mdx067.
    • Letter, Case report
    • Whence High-Grade Serous Ovarian Cancer.
    • Kohn EC, Ivy SP.
    • Am Soc Clin Oncol Educ Book. 2017 May;(37):443-448. doi: 10.1200/EDBK_174718.
    • Whole-genome sequencing identifies homozygous BRCA2 deletion guiding treatment in dedifferentiated prostate cancer.
    • Purshouse K, Schuh A, Fairfax BP, Knight S, Antoniou P, Dreau H, Popitsch N, Gatter K, Roberts I, Browning L, Traill Z, Kerr D, Verrill C, Tuthill M, Taylor JC, Protheroe A.
    • Cold Spring Harb Mol Case Stud. 2017 May;3(3):a001362. doi: 10.1101/mcs.a001362.
    • BRCA1 alterations with additional defects in DNA damage response genes may confer chemoresistance to BRCA-like breast cancers treated with neoadjuvant chemotherapy.
    • Takada M, Nagai S, Haruta M, Sugino RP, Tozuka K, Takei H, Ohkubo F, Inoue K, Kurosumi M, Miyazaki M, Sato-Otsubo A, Sato Y, Ogawa S, Kaneko Y.
    • Genes Chromosomes Cancer. 2017 May;56(5):405-420. doi: 10.1002/gcc.22445. Epub 2017 Mar 7.
    • BRCA1/2-negative hereditary triple-negative breast cancers exhibit BRCAness.
    • Domagala P, Hybiak J, Cybulski C, Lubinski J.
    • Int J Cancer. 2017 Apr 1;140(7):1545-1550. doi: 10.1002/ijc.30570. Epub 2017 Jan 24.
    • HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.
    • Davies H, Glodzik D, Morganella S, Yates LR, Staaf J, Zou X, Ramakrishna M, Martin S, Boyault S, Sieuwerts AM, Simpson PT, King TA, Raine K, Eyfjord JE, Kong G, Borg Å, Birney E, Stunnenberg HG, van de Vijver MJ, Børresen-Dale AL, Martens JW, Span PN, Lakhani SR, Vincent-Salomon A, Sotiriou C, Tutt A, Thompson AM, Van Laere S, Richardson AL, Viari A, Campbell PJ, Stratton MR, Nik-Zainal S.
    • Nat Med. 2017 Apr;23(4):517-525. doi: 10.1038/nm.4292. Epub 2017 Mar 13.
    • BRCA1-Mutated Estrogen Receptor-Positive Breast Cancer Shows BRCAness, Suggesting Sensitivity to Drugs Targeting Homologous Recombination Deficiency.
    • Lips EH, Debipersad R, Scheerman CE, Mulder L, Sonke GS, van der Kolk LE, Wesseling J, Hogervorst FB, Nederlof PM.
    • Clin Cancer Res. 2017 Mar 1;23(5):1236-1241. doi: 10.1158/1078-0432.CCR-16-0198. Epub 2016 Sep 12.
    • Therapeutic Strategies in Triple-Negative Breast Cancer.
    • Paradiso A, Singer CF.
    • Breast Care (Basel). 2017 Mar;12(1):6-7. doi: 10.1159/000460238. Epub 2017 Feb 28.

    Review:

    Biological Subtypes of Triple-Negative Breast Cancer.

    Review:

    Germline Mutations in Triple-Negative Breast Cancer.

    Review:

    Therapeutic Advances and New Directions for Triple-Negative Breast Cancer.

    • Therapeutic Advances and New Directions for Triple-Negative Breast Cancer.
    • Andreopoulou E, Kelly CM, McDaid HM.
    • Breast Care (Basel). 2017 Mar;12(1):21-28. doi: 10.1159/000455821. Epub 2017 Feb 7.

    Editorial:

    Therapeutic Strategies in Triple-Negative Breast Cancer.

    • The Prognostic Value of BRCA1 and PARP Expression in Epithelial Ovarian Carcinoma: Immunohistochemical Detection.
    • Hjortkjær M, Waldstrøm M, Jakobsen A, Kanstrup H, Søgaard-Andersen E, Dahl Steffensen K.
    • Int J Gynecol Pathol. 2017 Mar;36(2):180-189. doi: 10.1097/PGP.0000000000000310.
    • The EMSY threonine 207 phospho-site is required for EMSYdriven suppression of DNA damage repair.
    • Jelinic P, Eccles LA, Tseng J, Cybulska P, Wielgos M, Powell SN, Levine DA.
    • Oncotarget. 2017 Feb 21;8(8):13792-13804. doi: 10.18632/oncotarget.14637.
    • PARP Inhibitors in Reproductive System Cancers: Current Use and Developments.
    • O'Sullivan Coyne G, Chen AP, Meehan R, Doroshow JH.
    • Drugs. 2017 Feb;77(2):113-130. doi: 10.1007/s40265-016-0688-7.
    • [Can new molecular profiles in epithelial ovarian cancer modify therapeutics?]
    • Lavoué V, Rousselin A, Delplanque S, Pinsard M, Henno S, Foucher F, Levêque J, de la Motte Rouge T.
    • J Gynecol Obstet Hum Reprod. 2017 Feb;46(2):107-112. doi: 10.1016/j.jogoh.2016.09.002. Epub 2017 Jan 30.
    • Review, [Article in French]
    • A novel hysteroscopic approach for ovarian cancer screening/early diagnosis.
    • Gizzo S, Noventa M, Quaranta M, Vitagliano A, Saccardi C, Litta P, Antona D.
    • Oncol Lett. 2017 Feb;13(2):549-553. doi: 10.3892/ol.2016.5493. Epub 2016 Dec 14.
    • BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer.
    • Mori H, Kubo M, Nishimura R, Osako T, Arima N, Okumura Y, Okido M, Yamada M, Kai M, Kishimoto J, Miyazaki T, Oda Y, Otsuka T, Nakamura M.
    • PLoS One. 2016 Dec 15;11(12):e0167016. doi: 10.1371/journal.pone.0167016. eCollection 2016.
    • BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
    • Tanino H, Kosaka Y, Nishimiya H, Tanaka Y, Minatani N, Kikuchi M, Shida A, Waraya M, Katoh H, Enomoto T, Sengoku N, Kajita S, Hoffman RM, Watanabe M.
    • PLoS One. 2016 Dec 9;11(12):e0165721. doi: 10.1371/journal.pone.0165721. eCollection 2016.
    • miR-151-5p, targeting chromatin remodeler SMARCA5, as a marker for the BRCAness phenotype.
    • Tommasi S, Pinto R, Danza K, Pilato B, Palumbo O, Micale L, De Summa S.
    • Oncotarget. 2016 Dec 6;7(49):80363-80372. doi: 10.18632/oncotarget.10345.
    • Germline mutations in DNA repair genes may predict neoadjuvant therapy response in triple negative breast patients.
    • Spugnesi L, Gabriele M, Scarpitta R, Tancredi M, Maresca L, Gambino G, Collavoli A, Aretini P, Bertolini I, Salvadori B, Landucci E, Fontana A, Rossetti E, Roncella M, Naccarato GA, Caligo MA.
    • Genes Chromosomes Cancer. 2016 Dec;55(12):915-924. doi: 10.1002/gcc.22389. Epub 2016 Jul 26.
    • Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic.
    • Cerrato A, Morra F, Celetti A.
    • J Exp Clin Cancer Res. 2016 Nov 24;35(1):179.
    • Reduced PAK1 activity sensitizes FA/BRCA-proficient breast cancer cells to PARP inhibition.
    • Villamar Cruz O, Prudnikova TY, Araiza-Olivera D, Perez-Plasencia C, Johnson N, Bernhardy AJ, Slifker M, Renner C, Chernoff J, Arias-Romero LE.
    • Oncotarget. 2016 Nov 22;7(47):76590-76603. doi: 10.18632/oncotarget.12576.
    • Trabectedin as a chemotherapy option for patients with BRCA deficiency.
    • Monk BJ, Lorusso D, Italiano A, Kaye SB, Aracil M, Tanović A, D'Incalci M.
    • Cancer Treat Rev. 2016 Nov;50:175-182. doi: 10.1016/j.ctrv.2016.09.009. Epub 2016 Sep 15.
    • Review
    • Innovations that reach the patient: early health technology assessment and improving the chances of coverage and implementation.
    • van Harten WH, Retèl VP.
    • Ecancermedicalscience. 2016 Oct 28;10:683. eCollection 2016.
    • Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study.
    • Gross E, van Tinteren H, Li Z, Raab S, Meul C, Avril S, Laddach N, Aubele M, Propping C, Gkazepis A, Schmitt M, Meindl A, Nederlof PM, Kiechle M, Lips EH.
    • BMC Cancer. 2016 Oct 19;16(1):811.
    • The current status of PARP inhibitors in ovarian cancer.
    • McLachlan J, George A, Banerjee S.
    • Tumori. 2016 Oct 13;102(5):433-440. doi: 10.5301/tj.5000558. Epub 2016 Sep 24.
    • Review
    • Association of the germline BRCA2 missense variation Glu2663Lys with high sensitivity to trabectedin-based treatment in soft tissue sarcoma.
    • Miolo G, Viel A, Canzonieri V, Baresic T, Buonadonna A, Santeufemia DA, Lara DP, Corona G.
    • Cancer Biol Ther. 2016 Oct 2;17(10):1017-1021.
    • Case report
    • Ovarian cancer treatment in mutation carriers/brcaness.
    • Lorusso D, Perotto S.
    • Minerva Ginecol. 2016 Oct;68(5):566-78. Epub 2016 Jan 19.
    • Review
    • [BRCA1 and BRCA2 - pathologists starting kit].
    • Škapa P.
    • Cesk Patol. 2016 Fall;52(4):193-196.
    • [Oncopathological aspects of BRCA1 and BRCA2 genes inactivation in tumors of ovary, fallopian tube and pelvic peritoneum].
    • Škapa P, Dundr P.
    • Cesk Patol. 2016 Fall;52(4):199-204.
    • The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 2: extending the scope beyond olaparib and BRCA1/2 mutations.
    • Miller RE, Ledermann JA.
    • Clin Adv Hematol Oncol. 2016 Sep;14(9):704-11.
    • Biology and Management of Patients With Triple-Negative Breast Cancer.
    • Sharma P.
    • Oncologist. 2016 Sep;21(9):1050-62. doi: 10.1634/theoncologist.2016-0067. Epub 2016 Jul 11.
    • Post-transcriptional Regulation of BRCA2 through Interactions with miR-19a and miR-19b.
    • Mogilyansky E, Clark P, Quann K, Zhou H, Londin E, Jing Y, Rigoutsos I.
    • Front Genet. 2016 Aug 31;7:143. doi: 10.3389/fgene.2016.00143. eCollection 2016.
    • Cytotoxic and targeted therapy for hereditary cancers.
    • Iyevleva AG, Imyanitov EN.
    • Hered Cancer Clin Pract. 2016 Aug 23;14(1):17. doi: 10.1186/s13053-016-0057-2. eCollection 2016.
    • BRCA1-like profile predicts benefit of tandem high dose epirubicin-cyclophospamide-thiotepa in high risk breast cancer patients randomized in the WSG-AM01 trial.
    • Schouten PC, Gluz O, Harbeck N, Mohrmann S, Diallo-Danebrock R, Pelz E, Kruizinga J, Velds A, Nieuwland M, Kerkhoven RM, Liedtke C, Frick M, Kates R, Linn SC, Nitz U, Marme F.
    • Int J Cancer. 2016 Aug 15;139(4):882-889. doi: 10.1002/ijc.30078. Epub 2016 May 5.
    • A Radiotracer Strategy to Quantify PARP-1 Expression In Vivo Provides a Biomarker That Can Enable Patient Selection for PARP Inhibitor Therapy.
    • Makvandi M, Xu K, Lieberman BP, Anderson RC, Sander Effron S, Winters HD, Zeng C, McDonald ES, Pryma DA, Greenberg RA, Mach RH.
    • Cancer Res. 2016 Aug 1;76(15):4516-24. doi: 10.1158/0008-5472.CAN-16-0416. Epub 2016 Jun 3.
    • Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple Negative Breast Cancer.
    • Telli ML, Timms KM, Reid JE, Hennessy B, Mills GB, Jensen KC, Szallasi Z, Barry WT, Winer EP, Tung N, Isakoff SJ, Ryan PD, Greene-Colozzi A, Gutin A, Sangale Z, Iliev D, Neff C, Abkevich V, Jones JT, Lanchbury JS, Hartman AR, Garber JE, Ford JM, Silver DP, Richardson AL.
    • Clin Cancer Res. 2016 Aug 1;22(15):3764-73. doi: 10.1158/1078-0432.CCR-15-2477. Epub 2016 Mar 8.
    • BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer.
    • Moschetta M, George A, Kaye SB, Banerjee S.
    • Ann Oncol. 2016 Aug;27(8):1449-55. doi: 10.1093/annonc/mdw142. Epub 2016 Mar 31.
    • DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities.
    • Dhawan M, Ryan CJ, Ashworth A.
    • Oncologist. 2016 Aug;21(8):940-5. doi: 10.1634/theoncologist.2016-0135. Epub 2016 Jun 17.
    • Levels of DNA Methylation Vary at CpG Sites across the BRCA1 Promoter, and Differ According to Triple Negative and "BRCA-Like" Status, in Both Blood and Tumour DNA.
    • Daniels SL, Burghel GJ, Chambers P, Al-Baba S, Connley DD, Brock IW, Cramp HE, Dotsenko O, Wilks O, Wyld L, Cross SS, Cox A
    • PLoS One. 2016 Jul 27;11(7):e0160174. doi: 10.1371/journal.pone.0160174.
    • DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics.
    • Rabenau K, Hofstatter E.
    • Clin Ther. 2016 Jul;38(7):1577-88. doi: 10.1016/j.clinthera.2016.06.006. Epub 2016 Jun 29.
    • BRCAness is beneficial for indicating triple negative breast cancer patients resistant to taxane.
    • Ishikawa T, Narui K, Tanabe M, Kida K, Oba MS, Yamada A, Ichikawa Y, Endo I.
    • Eur J Surg Oncol. 2016 Jul;42(7):999-1001. doi: 10.1016/j.ejso.2016.02.246. Epub 2016 Mar 2.
    • Evaluation of the methods to identify patients who may benefit from PARP inhibitor use.
    • Lim D, Ngeow J.
    • Endocr Relat Cancer. 2016 Jun;23(6):R267-85. doi: 10.1530/ERC-16-0116. Epub 2016 May 25.
    • Decisions on Further Research for Predictive Biomarkers of High-Dose Alkylating Chemotherapy in Triple-Negative Breast Cancer: A Value of Information Analysis.
    • Miquel-Cases A, Retèl VP, van Harten WH, Steuten LM.
    • Value Health. 2016 Jun;19(4):419-30. doi: 10.1016/j.jval.2016.01.015. Epub 2016 Apr 6.
    • Gynecologic Cancers: Emerging Novel Strategies for Targeting DNA Repair Deficiency.
    • Kristeleit RS, Miller RE, Kohn EC.
    • Am Soc Clin Oncol Educ Book. 2016 May;(36):e259-e268. doi: 10.1200/EDBK_159086.
    • Ovarian cancer: Status of homologous recombination pathway as a predictor of drug response.
    • De Picciotto N, Cacheux W, Roth A, Chappuis PO, Labidi-Galy SI.
    • Crit Rev Oncol Hematol. 2016 May;101:50-9. doi: 10.1016/j.critrevonc.2016.02.014. Epub 2016 Feb 27.
    • Identification of BRCA1 Deficiency Using Multi-Analyte Estimation of BRCA1 and Its Repressors in FFPE Tumor Samples from Patients with Triple Negative Breast Cancer.
    • Korlimarla A, Prabhu JS, Remacle J, Rajarajan S, Raja U, C E A, Srinath BS, Manjunath S, K S G, Correa M, M S N P, Sridhar TS.
    • PLoS One. 2016 Apr 14;11(4):e0153113. doi: 10.1371/journal.pone.0153113. eCollection 2016.
    • A BRCA1 deficient, NFκB driven immune signal predicts good outcome in triple negative breast cancer.
    • Buckley NE, Haddock P, De Matos Simoes R, Parkes E, Irwin G, Emmert-Streib F, McQuaid S, Kennedy R, Mullan P.
    • Oncotarget. 2016 Apr 12;7(15):19884-96. doi: 10.18632/oncotarget.7865.
    • Progress in the treatment of ovarian cancer-lessons from homologous recombination deficiency-the first 10 years.
    • Kaye SB.
    • Ann Oncol. 2016 Apr;27 Suppl 1:i1-i3. doi: 10.1093/annonc/mdw082.
    • Relationship of immunohistochemistry, copy number aberrations and epigenetic disorders with BRCAness pattern in hereditary and sporadic breast cancer.
    • Murria Estal R, Palanca Suela S, de Juan Jiménez I, Alenda Gonzalez C, Egoavil Rojas C, García-Casado Z, López Guerrero JA, Juan Fita MJ, Sánchez Heras AB, Segura Huerta Á, Santaballa Bertrán A, Chirivella González I, Llop García M, Pérez Simó G, Barragán González E, Bolufer Gilabert P.
    • Fam Cancer. 2016 Apr;15(2):193-200. doi: 10.1007/s10689-015-9864-2.
    • Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer.
    • Zhang M, Liu G, Xue F, Edwards R, Sood AK, Zhang W, Yang D.
    • Gynecol Oncol. 2016 Apr;141(1):57-64. doi: 10.1016/j.ygyno.2016.01.004.
    • DNA repair in lung cancer: potential not yet reached.
    • Mamdani H, Jalal SI.
    • Lung Cancer Manag. 2016 Apr;5(1):5-8. doi: 10.2217/lmt-2016-0004. Epub 2016 Apr 6.
    • Editorial
    • Different Array CGH profiles within hereditary breast cancer tumors associated to BRCA1 expression and overall survival.
    • Alvarez C, Aravena A, Tapia T, Rozenblum E, Solís L, Corvalán A, Camus M, Alvarez M, Munroe D, Maass A, Carvallo P.
    • BMC Cancer. 2016 Mar 15;16(1):219. doi: 10.1186/s12885-016-2261-x.
    • Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial.
    • Lorusso D, Scambia G, Pignata S, Sorio R, Amadio G, Lepori S, Mosconi A, Pisano C, Mangili G, Maltese G, Sabbatini R, Artioli G, Gamucci T, Di Napoli M, Capoluongo E, Ludovini V, Raspagliesi F, Ferrandina G.
    • Ann Oncol. 2016 Mar;27(3):487-93. doi: 10.1093/annonc/mdv608. Epub 2015 Dec 17.
    • New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    • Liu FW, Tewari KS.
    • Curr Treat Options Oncol. 2016 Mar;17(3):12. doi: 10.1007/s11864-015-0378-9.
    • Complete Durable Response From Carboplatin and Olaparib in a Heavily Pretreated Triple-Negative Metastatic Breast Cancer With Germline BRCA2 and "BRCAness" Mutations.
    • Hong S, Funchain P, Haddad A, Crowe J, Dalpiaz N, Abraham J.
    • J Oncol Pract. 2016 Mar;12(3):270-2. doi: 10.1200/JOP.2016.010710.
    • Case report
    • Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair.
    • Villalona-Calero MA, Duan W, Zhao W, Shilo K, Schaaf LJ, Thurmond J, Westman JA, Marshall J, Xiaobai L, Ji J, Rose J, Lustberg M, Bekaii-Saab T, Chen A, Timmers C.
    • J Natl Cancer Inst. 2016 Feb 4;108(7). pii: djv437. doi: 10.1093/jnci/djv437. Print 2016 Jul.
    • Triple-negative breast cancer: advancements in characterization and treatment approach.
    • Hurvitz S, Mead M.
    • Curr Opin Obstet Gynecol. 2016 Feb;28(1):59-69. doi: 10.1097/GCO.0000000000000239.
    • Review
    • CAF-like state in primary skin fibroblasts with constitutional BRCA1 epimutation sheds new light on tumor suppressor deficiency-related changes in healthy tissue.
    • Etzold A, Galetzka D, Weis E, Bartsch O, Haaf T, Spix C, Itzel T, Schweiger S, Strand D, Strand S, Zechner U.
    • Epigenetics. 2016 Feb;11(2):120-31. doi: 10.1080/15592294.2016.1140295. Epub 2016 Mar 7.
    • BRCAness revisited.
    • Lord CJ, Ashworth A.
    • Nat Rev Cancer. 2016 Feb;16(2):110-20. doi: 10.1038/nrc.2015.21. Epub 2016 Jan 18.
    • Review, Editorial / Commentary
    • DNA Methylation and microRNA patterns are in association with the expression of BRCA1 in ovarian cancer.
    • Shariati-Kohbanani M, Zare-Bidaki M, Taghavi MM, Taghipour Z, Shabanizadeh A, Kennedy D, Dahim H, Salahshoor MR, Jalili C, Kazemi Arababadi M.
    • Cell Mol Biol (Noisy-le-grand). 2016 Jan 11;62(1):16-23.
    • Review
    • Epigenetic regulation of ID4 in the determination of the BRCAness phenotype in breast cancer.
    • Branham MT, Campoy E, Laurito S, Branham R, Urrutia G, Orozco J, Gago F, Urrutia R, Roqué M.
    • Breast Cancer Res Treat. 2016 Jan;155(1):13-23. doi: 10.1007/s10549-015-3648-0. Epub 2015 Nov 27.
    • High XIST and Low 53BP1 Expression Predict Poor Outcome after High-Dose Alkylating Chemotherapy in Patients with a BRCA1-like Breast Cancer.
    • Schouten PC, Vollebergh MA, Opdam M, Jonkers M, Loden M, Wesseling J, Hauptmann M, Linn SC.
    • Mol Cancer Ther. 2016 Jan;15(1):190-8. doi: 10.1158/1535-7163.MCT-15-0470. Epub 2015 Dec 4.
    • Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency.
    • Kovac M, Blattmann C, Ribi S, Smida J, Mueller NS, Engert F, Castro-Giner F, Weischenfeldt J, Kovacova M, Krieg A, Andreou D, Tunn PU, Dürr HR, Rechl H, Schaser KD, Melcher I, Burdach S, Kulozik A, Specht K, Heinimann K, Fulda S, Bielack S, Jundt G, Tomlinson I, Korbel JO, Nathrath M, Baumhoer D.
    • Nat Commun. 2015 Dec 3;6:8940. doi: 10.1038/ncomms9940.
    • Copy number profiling by array comparative genomic hybridization identifies frequently occurring BRCA2-like male breast cancer.
    • Biesma HD, Schouten PC, Lacle MM, Sanders J, Brugman W, Kerkhoven R, Mandjes I, van der Groep P, van Diest PJ, Linn SC.
    • Genes Chromosomes Cancer. 2015 Dec;54(12):734-44. doi: 10.1002/gcc.22284. Epub 2015 Sep 10.
    • Decreased Expression of BRCA2 Accelerates Sporadic Breast Cancer Progression.
    • Saha S, Mandal P, Ganguly S, Jana D, Ayaz A, Banerjee A, Chouhan R, Sarkar DK.
    • Indian J Surg Oncol. 2015 Dec;6(4):378-83. doi: 10.1007/s13193-015-0449-1. Epub 2015 Aug 21.
    • Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer.
    • Konstantinopoulos PA, Ceccaldi R, Shapiro GI, D'Andrea AD.
    • Cancer Discov. 2015 Nov;5(11):1137-54. doi: 10.1158/2159-8290.CD-15-0714. Epub 2015 Oct 13.
    • Promoter methylation of BRCA1 is associated with estrogen, progesterone and human epidermal growth factor receptor-negative tumors and the prognosis of breast cancer: A meta-analysis.
    • Guo T, Ren Y, Wang B, Huang Y, Jia S, Tang W, Luo Y.
    • Mol Clin Oncol. 2015 Nov;3(6):1353-1360. Epub 2015 Aug 11.
    • BRCA1 and BARD1 colocalize mainly in the cytoplasm of breast cancer tumors, and their isoforms show differential expression.
    • Wiener D, Gajardo-Meneses P, Ortega-Hernández V, Herrera-Cares C, Díaz S, Fernández W, Cornejo V, Gamboa J, Tapia T, Alvarez C, Carvallo P.
    • Breast Cancer Res Treat. 2015 Oct;153(3):669-78. doi: 10.1007/s10549-015-3575-0. Epub 2015 Sep 22.
    • BRCAness in endometrial cancer.
    • Stephan JM, Cohen E, Gonzalez J.
    • Gynecologic Oncology. 2015 Oct;139(1):188. 2015 WAGO ABSTRACTS. doi: 10.1016/j.ygyno.2015.07.044.
    • Conference abstract
    • Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition.
    • Wiegmans AP, Yap PY, Ward A, Lim YC, Khanna KK.
    • Mol Cancer Ther. 2015 Oct;14(10):2321-31. doi: 10.1158/1535-7163.MCT-15-0374. Epub 2015 Aug 20.
    • BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential.
    • Severson TM, Peeters J, Majewski I, Michaut M, Bosma A, Schouten PC, Chin SF, Pereira B, Goldgraben MA, Bismeijer T, Kluin RJ, Muris JJ, Jirström K, Kerkhoven RM, Wessels L, Caldas C, Bernards R, Simon IM, Linn S.
    • Mol Oncol. 2015 Oct;9(8):1528-38. doi: 10.1016/j.molonc.2015.04.011. Epub 2015 May 7.
    • Early stage cost-effectiveness analysis of a BRCA1-like test to detect triple negative breast cancers responsive to high dose alkylating chemotherapy.
    • Miquel-Cases A, Steuten LM, Retèl VP, van Harten WH.
    • Breast. 2015 Aug;24(4):397-405. doi: 10.1016/j.breast.2015.03.002. Epub 2015 Apr 28.
    • Robust BRCA1-like classification of copy number profiles of samples repeated across different datasets and platforms.
    • Schouten PC, Grigoriadis A, Kuilman T, Mirza H, Watkins JA, Cooke SA, van Dyk E, Severson TM, Rueda OM, Hoogstraat M, Verhagen CV, Natrajan R, Chin SF, Lips EH, Kruizinga J, Velds A, Nieuwland M, Kerkhoven RM, Krijgsman O, Vens C, Peeper D, Nederlof PM, Caldas C, Tutt AN, Wessels LF, Linn SC.
    • Mol Oncol. 2015 Aug;9(7):1274-86. doi: 10.1016/j.molonc.2015.03.002. Epub 2015 Mar 20.
    • Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs.
    • Marquard AM, Eklund AC, Joshi T, Krzystanek M, Favero F, Wang ZC, Richardson AL, Silver DP, Szallasi Z, Birkbak NJ.
    • Biomark Res. 2015 May 1;3:9. doi: 10.1186/s40364-015-0033-4. eCollection 2015.
    • Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers.
    • Watkins J, Weekes D, Shah V, Gazinska P, Joshi S, Sidhu B, Gillett C, Pinder S, Vanoli F, Jasin M, Mayrhofer M, Isaksson A, Cheang MC, Mirza H, Frankum J, Lord CJ, Ashworth A, Vinayak S, Ford JM, Telli ML, Grigoriadis A, Tutt AN.
    • Cancer Discov. 2015 May;5(5):488-505. doi: 10.1158/2159-8290.CD-14-1092. Epub 2015 Mar 13.
    • Therapies for triple negative breast cancer.
    • Andreopoulou E, Schweber SJ, Sparano JA, McDaid HM.
    • Expert Opin Pharmacother. 2015 May;16(7):983-98.
    • Review
    • Breast Cancers with a BRCA1-like DNA Copy Number Profile Recur Less Often Than Expected after High-Dose Alkylating Chemotherapy.
    • Schouten PC, Marmé F, Aulmann S, Sinn HP, van Essen HF, Ylstra B, Hauptmann M, Schneeweiss A, Linn SC.
    • Clin Cancer Res. 2015 Feb 15;21(4):763-70. doi: 10.1158/1078-0432.CCR-14-1894. Epub 2014 Dec 5.
    • BRCAness predicts resistance to taxane-containing regimens in triple negative breast cancer during neoadjuvant chemotherapy.
    • Akashi-Tanaka S, Watanabe C, Takamaru T, Kuwayama T, Ikeda M, Ohyama H, Mori M, Yoshida R, Hashimoto R, Terumasa S, Enokido K, Hirota Y, Okuyama H, Nakamura S.
    • Clin Breast Cancer. 2015 Feb;15(1):80-5. doi: 10.1016/j.clbc.2014.08.003. Epub 2014 Sep 28.
    • Targeting triple-negative breast cancer and high-grade ovarian carcinoma: refining BRCAness beyond BRCA1/2 mutations?
    • Jacot W, Theillet C, Guiu S, Lamy PJ.
    • Future Oncol. 2015 Feb;11(4):557-9. doi: 10.2217/fon.14.268.
    • Letter, Editorial / Commentary
    • Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
    • Timms KM, Abkevich V, Hughes E, Neff C, Reid J, Morris B, Kalva S, Potter J, Tran TV, Chen J, Iliev D, Sangale Z, Tikishvili E, Perry M, Zharkikh A, Gutin A, Lanchbury JS.
    • Breast Cancer Res. 2014 Dec 5;16(6):475. doi: 10.1186/s13058-014-0475-x.
    • TGFβ Induces "BRCAness" and Sensitivity to PARP Inhibition in Breast Cancer by Regulating DNA-Repair Genes.
    • Liu L, Zhou W, Cheng CT, Ren X, Somlo G, Fong MY, Chin AR, Li H, Yu Y, Xu Y, O'Connor ST, O'Connor TR, Ann DK, Stark JM, Wang SE.
    • Mol Cancer Res. 2014 Nov;12(11):1597-609. doi: 10.1158/1541-7786.MCR-14-0201. Epub 2014 Aug 7.
    • Functional Ex Vivo Assay to Select Homologous Recombination-Deficient Breast Tumors for PARP Inhibitor Treatment.
    • Naipal KA, Verkaik NS, Ameziane N, van Deurzen CH, Ter Brugge P, Meijers M, Sieuwerts AM, Martens JW, O'Connor MJ, Vrieling H, Hoeijmakers JH, Jonkers J, Kanaar R, de Winter JP, Vreeswijk MP, Jager A, van Gent DC.
    • Clin Cancer Res. 2014 Sep 15;20(18):4816-26. doi: 10.1158/1078-0432.CCR-14-0571. Epub 2014 Jun 24.
    • Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited.
    • Lupo B, Trusolino L.
    • Biochim Biophys Acta. 2014 Aug;1846(1):201-15. doi: 10.1016/j.bbcan.2014.07.004. Epub 2014 Jul 12.
    • BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients - A study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD).
    • Ruscito I, Dimitrova D, Vasconcelos I, Gellhaus K, Schwachula T, Bellati F, Zeillinger R, Benedetti-Panici P, Vergote I, Mahner S, Cacsire-Tong D, Concin N, Darb-Esfahani S, Lambrechts S, Sehouli J, Olek S, Braicu EI.
    • Eur J Cancer. 2014 Aug;50(12):2090-8. doi: 10.1016/j.ejca.2014.05.001. Epub 2014 Jun 2.
    • An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer.
    • Shah MM, Dobbin ZC, Nowsheen S, Wielgos M, Katre AA, Alvarez RD, Konstantinopoulos PA, Yang ES, Landen CN.
    • Gynecol Oncol. 2014 Aug;134(2):331-7. doi: 10.1016/j.ygyno.2014.05.009. Epub 2014 May 15.
    • Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells.
    • Ha K, Fiskus W, Choi DS, Bhaskara S, Cerchietti L, Devaraj SG, Shah B, Sharma S, Chang JC, Melnick AM, Hiebert S, Bhalla KN.
    • Oncotarget. 2014 Jul 30;5(14):5637-50.
    • Predictive biomarkers for cancer therapy with PARP inhibitors.
    • Michels J, Vitale I, Saparbaev M, Castedo M, Kroemer G.
    • Oncogene. 2014 Jul 24;33(30):3894-907. doi: 10.1038/onc.2013.352. Epub 2013 Sep 16.
    • Review
    • Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers.
    • Watkins JA, Irshad S, Grigoriadis A, Tutt AN.
    • Breast Cancer Res. 2014 Jun 3;16(3):211. doi: 10.1186/bcr3670.
    • Phosphorylation of ribosomal protein S6 confers PARP inhibitor resistance in BRCA1-deficient cancers.
    • Sun CK, Zhang F, Xiang T, Chen Q, Pandita TK, Huang Y, Hu MC, Yang Q.
    • Oncotarget. 2014 May 30;5(10):3375-85.
    • Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy.
    • Vollebergh MA, Lips EH, Nederlof PM, Wessels LF, Wesseling J, Vd Vijver MJ, de Vries EG, van Tinteren H, Jonkers J, Hauptmann M, Rodenhuis S, Linn SC.
    • Breast Cancer Res. 2014 May 15;16(3):R47. doi: 10.1186/bcr3655.

    Editorial:

    Tumor homologous recombination deficiency assays: another step closer to clinical application?

    • PCAT-1, a Long Noncoding RNA, Regulates BRCA2 and Controls Homologous Recombination in Cancer.
    • Prensner JR, Chen W, Iyer MK, Cao Q, Ma T, Han S, Sahu A, Malik R, Wilder-Romans K, Navone N, Logothetis CJ, Araujo JC, Pisters LL, Tewari AK, Canman CE, Knudsen KE, Kitabayashi N, Rubin MA, Demichelis F, Lawrence TS, Chinnaiyan AM, Feng FY.
    • Cancer Res. 2014 Mar 15;74(6):1651-60. doi: 10.1158/0008-5472.CAN-13-3159. Epub 2014 Jan 28.
    • Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors.
    • O'Sullivan CC, Moon DH, Kohn EC, Lee JM.
    • Front Oncol. 2014 Feb 28;4:42. eCollection 2014.
    • 'BRCAness' and its implications for platinum action in gynecologic cancer.
    • Muggia F, Safra T.
    • Anticancer Res. 2014 Feb;34(2):551-6.
    • Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity.
    • Bajrami I, Frankum JR, Konde A, Miller RE, Rehman FL, Brough R, Campbell J, Sims D, Rafiq R, Hooper S, Chen L, Kozarewa I, Assiotis I, Fenwick K, Natrajan R, Lord CJ, Ashworth A.
    • Cancer Res. 2014 Jan 1;74(1):287-97. doi: 10.1158/0008-5472.CAN-13-2541. Epub 2013 Nov 15.
    • Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.
    • De P, Sun Y, Carlson JH, Friedman LS, Leyland-Jones BR, Dey N.
    • Neoplasia. 2014 Jan;16(1):43-72.
    • ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition.
    • Gilardini Montani MS, Prodosmo A, Stagni V, Merli D, Monteonofrio L, Gatti V, Gentileschi MP, Barilà D, Soddu S.
    • J Exp Clin Cancer Res. 2013 Nov 19;32(1):95. doi: 10.1186/1756-9966-32-95.
    • Biology of hereditary breast and ovarian cancers.
    • Tommasi S.
    • Ann Oncol. 2013 Nov;24 Suppl 8:viii7. doi: 10.1093/annonc/mdt309.
    • BRCAness: a deeper insight into basal-like breast tumors.
    • De Summa S, Pinto R, Sambiasi D, Petriella D, Paradiso V, Paradiso A, Tommasi S.
    • Ann Oncol. 2013 Nov;24 Suppl 8:viii13-viii21. doi: 10.1093/annonc/mdt306.
    • BRCA1- and BRCA2-related mutations: therapeutic implications in ovarian cancer.
    • Pothuri B.
    • Ann Oncol. 2013 Nov;24 Suppl 8:viii22-viii27. doi: 10.1093/annonc/mdt307.
    • Loss of glucocorticoid receptor activation is a hallmark of BRCA1-mutated breast tissue.
    • Vilasco M, Communal L, Hugon-Rodin J, Penault-Llorca F, Mourra N, Wu Z, Forgez P, Gompel A; BRACAPS.
    • Breast Cancer Res Treat. 2013 Nov;142(2):283-96. doi: 10.1007/s10549-013-2722-8. Epub 2013 Oct 29.
    • BRCA1 promoter methylation is a marker of better response to anthracycline-based therapy in sporadic TNBC.
    • Ignatov T, Poehlmann A, Ignatov A, Schinlauer A, Costa SD, Roessner A, Kalinski T, Bischoff J.
    • Breast Cancer Res Treat. 2013 Sep;141(2):205-12. doi: 10.1007/s10549-013-2693-9. Epub 2013 Sep 13.
    • Hereditary breast and ovarian cancer susceptibility genes (Review).
    • Kobayashi H, Ohno S, Sasaki Y, Matsuura M.
    • Oncol Rep. 2013 Sep;30(3):1019-29. doi: 10.3892/or.2013.2541. Epub 2013 Jun 19.
    • Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile.
    • Cramer-Morales K, Nieborowska-Skorska M, Scheibner K, Padget M, Irvine DA, Sliwinski T, Haas K, Lee J, Geng H, Roy D, Slupianek A, Rassool FV, Wasik MA, Childers W, Copland M, Müschen M, Civin CI, Skorski T.
    • Blood. 2013 Aug 15;122(7):1293-304. doi: 10.1182/blood-2013-05-501072. Epub 2013 Jul 8.
    • Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival.
    • Gan A, Green AR, Nolan CC, Martin S, Deen S.
    • Hum Pathol. 2013 Aug;44(8):1638-47. doi: 10.1016/j.humpath.2013.01.015. Epub 2013 Apr 8.
    • Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review.
    • Chalasani P, Livingston R.
    • Oncologist. [2013 Aug;]18(8):909-16. doi: 10.1634/theoncologist.2013-0039. Epub 2013 Jul 23.
    • Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations.
    • George J, Alsop K, Etemadmoghadam D, Hondow H, Mikeska T, Dobrovic A, deFazio A; Australian Ovarian Cancer Study Group, Smyth GK, Levine DA, Mitchell G, Bowtell DD.
    • Clin Cancer Res. 2013 Jul 1;19(13):3474-84. doi: 10.1158/1078-0432.CCR-13-0066. Epub 2013 Apr 30.

    Research news:

    Genomic signatures of BRCA1 but not BRCA2 associated high-grade serous carcinoma resemble basal-like breast cancer.

    • Identification of miRNA modulators to PARP inhibitor response.
    • Neijenhuis S, Bajrami I, Miller R, Lord CJ, Ashworth A.
    • DNA Repair (Amst). 2013 Jun 1;12(6):394-402. doi: 10.1016/j.dnarep.2013.02.003. Epub 2013 Apr 6.
    • Platform comparisons for identification of breast cancers with a BRCA-like copy number profile.
    • Schouten PC, van Dyk E, Braaf LM, Mulder L, Lips EH, de Ronde JJ, Holtman L, Wesseling J, Hauptmann M, Wessels LF, Linn SC, Nederlof PM.
    • Breast Cancer Res Treat. 2013 Jun;139(2):317-27. doi: 10.1007/s10549-013-2558-2. Epub 2013 May 14.
    • Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers.
    • Lips EH, Mulder L, Oonk A, van der Kolk LE, Hogervorst FB, Imholz AL, Wesseling J, Rodenhuis S, Nederlof PM.
    • Br J Cancer. 2013 May 28;108(10):2172-7. doi: 10.1038/bjc.2013.144. Epub 2013 Apr 4.
    • Classifications within molecular subtypes enables identification of BRCA1/BRCA2 mutation carriers by RNA tumor profiling.
    • Larsen MJ, Kruse TA, Tan Q, Lænkholm AV, Bak M, Lykkesfeldt AE, Sørensen KP, Hansen TV, Ejlertsen B, Gerdes AM, Thomassen M.
    • PLoS One. 2013 May 21;8(5):e64268. doi: 10.1371/journal.pone.0064268. Print 2013.
    • PARP Inhibitors: Targeting the Right Patients.
    • Azvolinsky A.
    • J Natl Cancer Inst. 2012 Dec 19;104(24):1851-2. doi: 10.1093/jnci/djs514. Epub 2012 Dec 10.
    • Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival.
    • Mukhopadhyay A, Plummer ER, Elattar A, Soohoo S, Uzir B, Quinn JE, McCluggage WG, Maxwell P, Aneke H, Curtin NJ, Edmondson RJ.
    • Cancer Res. 2012 Nov 15;72(22):5675-82. doi: 10.1158/0008-5472.CAN-12-0324. Epub 2012 Oct 11.
    • Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer.
    • Abkevich V, Timms KM, Hennessy BT, Potter J, Carey MS, Meyer LA, Smith-McCune K, Broaddus R, Lu KH, Chen J, Tran TV, Williams D, Iliev D, Jammulapati S, Fitzgerald LM, Krivak T, Deloia JA, Gutin A, Mills GB, Lanchbury JS.
    • Br J Cancer. 2012 Nov 6;107(10):1776-82. doi: 10.1038/bjc.2012.451. Epub 2012 Oct 9.
    • Targeting BRCA1 localization to augment breast tumor sensitivity to poly(ADP-Ribose) polymerase inhibition.
    • Yang ES, Nowsheen S, Rahman MA, Cook RS, Xia F.
    • Cancer Res. 2012 Nov 1;72(21):5547-55. doi: 10.1158/0008-5472.CAN-12-0934. Epub 2012 Sep 7.
    • Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.
    • Oplustilova L, Wolanin K, Mistrik M, Korinkova G, Simkova D, Bouchal J, Lenobel R, Bartkova J, Lau A, O'Connor MJ, Lukas J, Bartek J.
    • Cell Cycle. 2012 Oct 15;11(20):3837-50. doi: 10.4161/cc.22026. Epub 2012 Sep 14.

    Comment:

    Addicted to PAR? A closer look at PARP inhibitor sensitivity.

    Comment:

    Predicting PARP inhibitor sensitivity and resistance.

    • Clinical correlates of 'BRCAness' in triple-negative breast cancer of patients receiving adjuvant chemotherapy.
    • Oonk AM, van Rijn C, Smits MM, Mulder L, Laddach N, Savola SP, Wesseling J, Rodenhuis S, Imholz AL, Lips EH.
    • Ann Oncol. 2012 Sep;23(9):2301-5. doi: 10.1093/annonc/mdr621. Epub 2012 Feb 21.

    Free text: Clinical Correlates of 'BRCAness' in Triple-Negative Breast Cancer of Patients Receiving Adjuvant Chemotherapy. (Medscape)

    • Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib.
    • Daemen A, Wolf DM, Korkola JE, Griffith OL, Frankum JR, Brough R, Jakkula LR, Wang NJ, Natrajan R, Reis-Filho JS, Lord CJ, Ashworth A, Spellman PT, Gray JW, van't Veer LJ.
    • Breast Cancer Res Treat. 2012 Sep;135(2):505-17. doi: 10.1007/s10549-012-2188-0. Epub 2012 Aug 9.
    • BRCA1-methylated sporadic breast cancers are BRCA-like in showing a basal phenotype and absence of ER expression.
    • Bal A, Verma S, Joshi K, Singla A, Thakur R, Arora S, Singh G.
    • Virchows Arch. 2012 Sep;461(3):305-12. doi: 10.1007/s00428-012-1286-z. Epub 2012 Jul 21.
    • Molecular insights on basal-like breast cancer.
    • Valentin MD, da Silva SD, Privat M, Alaoui-Jamali M, Bignon YJ.
    • Breast Cancer Res Treat. 2012 Jul;134(1):21-30. doi: 10.1007/s10549-011-1934-z. Epub 2012 Jan 11.
    • Review
    • Methylation of O6-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients.
    • Fumagalli C, Pruneri G, Possanzini P, Manzotti M, Barile M, Feroce I, Colleoni M, Bonanni B, Maisonneuve P, Radice P, Viale G, Barberis M.
    • Breast Cancer Res Treat. 2012 Jul;134(1):131-7. doi: 10.1007/s10549-011-1945-9. Epub 2012 Jan 8.
    • BRCAness: finding the Achilles heel in ovarian cancer.
    • Rigakos G, Razis E.
    • Oncologist. [2012 Jul;]17(7):956-62. doi: 10.1634/theoncologist.2012-0028. Epub 2012 Jun 6.
    • Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents.
    • Birkbak NJ, Wang ZC, Kim JY, Eklund AC, Li Q, Tian R, Bowman-Colin C, Li Y, Greene-Colozzi A, Iglehart JD, Tung N, Ryan PD, Garber JE, Silver DP, Szallasi Z, Richardson AL.
    • Cancer Discov. 2012 Apr;2(4):366-75. doi: 10.1158/2159-8290.CD-11-0206. Epub 2012 Mar 22.
    • Somatic mutations in the BRCA1 gene in Chinese women with sporadic breast cancer.
    • Zhang M, Xu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y.
    • Breast Cancer Res Treat. 2012 Feb;132(1):335-40. doi: 10.1007/s10549-011-1887-2. Epub 2011 Nov 25.
    • BRCAness profile of sporadic ovarian cancer predicts disease recurrence.
    • Wysham WZ, Mhawech-Fauceglia P, Li H, Hays L, Syriac S, Skrepnik T, Wright J, Pande N, Hoatlin M, Pejovic T.
    • PLoS One. 2012;7(1):e30042. doi: 10.1371/journal.pone.0030042. Epub 2012 Jan 11.
    • Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers.
    • Vollebergh MA, Jonkers J, Linn SC.
    • Cell Mol Life Sci. 2012 Jan;69(2):223-45. doi: 10.1007/s00018-011-0809-0. Epub 2011 Sep 16.
    • Review